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ABSTRACT
Economics of Breast Cancer Preventive Strategies in a Medicaid Program
Rohit D. Borker
The primary objective of the study was to estimate the long-term benefits and costs of
chemopreventive tamoxifen and mammography screening in women who are otherwise
healthy but at high risk of developing breast cancer. Three hypothetical cohorts of highrisk women were initiated at age forty. The first cohort consumed chemopreventive
tamoxifen and underwent routine mammography screening. The second cohort also
consumed chemopreventive tamoxifen but underwent mammography screening at realworld rates. The third cohort (control cohort) did not consume chemopreventive
tamoxifen and underwent mammography screening at real-world rates. The study also
assessed the proportion of women in the West Virginia Medicaid Program (WVMP) who
were healthy but at a high risk of developing breast cancer. Secondary objectives of the
study involved determining breast cancer knowledge, utilization of breast cancer
preventive strategies, and willingness to consume chemopreventive tamoxifen.
Chemopreventive tamoxifen coupled with routine mammography screening resulted in an
incremental life expectancy gain of 0.122 years at an incremental cost of $5,969.70
resulting in an incremental cost effectiveness ratio (ICER) of $48,931.80 per life year
gained (3 % discount rate) as compared to control cohort. Chemopreventive tamoxifen
coupled with mammography screening at real-world rates resulted in an incremental life
expectancy gain of 0.076 years at an incremental cost of $4,916.84 resulting in an
incremental cost effectiveness ratio (ICER) of $64,695.20 per life year gained (3 %
discount rate) as compared to control cohort. Sensitivity analysis indicated robustness of
results over a wide rage of assumptions. About half of the surveyed population was at a
high risk of developing breast cancer and thus eligible to receive chemopreventive
tamoxifen. However, only about 17 % respondents indicated their inclination towards
consuming chemopreventive tamoxifen. A low but significant correlation was observed
between the respondent’s perceived risk and real risk indicating the need for increasing
breast cancer awareness. Respondent’s actual risk of developing breast cancer did not
appear to have any relationship with willingness to consume chemopreventive tamoxifen.
In summary, chemopreventive tamoxifen plus mammography screening in high-risk
women is a cost-effective strategy. However, at present, very few of these high-risk
women may actually utilize chemoprevention.
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CHAPTER 1

INTRODUCTION
Epidemiology and Cost of Breast Cancer

Breast cancer is the development of malignant tumor from the cells of the breast.
Although breast cancer is one of the best studied human tumors, it still remains poorly
understood. As a result, 30 % to 40 % of women who develop breast cancer die from it
(Kopans, 1998). It is one of the most common cancers ranking second only to lung
cancer in terms of cancer attributed deaths in women. In fact, breast cancer remains the
leading cause of non-preventable cancer deaths in American women (Kopans, 1998).
The American Cancer Society (ACS) estimates about 40,200 breast cancer deaths in the
United States in 2001 (American Cancer Society, 2001-2002). Furthermore,
approximately 1 in every 8 women will develop breast cancer by age of 85 years
(American Cancer Society, 2001-2002) and about 192,200 new cases of invasive breast
cancer will be diagnosed among women in the United States in 2001 (American Cancer
Society, 2001-2002).
The breast cancer incidence over the years can be categorized into three distinct
phases: (1) between 1940 and 1982, there was a steady rate of increase of about 1 %
annually (Garfinkel, 1994), (b) between 1982 and 1987, the increase was about 4 %
annually (Garfinkel, 1994), and (c) between 1990 and 1994, the incidence of developing
breast cancer stabilized at about 110.2 cases per 100,000 women (Ries et al, 1997). In
addition to these invasive cases, about 39,900 new cases of ductal carcinoma in-situ
(DCIS) (Stage 0) are diagnosed each year.
Carcinoma in situ refers to non-invasive type of breast cancers in which the
cancer cells inside the ducts do not spread through the walls of the ducts into fatty tissue
of the breast. Between 1983 to 1993, in situ breast cancer rates have increased from 2.3
to 6.2 per 100,000 among women under age of 50, and from 14.3 to 54.6 per 100,000
1
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among women aged 50 and older (Ries et al, 1997). As a result, breast cancer has been
identified as a major public health problem (Serxner, Chung, 1992).
Breast cancer also entails substantial economic burden, both for an individual as
well as for the society. For instance, the National Institutes of Health (NIH) estimates
that a significant proportion of direct medical costs associated with cancer are due to
breast cancers ($6 billion), lung cancers ($5 billion), and prostate cancers ($5 billion)
(1990 US Dollars) (American Cancer Society, 2002). Furthermore, lifetime cost of
breast cancer has been estimated to be about $36,926 per patient (1984 dollars) (Baker et
al., 1991). This translates to about $94,000 per patient when inflated to 2001 dollars
(assuming all other factors remain constant) based on Medical Care component of
Consumer Price Index (CPI) (U.S. Bureau of Labor Statistics). This considerable
economic burden coupled with clinical significance has prompted interest in breast
cancer preventive strategies that are not only effective, but also economically viable.
Risk factors for Breast Cancer

Risk of breast cancer increases with increasing age. Other factors that increase
breast cancer risk are family history of breast cancer, biopsy confirmed atypical
hyperplasia, a long menstrual history (menstrual period that starts early in life and ends
late), and nulliparity or first live birth after age 30. Moreover, dietary and lifestyle
behaviors such as alcohol intake, fat intake, recent consumption of oral contraceptives or
post menopausal estrogen, weight gain and physical inactivity, among others, have also
been linked to breast cancer risk although the causal role for some of these factors is still
to be established. Each of these risk factors is discussed in more details in Chapter 2.
Breast Cancer Prevention Strategies

Currently no strategy exists to prevent breast cancer. Hence, the focus is on either
reducing the risk of incident breast cancer or on detection of the already developed
cancers at an earlier stage, thereby reducing mortality from it (Bush et al., 1993; Shapiro
et al., 1982; Tabar et al., 1985). Strong evidence suggests that early detection has
reduced breast cancer mortality in some groups of women (Tabar et al., 1985; Tabar et
2
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al., 1995; Kerlikowske et al., 1995; Hendrick et al., 1997). Despite the effectiveness of
detecting breast tumors early, the sheer number of women affected by breast cancer has
prompted efforts to control the disease using primary prevention strategies which
involves reducing the incidence of breast cancer (National Cancer Institute, 2003). Both
the primary and the secondary breast cancer preventive strategies are discussed next.
Primary Prevention of Breast Cancer
The rationale for primary prevention of breast cancer was based on wide variation
in breast cancer rates across the world suggesting that environmental and lifestyle
determinants were linked to breast cancer. For instance, it was reported that Japanese
migrants to the United States acquired a significant portion of breast cancer risk of the
host country within two generations (National Cancer Institute, 2003). Subsequently,
studies have been conducted to examine the effects of environmental, dietary, and
lifestyle factors on breast cancer risk (National Cancer Institute 2003; Wolff et al., 1993;
Shames et al., 1994; Krieger et al., 1994; Hunter et al., 1997; Hunter et al., 1996). The
results of these studies have been inconsistent and hence evidence linking these factors to
the risk of breast cancer is weak. Lack of evidence coupled with inadequate
understanding of the biologic mechanisms through which the risk factors interact has
further limited the potential for primary prevention of breast cancer (Bush T et al., 1993).
Nevertheless, a number of potential strategies are currently being evaluated in primary
prevention of breast cancer. The term ‘prevention’ in the present context of primary
prevention refers to a reduction in incidence (risk) of breast cancer over a defined period
of time. Thus, although a strategy might prevent the appearance of significant number of
tumors in a population over a defined period of time, it does not imply that initiation of
breast cancers has been prevented or that tumors have been permanently eliminated.
Primary prevention strategies are discussed next.
Prophylactic Mastectomy
Non-pharmacologic primary prevention strategies such as prophylactic
mastectomy have been investigated with some promising results. A study reported an 89
% breast cancer risk reduction in moderate-risk women and a 90 to94 % risk reduction in
3
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high-risk women, who underwent mastectomy (Hartmann, Schaid, Woods, et al., 1999).
The potential for widespread implementation of prophylactic mastectomy in breast cancer
risk reduction is, however, limited as most women who will undergo mastectomy (a
procedure which involves extensive and potentially disfiguring surgery that may
psychologically affect a patient’s long-term quality of life (Stegfanek et al., 1995) will
not go on to develop breast cancer (National Cancer Institute, 2003). Moreover, a task
force set up by the National Institutes of Health and the National Human Genome
Research Institute concluded that there is not enough evidence to support or recommend
either for or against prophylactic mastectomy (Burke et al., 1997).
Chemoprevention
Limited ability to modify breast cancer risk factors provided an impetus for
investigating chemoprevention (Bush et al., 1993) as a primary preventive strategy.
Research in carcinogenesis has shown that greater than 90 % of cancers are associated
with mutagens and mitogens (Kelloff et al., 1997(a); Kelloff et al., 1997(b)). As a result,
current research in breast cancer has been directed towards searching for agents that
inhibit or reverse cellular processes resulting from mutagensis and mitigenesis. This
process is called chemoprevention and is defined as prevention of cancer using
pharmacological agents that inhibit or reverse the process of carcinogenesis (Sporn et al.,
1979). This approach has yielded agents, which fall under the broad categories of
retinoids, and antiestrogens/ antiandrogens (Kelloff et al., 1999). The later category
includes a class of therapeutic agents known as selective estrogen receptor modulators
(SERMs) which has shown most promise in chemoprevention of breast cancer (National
Cancer Institute, 2003). Tamoxifen, which is a SERM, is one such agent that reduced the
risk of breast cancer in high-risk women in the National Surgical Adjuvant Breast and
Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT) protocol P-1 study
(Fisher et al., 1998).
Currently, tamoxifen appears to be the most promising agent in primary
prevention of breast cancer. Also, it is the only United States Food and Drug
Administration (US FDA) approved drug for reducing breast cancer risk in high-risk
4
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women (American Society of Clinical Oncology, 2002). Hence, for the purpose of this
study, tamoxifen will be considered as a strategy of choice for primary prevention of
breast cancer in women who are otherwise healthy but at high risk of developing the
disease.
Promising as it may seem, the scope of primary prevention has been restricted to
women at high risk of developing breast cancer because of inherent limitations of these
strategies. Owing to failure of etiologic studies in breast cancer research to identify
primary prevention strategies suitable for the general population, reducing mortality
through early detection of breast cancer still remains the mainstay (National Cancer
Institute).
Secondary Prevention of Breast Cancer
The ACS guidelines list clinical breast examination (CBE), breast selfexamination (BSE) and mammography as secondary prevention strategies for early
detection of breast cancer (American Cancer Society, 2001-2002). Following is a brief
description of each of these strategies.
Clinical Breast Examination
A recent pooled analysis study investigated the role of clinical breast examination
(CBE) in early detection of breast cancer (Barton et al., 1999). The study reported a
reduction in breast cancer mortality in a group of patients screened by both CBE and
mammography. However, the study indicated that evidence pertaining to CBE’s
contribution in reducing the mortality was less direct and that precision of CBE was
difficult to assess due to lack of consistent and standardized examination techniques.
Based on the pooled analysis, the CBE sensitivity (ability to detect cancer when the
woman being screened has the disease) was estimated at 54 %, while the specificity (the
ability to correctly identify a woman being screened as not having breast cancer when she
does not have the disease) was 94 %.

5
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Breast Self-examination
There have been mixed results regarding the efficacy of breast self examination
(BSE) in reducing breast cancer related mortality. A study by Thomas et al., (1997)
reported neither lower death rates nor a shift towards the diagnosis of less advanced
disease among subjects practicing BSE. Results from non-randomized trials in United
Kingdom have not been very encouraging either. For instance, the relative risk of death
from breast cancer was 1.13 (95 % CI: 0.95-1.35) for one BSE center and 0.78 (95 % CI:
0.61-1.00) in the other center (UK Trial of Early Detection of Breast Cancer Group,
1993). However, a Finnish cohort study by Gastrin et al (1994), followed a large number
of women and reported significantly lower breast cancer mortality rates in the group who
performed BSE in comparison to the group of women who did not practice BSE.
Screening Mammography
Mammography is the most effective method for breast cancer screening, because
of its ability to detect cancers before physical symptoms become apparent (American
Cancer Society, 1997). In fact, the primary reason to perform mammography screening
is to detect the occult cancer at an early stage so that the natural history of the disease can
be interrupted, subsequently, reducing number of deaths from breast cancer (Kopans,
1998). Mammograms has sensitivity of about 76 % to 94 %, which is much higher then
that of clinical breast examination which has sensitivity in the range of 57 % to 70 %.
Also, screening mammography’s specificity is greater than 90 % (American Cancer
Society, 1997). Moreover, radiation exposure with mammography is in a range of about
0.1 to 0.2 rad dose per x-ray, not significant enough to pose any radiation exposure
problems (American Cancer Society, 1997).
A large number of trials have shown that mammography effectively detects breast
cancer at early stages, consequently increasing survival and decreasing breast cancer
mortality by at least 30 % (Costanza, 1992; Shapiro, 1988; Shapiro, 1989; Seidman et al.,
1987; Tabar et al., 1992). Controversy, however, surrounds with respect to the
appropriate age at which to begin regular mammography screening (Ransohoff et al.,
1997). A Health Insurance Plan study reported breast cancer mortality reduction
6
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attributable to mammography screening in women aged 50 to 64 years but failed to show
similar results for women between 40 to 49 years of age (Shapiro, 1988). Based on series
of randomized controlled trials, case-control trials and demonstration projects, the NIH
Consensus Development Conference in 1997 concluded that “the available data do not
warrant a single recommendation for mammography for all women in their forties. Each
women should decide for herself whether to undergo mammography (NIH Consensus
Statement, 1997).” The ACS however took a different stand based on the same evidence
and recommended an annual mammography for all women in their forties (American
Cancer Society’s Workshop on Guidelines for Breast Cancer Detection, 1997).
In conclusion, regardless of differences in effectiveness of mammography
screening across different age groups, it is well established that mammography is the
single most effective secondary prevention strategy for breast cancer in comparison with
other secondary prevention strategies (National Cancer Institute). Consequently,
mammography will be considered as the strategy of choice for secondary prevention of
breast cancer in present study.
Economics of Prevention

Rapidly rising costs of medical technologies and services is increasingly reducing
the ability to give all patients the care that would benefit them (Brook et al., 1990).
Consequently, it has become necessary to define and determine the appropriateness of
care in such an increasingly cost-conscious environment (Brook et al., 1990). Issues
pertaining to effectiveness of preventive services and economic utility have become
critical. An important aspect of any preventive intervention in an environment of finite
resources is whether there are economic benefits to help offset the additional cost of
prevention.
The clinical effectiveness of both primary and secondary breast cancer preventive
strategies has been well established as is evident from the above discussion. However, a
decision to implement any such prevention strategies require evidence of not only their
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effectiveness but also the costs that are incurred due to their implementation (Wright,
1986).
Economics of Primary Prevention
Very few studies have addressed the cost-effectiveness of tamoxifen in primary
prevention of breast cancer. A Medline search (1966-present) identified only three
studies, which have scientifically evaluated economic efficiency of using tamoxifen in
women who are otherwise healthy but at a high risk of developing breast cancer. A study
by Noe L et al., (1999) used a Markov model to study the incremental cost-effectiveness
of tamoxifen in primary prevention of breast cancer. Incremental cost-effectiveness of
tamoxifen was found to be $41,372 per life years gained for women age 35 to 49 years
and $68,349 and $74,981 per life years gained for women in their fifties and sixties
respectively.
In an another study, which also employed the Markov model, the incremental
cost-effectiveness of tamoxifen in primary prevention of breast cancer was found to be
$46,619 per life years saved for women who started on tamoxifen therapy at the age of 35
years (Grann et al., 2000). A study by Smith et al (2000) analyzed a base-case of highrisk women regardless of age and estimated a significantly lower cost-effectiveness ratio
for tamoxifen of $8,479 per life year saved. A major limitation of the latter analysis was
the assumption of lifetime effectiveness of tamoxifen in breast cancer prevention. These
studies are discussed in more details in Chapter 2.

Economics of Secondary Prevention
Mammography has been the single most effective method for early detection of
breast cancer, since it can identify cancers several years before the cancer becomes
clinically evident (American Cancer Society, 2001-2002). There have been many
studies, which have evaluated the cost-effectiveness of mammography in secondary
prevention of breast cancer (Salzmann et al., 1997; Lindfors et al., 1995; Feig, 1995). A
study by Salzmann et al., (1997) calculated average cost-effectiveness by comparing
8
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screening among different age cohorts of women (40-49 years, 50-69 years) versus no
screening. The study reported a cost-effectiveness ratio of $105,000 per life years saved
for women undergoing screening in their forties. For women above 50 years, the costeffectiveness ratio was better at $21,000 per life year saved. However, the costeffectiveness ratio has shown wide variations across studies. For instance, a study by
Rosenquist C et al., (1998) reported the marginal cost per life year saved from
mammography screening to be as low as $16,100 to $18,800. Part of the differences in
mortality reduction can be attributed to mammography screening and to failure on part of
some economic studies to include time lag between actual initiation of mammography
and time when benefits in terms of mortality reduction start accruing (Salzmann et al.,
1997).
Economics of Combining Prevention Strategies
Chemopreventive tamoxifen and mammography screening have different roles in
breast cancer prevention management. Chemopreventive tamoxifen reduces the risk of
breast cancer while mammography screening results in early detection of breast tumors
thereby improving survival. Their unique mode of actions makes these two strategies
complimentary rather than competitive. The rationale for investigating the economics of
tamoxifen and mammography screening in combination, thus, is based on the reasoning
that chemopreventive tamoxifen does not eliminate the need for mammography
screening. In other words, women who are eligible to receive preventive tamoxifen
therapy would need to undergo routine mammography screening irrespective of whether
they are taking chemopreventive tamoxifen or not. Thus, a policy for introducing
tamoxifen for prevention of breast cancer should also consider the simultaneous effects
(both costs and effectiveness) of mammography screening. This presents policy makers
with two main scenarios: (1) use chemopreventive tamoxifen in tandem with
mammography screening or (2) continue using mammography screening alone. An
incremental analysis of these two scenarios will quantify cost and benefits of introducing
chemopreventive tamoxifen versus not using chemoprevention.
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The greatest reduction in breast cancer mortality will result from the most
optimum utilization of both preventive strategies. Hence, the first intervention that was
included in the model was chemopreventive tamoxifen with routine mammography
screening in accordance with the ACS guidelines. However, the optimal utilization will
also come at a substantial cost in terms of cost of tamoxifen therapy and screening
mammography. Hence, it is important to assess whether these additional costs that result
from optimal utilization justify the benefits that they deliver in terms of reduction in
breast cancer mortality. As is usually the case in real world setting, optimal utilization of
interventions is seldom observed which compromises the effectiveness of that
intervention. This sub-optimal utilization may also affect the total costs of the
intervention in terms of decreasing intervention costs (due to lower utilization of the
intervention as compared to optimal setting) and increasing non-intervention costs (due to
increased proportion of detected cancers in later stages than in earlier stages thereby
increasing treatment cost, etc). Hence, a second intervention was added where by the
women took chemopreventive tamoxifen but underwent mammography screening at rates
that were observed in real world setting. The third intervention, which acted as the
control intervention, depicted the ‘current state of affair’ wherein women did not
consume chemopreventive tamoxifen but underwent mammography at rates observed in a
real world setting. An incremental cost effectiveness analysis of these interventions will
quantify and compare the costs and benefits of each of the three strategies enabling policy
makers to choose the most efficient strategy among the three.
Previous attempts at quantifying these costs and benefits of chemopreventive
tamoxifen and thereby determining its efficiency in third party payer setting assumed a
somewhat narrow perspective by excluding costs and benefits of mammography
screening, an essential and expensive component of breast cancer prevention
management. Thus, although these studies did provide information on economic
efficiency of tamoxifen therapy, they did not address the issue of overall economics of
breast cancer prevention.
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Breast Cancer Economics and Medicaid

Although the cost-effectiveness model to be developed in the present study will
be applicable in most third party payer settings, this study will determine the incremental
cost-effectiveness of the different scenarios in the West Virginia Medicaid Program
(WVMP).
Rationale for selecting the West Virginia Medicaid Program
Medicaid is the primary source of health care for low-income families with
children, the low-income elderly, and disabled persons. The Medicaid program provides
coverage on a wide range of basic health and long-term care services for more than 34
million individuals (www.urban.org/news/factsheets/medicaidFS.html). Title XIX of the Social
Security Act requires that in order to receive Federal matching funds, the state Medicaid
program must cover certain basic services including inpatient hospital services, outpatient
hospital services, physician services, medical and surgical services, laboratory and x-ray
services and early and periodic screening, diagnosis, and treatment (EPSDT) services
(www.hcfa.gov/medicaid/mservice.html).
On January 2001, the Congressional Budget Office (CBO) released baseline
projections for Federal Medicaid spending. The CBO estimated that the rate of Medicaid
expenditure growth will rise from 8.7 % in Federal fiscal year 2000 to 10.6 % in 2001. In
addition to the CBO, many state level projections also forecast a rise in the rate of growth
of Medicaid expenditures.
Increases in outpatient prescription drug expenditures have been reported to be
the primary reason for significant increases in state Medicaid expenditures. Overall,
Medicaid prescription drugs expenditures rose 20 % in 1998. Moreover, Centers for
Medicare and Medicaid (CMS) projects that Medicaid prescription drug expenditures will
rise about 70 % faster than overall Medicaid expenditures between 2001 and 2006. Since
other major federal programs including Medicare do not cover prescription drugs, the
increasing cost and utilization of prescription drugs creates substantial financial burden
on Medicaid Programs (The Urban Institute, www.urban.org/news/factsheets/medicaidFS.html).
11

Introduction

Under such circumstances of rising Medicaid prescription drug expenditures,
additional costs of newer drugs or preventive indications for drugs such as tamoxifen
may entail a significant financial burden on the system. These additional costs, however,
may be offset in case of some drugs through their appropriate and effective use, which
may reduce other medical costs through decrease in physician office, ER visits, and
hospitalizations (The Urban Institute, www.urban.org/news/factsheets/medicaidFS.html).
According to the CMS (1998), out of 308,910 Medicaid enrollees in the WVMP,
about 30 % (90,360) were women. Some proportion of these women will be at high risk
of developing breast cancer. Introducing tamoxifen as a preventive strategy will entail
certain drug costs to the Medicaid program including costs associated with the treatment
of adverse effects of tamoxifen. These costs will be over and above the cost of
mammography screening, which the Medicaid program is already incurring. The
Medicaid program will also experience some cost savings due to a reduction in the
number of breast cancers through use of chemopreventive tamoxifen. A costeffectiveness analysis will thus be required to determine if beneficial effects of tamoxifen
help offset its additional costs in presence of mammography screening.
The Medicaid program provides an appropriate female population to study the
economic efficiency of tamoxifen and mammography screening. The results of the
proposed study will determine whether or not tamoxifen as a chemopreventive agent and
mammography screening as a secondary preventive technique will lead to cost-savings in
the Medicaid population and help Medicaid reduce its overall expenditures. The
following section details a list of research questions, the answers to which will help to
understand the economics of breast cancer prevention in the Medicaid setting.
Research Questions

Q1. What are the incremental costs and consequences of introducing chemopreventive
tamoxifen in tandem with mammography screening in the West Virginia Medicaid
Program (WVMP)?
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Q2. What proportion of women enrollees in the WVMP are at a high risk of developing
breast cancer and thus eligible for chemopreventive tamoxifen intervention?
Q3. What proportion of women enrollees in the WVMP are willing to accept
chemopreventive tamoxifen for reducing their risk of breast cancer?
Q4. What is the relationship between their actual risk and perceived risk of developing
breast cancer, their knowledge of breast cancer and breast cancer preventive strategies
and willingness to consume chemopreventive drugs?
Conceptual Framework

This study will be conducted in two phases. Phase I involves construction of an
economic model to compare the incremental cost-effectiveness of breast cancer
preventive strategies. Phase II will estimate the proportion of WVMP women population
at high risk of developing breast cancer. Information on women’s perceived risk of
developing breast cancer and their knowledge about breast cancer preventive strategies
will also be assessed in phase II.
Phase I
Phase I involves developing a decision analytic model to systematically compare
different breast cancer preventive interventions discussed in the earlier section titled
“Economics of Combining Prevention Strategies.” In general, a health condition can be
managed using different therapeutic options. These options may have different effects on
the natural history of the disease. The challenge then is to quantify these effects and
identify those therapies that deliver maximum benefits in the most efficient manner for a
given health condition. Decision analysis process allows quantification of these effects
methodically determining the costs and consequences of the intervention.
The current study will simulate three hypothetical cohorts of 40-year old women
who are otherwise healthy but at a high risk of developing breast cancer. The first cohort
assumes that all women will begin taking chemopreventive tamoxifen and will undergo
routine mammography screening in accordance with the ACS recommended screening
guidelines. Compliance with tamoxifen will however be adjusted for actual tamoxifen
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compliance rates as observed in the tamoxifen chemopreventive trial (Fisher et al., 1998).
The second cohort represents a much more likely scenario wherein all women will begin
taking chemopreventive tamoxifen and will undergo mammography screening at rates,
which are observed in real-world setting. The third cohort represents the control cohort
in that these women will not take chemopreventive tamoxifen and will undergo
mammography screening at ‘observed’ rates (as observed in real-world setting), which
will similar to the rates assumed in the second cohort but lower than the optimal
mammography compliance assumed in the first cohort.
The present study involves extrapolating results from the short-term (5 year)
BCPT and mammography trials over the patient’s lifetime to quantify effects of
introducing chemopreventive tamoxifen in addition to mammography screening. In such
cases, Markov models have been found to be particularly useful and highly applicable
due to their ability to intuitively handle both costs and outcomes simultaneously over
chronic time intervals (Briggs A et al., 1998). Markov models have been regularly
employed in medical decision making for many years (Sonnenberg et al., 1993). More
on actual working of Markov models are presented in Chapter 2.
The decision to follow women at the age of forty was based on the rationale that
only women in their forties and above have been recommended annual mammography
screening by the ACS. Relatively low sensitivity of mammography (Hicks et al., 1979)
accompanied by relatively low breast cancer incidence rates (Harris et al., 1991) makes
routine mammography screening very inefficient in women below 40 years of age.
The primary outcomes of Phase I are incremental life expectancy gains and
incremental costs for each of the three scenarios: (1) optimal utilization rates of both
chemopreventive tamoxifen and screening mammography, (2) chemopreventive
tamoxifen utilization rates are optimal while the mammography screening rates are
‘observed’ rates (screening rates observed in WVMP setting), and (3) no tamoxifen is
being consumed and mammography screening rates are ‘observed’ rates. Incremental
analysis of scenario 1 over scenario 3 will provide cost per life expectancy gain estimates
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of most optimal scenario (chemopreventive tamoxifen and routine mammography
screening as per the ACS screening guidelines) versus maintaining status quo
(mammography screening at rates observed in real-world setting). Incremental analysis of
scenario 2 over scenario 3 will provide cost per life expectancy gain estimates of most
likely scenario (chemopreventive tamoxifen and mammography screening at rates
observed in real-world setting) versus maintaining status quo (mammography screening
at rates observed in real-world setting).
The incremental cost-effectiveness ratio (ICER) used in the simulation model will be
based on the following equation,
∆Cost

ICER =

Tamoxifen Therapy

+ ∆Cost

Mammogram
∆LE

+ ∆Cost

AdverseEvents

+ ∆Cost

BreastCancer

Interevention

where,
∆CostTamoxifen Therapy = Tamoxifen intervention costs (costs due to use of tamoxifen)
∆CostMammogram = Mammography intervention cost (costs due to incremental
mammography rates)
∆CostAdverse Events = Difference in morbidity costs (costs due to increased adverse events)
∆Cost Breast Cancer Treatment = Difference in IBC and NIBC treatment related costs
∆LEIntervention = Changes in life expectancy (LE) due to tamoxifen and mammography
screening
The numerator in the above ICER equation denotes the change in costs resulting
from the intervention. The denominator denotes changes in life expectancy as a result of
the intervention.
Phase II
Several models exist for breast cancer risk assessment that combine different
characteristics of a woman into a qualitative or quantitative risk profile (McTiernan et al.,
1997). This study will employ the Gail model (Gail et al., 1989) to assess an individual
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woman’s risk of developing breast cancer. The Gail model estimates the probability of a
woman with given set of risk factors of developing breast cancer over a specified period
of time. It was developed employing data from a subset of the 284,780 women
participating in the Breast Cancer Detection Demonstration Project (BCDDP) (Baker,
1982). The risk factors employed in Gail model include family history of breast cancer in
first-degree relatives, age at first childbirth, early menarche, and history of previous
benign breast biopsies. Atypical hyperplasia, which was later identified as a risk factor,
was included in the breast cancer risk estimation in the Gail risk algorithm. The risk
factors for breast cancer are discussed in more details in Chapter 2.
The Gail model is considered the best available means of estimating an
individual's risk of developing breast cancer. Although few studies have assessed the
validity of Gail model in breast cancer risk prediction, the Gail model is often regarded as
a ‘gold standard’ for individual breast cancer risk prediction (Spiegelman et al., 1994). A
study by Spiegelman (1994) concluded that Gail model over predicted absolute breast
cancer risk. Two other studies (Gail M et al., 1992; Vogel et al., 1993) have validated the
Gail model. Both the studies also reported that the Gail model over-predicted breast
cancer risk. However, as previously noted, Gail model is the best available means of
breast cancer risk prediction, and hence was used for breast cancer risk assessment in this
study.
Information on a woman’s breast cancer risk factors will be obtained by means of
a mail survey to randomly selected WVMP women recipients aged 40 years and above.
Information provided by survey respondents on risk factors will be entered into the
‘Breast Risk Assessment’ program (Gail M et al. model,1989) developed by Cardinal
Health System Inc. (Copyright 2000, Cardinal Health Systems Inc.). All women who
have a breast cancer relative risk (as calculated by the Gail algorithm) of > 1.7 will be
considered to be at high risk of the disease. The relative risk figure of 1.7 represents the
breast cancer risk of a 60-year old woman with no other breast cancer risk factors other
than her age. Subsequent to the individualized risk calculation, the proportion of women
at high risk will be determined. The resultant percent value will be extrapolated to the
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WVMP women population 40 years and above to estimate the total number of women in
WVMP who will be at high risk of developing breast cancer and thus eligible to receive
tamoxifen for chemoprevention of breast cancer.
According to Gail et al., (1992), "there is increasing emphasis on need for
counseling to assist women to make informed health decisions." To make such informed
health related decisions about preventive services, women should understand and be
aware of their own individualized risk of developing breast cancer. Consequently, this
study will investigate the relationship between "real risk" as calculated from the Gail
model and "perceived risk" of the subject. High correlation will be suggestive of a
beneficial trend while low correlation will be a disturbing finding. The latter case
demands awareness-enhancing counseling intervention to enable women to make an
informed health decision about options that are available to them for ‘prevention’ of
breast cancer. The survey will also obtain information on Medicaid recipient’s general
knowledge of breast cancer prevention strategies and the levels of compliance with these
prevention strategies.
Study Goals and Objectives

The primary goal of this study is to quantify total costs and consequences of
breast cancer preventive strategies in WVMP women enrollees who are healthy but at a
high risk of developing breast cancer. Secondary goals of this study include assessment
of breast cancer preventive behaviors and perceptions regarding breast cancer prevention
management in this population. Specific objectives for Phase I and II of the study are
discussed below.
Phase I
The first phase of this study involved development of a Markov model (Beck J et
al., 1983) to evaluate the long-term costs and benefits of tamoxifen and mammography
screening in prevention of breast cancer. This model was used to calculate the
incremental cost-effectiveness ratio (ICER) of introducing tamoxifen in addition to
existing mammography screening utilization (optimal screening rates in scenario 1 and
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observed screening rates in scenario two) versus maintaining a status quo (no tamoxifen
and observed mammography compliance rates).
Objectives for Phase I
Objective 1: To develop a Markov process to assess the long term clinical benefits of
increased life expectancy from using chemopreventive tamoxifen in conjunction with
mammography screening by women who are healthy but are at a high risk of developing
breast cancer.
Rationale: The current model follows a hypothetical cohort of women over their lifetime.
For health problems that are either chronic in nature or involve events that occur
repeatedly over time, a decision tree approach becomes unmanageable. It is difficult to
represent events that are repetitive or that occur with uncertain timings using a simple
decision tree model. Markov models overcome this hurdle by allowing provisions to
incorporate time dependent events.
Objective 2: To develop a cost-effectiveness model based on the Markov process that
determines the incremental costs and benefits of using tamoxifen in conjunction with
mammography screening versus mammography screening alone in women who are
healthy but are at a high risk of developing breast cancer.
Rationale: Rapidly rising costs of medical technologies and services is increasingly
reducing the ability to give all patients the care that would benefit them (Brook et al.,
1990). The clinical effectiveness of both primary and secondary breast cancer prevention
strategies have been well established. However, a decision to implement any such
preventive strategies require evidence of not only their clinical effectiveness but also the
costs that are incurred due to their implementation (Wright, 1986).
Phase II
The primary goal of phase II was to determine the proportion of women in the
WVMP who were at high risk of developing breast cancer. Secondary goals included
investigating relationships between women’s actual risk and their perceived risk of
developing breast cancer, knowledge about breast cancer preventive strategies, current
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usage of preventive strategies and inclination towards using drugs for chemoprevention
of breast cancer.
Objectives for phase II
Objective 1: To estimate individual woman’s 5-year risk of developing breast cancer in a
sample of women aged > 40 years in the WVMP.
Rationale: Total benefits of a preventive service are dependent, in part, on the baseline
risk of population in which those preventive services are being offered (Grann V et al.,
2000). Chemopreventive tamoxifen is indicated for reducing risk of breast cancer in only
those women who are at high risk of developing breast cancer. Hence, only those
Medicaid enrollees who are at high risk for breast cancer will be eligible to receive
chemopreventive tamoxifen. Identifying proportion of these high-risk women will help
estimate baseline risk of population eligible to receive tamoxifen and assist in quantifying
total costs and benefits of introducing chemopreventive tamoxifen in the WVMP.
Objective 2: To assess the sampled women’s perceptions of their 5-year and lifetime risk
of developing breast cancer.
Rationale: Studies indicate that a woman’s perceived risk of developing breast cancer can
partly affect her screening practices (Aiken L et al., 1994; Zapka J et al., 1989; Lerman C
et al., 1990; McCance K et al., 1990). However, women have unrealistic perceptions
about their risk of developing breast cancer (Woloshin et al., 1999). These unrealistic
perceptions may generate unnecessary anxiety and may affect appropriate utilization of
breast cancer preventive strategies (Lerman C et al., 1995). Consequently, to be able to
make informed decisions regarding breast cancer ‘prevention,’ women need to
understand their risk of developing breast cancer (Black W et al., 1995). From a public
policy perspective, it then becomes important for policy makers to understand women’s
perceptions of breast cancer risk so as to be able to communicate more accurate
information to these women about their risk. The survey in the present study addresses
this issue by estimating the perceived risk of breast cancer in the WVMP.
Objective 3: To assess the sampled women’s knowledge of breast cancer prevention
strategies
Rationale: Increasing women’s knowledge on breast cancer risk and benefits associated
with screening may positively influence screening behaviors (Aiken L et al., 1994).
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However, before knowledge enhancing interventions can be designed and implemented,
it is important to assess the baseline breast cancer screening knowledge among women in
the WVMP. The present study will address this issue of assessing baseline knowledge on
breast cancer and its prevention.
Objective 4: To estimate utilization of chemopreventive tamoxifen and assess levels of
adherence to mammography screening guidelines among the sampled women.
Rationale: Studies indicate that women in lower income groups tend to under-utilize
screening mammography, present with advanced stages of diseases, and subsequently
have higher rates of breast cancer attributed mortality (Davis T et al., 1996). The extent
of mammography screening under-utilization in the current West Virginia Medicaid
women population is unknown and thus needs to be estimated. Mammography screening
rates will be assessed through the mail survey.
Objective 5: To assess sampled women’s willingness to use tamoxifen for
chemoprevention of breast cancer.
Rationale: For high-risk women, tamoxifen has become the latest available option in
primary prevention of breast cancer. However, the benefits of tamoxifen in
chemoprevention of breast cancer will depend upon its acceptance in the eligible
population. Thus, it is important to understand the inclination of this group of high-risk
but otherwise healthy women towards taking tamoxifen in primary prevention of breast
cancer.
Significance of Research

According to the United States Preventive Services Task Force, effectiveness of
an intervention should be the prime requirement for its acceptance in health care,
especially for those interventions that are preventive in nature (U.S. Department of
Health and Human Services, 1996). Results of the BCPT trial indicated chemopreventive
tamoxifen’s ability to significantly reduce the risk of breast cancer in healthy women who
are at a high risk of developing breast cancer (Fisher et al., 1998). Ability of
mammography screening to detect breast tumors at an earlier stage thereby reducing
breast cancer mortality has also been well documented (Costanza, 1992; Shapiro, 1988;
Shapiro, 1989; Seidman et al., 1987; Tabar et al., 1992). Hence, based on
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recommendations of the task force, these interventions meet the criteria for their
implementation in medical care practice, at least from a clinical perspective. However, in
the same context, the task force guidelines also highlighted that effectiveness alone is not
a sufficient criterion to initiate services in most practical health care contexts,
emphasizing the important role of cost-effectiveness approach in policy decisions.
The significance of cost-effectiveness approach is especially relevant for health
insurance systems such as the state Medicaid programs as they provide insurance to
populations that are generally in worse health than the general population and rely on
Medicaid coverage for their prescription drugs and other preventive services (Bruen B,
2002; CMS, (www.hcfa.gov/medicaid/mservice.html). Consequently, introducing newer
interventions in addition to existing ones will strain Medicaid budgets which are already
experiencing difficulty due to federal and state budget deficits (Bruen B, 2002).
Consequently, there is growing pressure on these agencies to evaluate all new
interventions before implementation.
Cost-effectiveness analysis, which combines information on the health benefits,
health risks, and costs of health care services, is one such approach that can incorporate
and complement evidence on effectiveness for informed policy decision making (U.S.
Department of Health and Human Services, 1996). The Phase I of the current study
addresses this issue by quantifying and interpreting long term survival benefits and long
terms costs of chemopreventive tamoxifen in presence of more traditional preventive
strategy, mammography screening. Results from phase I will enumerate additional costs
and benefits of chemopreventive tamoxifen and mammography screening, thereby
establishing their combined efficiency in delivering health benefits.
However, another issue beyond traditional cost-effectiveness approach is that of
affordability (Trueman et al., 2001). Cost-effectiveness of an intervention does not
automatically guarantee its affordability for a given health system. In the present context,
ability of the WVMP to afford chemopreventive tamoxifen in addition to ongoing
mammography screening, will not only depend on tamoxifen’s cost-effectiveness profile
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but also on number of women in WVMP who will actually consume the drug. This rate
of acceptance will in turn be dictated by two main factors: (1) the proportion of women
who are at high risk of breast cancer and thus eligible to receive chemopreventive
tamoxifen, and (2) the extent of acceptance of chemopreventive tamoxifen among these
high risk women. Currently, no information exists with regards to either of the two stated
factors in the WVMP setting. Consequently, phase II of the study was developed in order
to assess WVMP women’s breast cancer risk profile (and thereby their eligibility to
receive chemopreventive tamoxifen) and willingness of these women to consume the
drug. Analysis of phase II data will help estimate the proportion of WVMP women
population who are eligible to receive chemoprevention as well as their willingness to
consume tamoxifen. Combining resultant data with cost effectiveness data from phase I
will provide the overall impact (and thus affordability) of introducing chemopreventive
tamoxifen in addition to mammography screening to WVMP.
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CHAPTER 2

REVIEW OF LITERATURE
Ability to estimate costs and benefits of breast cancer preventive strategies in
women who are at high-risk of developing the disease is based on the premise that these
subgroup of high-risk women can be appropriately identified. Hence, the first section of
this chapter involves detailed discussion of breast cancer risk factors and their use in
models for identifying this population of women who are healthy but are at a high risk of
developing breast cancer. Clinical effectiveness of breast cancer preventive strategies
will be discussed next. Existing literature on economic evaluation of breast cancer
preventive strategies in high-risk populations will be critically examined in sections
thereafter. Finally, studies investigating relationship between perceived risk of breast
cancer, breast cancer knowledge and screening behavior will be reviewed.
Risk factors for Breast Cancer

Although it is still not possible to exactly predict who will develop breast cancer,
there are specific risk factors that place some women at higher risk of developing the
disease than others. Some of these risk factors have found wide acceptance among
today’s scientific community (Vogel, 1991) and include age, family history of breast
cancer, prior history of breast cancer, benign breast disease of proliferative patterns or
atypical hyperplasia, and endogenous endocrine factors such as menses duration, age of
menarche, and late pregnancies (Henderson, 1993). These risk factors are also termed as
non-modifiable risk factors as most women have little or no control over them.
Other risk factors for instance, environmental factors, which include dietary
habits, alcohol consumption, smoking, exposure to ionizing radiation, use of oral
contraceptives, and use of exogenous hormones in estrogen replacement therapy are
modifiable. However, a strong association between the modifiable risk factors and breast
cancer has yet to be established (Henderson, 1993).
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Non-modifiable Risk Factors
Gender: Being female can be considered to be the single most important risk factor for
developing breast cancer. Less than 1 % of all reported breast cancer occur in males
(Kopans, 1998).
Age: The probability that a woman will develop breast cancer increases with age, and
most breast cancers occur in the postmenopausal years (Henderson, 1993). Thus, besides
being female, age might be considered the single most important risk factor for breast
cancer. For instance, the risk of a 60-year old woman developing breast cancer is about
15 times that of a 30-year old woman (Kopans, 1998; American Cancer Society, 20012002; Henderson, 1993).
Family history: Family history of breast cancer, either in the maternal or paternal line,
increases the individual’s risk of developing breast cancer. Further, a relatively
substantial increase in risk is associated with breast cancer in a first degree relative:
mother, sister, or daughter and when two or more first-degree relatives have breast
cancer, the risk of developing breast cancer is further increased (Henderson, 1993).
Prior history of breast cancer: Studies (Kopans, 1998; Henderson, 1993) report that a
woman who has already had a breast cancer is at a greater risk of breast cancer recurrence
as compared to a woman with no history of breast cancer. Studies report this increased
risk in the range of 1 % to 14 % depending upon the period of follow up as the risk
increases with time.
Hormonal Status: Woman who have an early menarche or a late menopause are reported
to be at a higher risk for developing breast cancer (Kopans, 1998). A study (Kvale G et
al., 1988) involving 63,000 Norwegian women, reported that risk increased by 4 % for
every year of decrease in the age of menarche between ages 13and 16. The same study
also reported of a 3.6 % increase in risk for each year of delayed menopause. This may
be probably related to duration and type of hormonal effects on the breast (MacMohan,
1973).
Age at first full-term pregnancy: Late full term pregnancy is reported to be a risk factor
for developing breast cancer. Thus, a woman whose age at first birth was less than 19
years has approximately 50 % the breast cancer risk of a nulliparous woman (MacMohal
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et al., 1970). Moreover, a woman who has her first full term pregnancy by 18 years of
age has approximately one-fourth to one-third the risk of developing breast cancer in
comparison to a woman whose first full term pregnancy occurs after 30-years of age
(MacMohal et al., 1970).
Benign breast disease and atypical proliferative changes: Lack of sufficient data suggests
that benign breast disease may not be associated with increased risks of breast cancer.
However, benign breast disease accompanied by proliferative changes have been reported
to increase risk of developing breast cancer. Moreover, proliferation involving atypical
epithelial hyperplasia is associated with significantly increased risk. For instance,
women with atypical proliferative changes were 5 times more likely to develop breast
cancer than those women with non-proliferative changes (Dupont et al., 1985).
Modifiable Risk Factors
Use of exogenous hormones: Large numbers of case-control studies concerning estrogen
replacement have been conducted over the years. However, the results of these studies
have been contradictory. Some studies have shown a visible increased risk after use of
estrogen replacement, while others have shown no such increase. In fact, some studies
have actually found a decrease in breast cancer risk (Henderson, 1993). Effect of use of
oral contraceptive use on risk of developing breast cancer has also been studied using
meta-analysis. When considered together, these studies indicate no significant increase
in risk of breast cancer with use of oral contraceptives in the case-control studies
(Romieu et al., 1990). However, according to Henderson (1993), prolonged use of an
oral contraceptive might be associated with increased risk of breast cancer.
Environmental factors: There is strong evidence that one or more environmental factors
are associated with risk of breast cancer. Dietary habits, which is an environmental
factor, however, has received the greatest attention (Henderson, 1993). Alcohol intake
has been very strongly associated with breast cancer risk with studies showing strong
correlation of breast cancer risk and alcohol intake (Longnecker, 1988).
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Models for Assessing Individual Risk for Breast Cancer

There has been an increased demand for methods assessing breast cancer risk as
women, medical professionals, and decision makers are becoming more aware of factors
that might affect risk for breast cancer (McTiernan et al., 1997). Risk assessment for
breast cancer involves identifying certain factors in an individual woman that are
pertinent to her risk, and combining those factors into a quantitative or qualitative profile
(McTiernan et al., 1997). Significant numbers of models have been developed to assess
these risks. Some of the important models will be discussed in this section. The models
predicting breast cancer risks can be categorized based on the methodology that was
employed in risk determination. Thus, some models incorporate empirical estimates,
others employ statistical modeling, while still others employ epidemiological literature
review in breast cancer risk assessments. A review of these models revealed that all the
stated models include at least the age and the family history as risk factors for predicting
individual risk for breast cancer.
Genetic Susceptibility Models
These models derive the breast risk algorithms based on evidence of rare
autosomal dominant allele that results in increased susceptibility to breast cancer.
Models such as Ottman et al., (1983), Anderson et al., (1985), and Claus et al., (1994) fall
in this category.
Ottman et al., (1983) model
This model uses life table analysis (cumulative risk) of a population-based series of
breast cancer patients and their relatives to estimate the probabilities of developing breast
cancer. The cases included white women diagnosed between 1971 and 1975 with
unilateral or bilateral breast cancer before age 65.
Anderson et al., (1985) model
This model examined 556 breast cancer pedigrees, and empirically calculated risks for
breast cancer among relatives of cases. The population for the model involved women
between 20 to 70 years. The factors for risk assessment included breast cancer in
mothers, sisters, second-degree relatives, age of onset in relatives, and laterality. This
model was intended to be used for genetic counseling.
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Claus et al., (1994) model
This model employed statistical modeling in breast cancer risk assessment. The model
included 4,730 breast cancer cases and 4,688 controls aged 30 to 54 years derived from
Cancer and Steroid Hormone Study (McTiernan et al., 1997). This model incorporated
the autosomal dominant major gene model to predict breast cancer risk for relatives of
breast cancer patients (Claus et al., 1994). Factors for predicting breast cancer risk in this
model included age, breast cancer in first and second-degree relatives, and age of onset in
relatives. Similar to above two models, this model is intended for genetic counseling.
Risk-based Categorization Models
Taplin et al., (1990) model
This model used a risk-based selective approach to screening and was developed in a
health maintenance organization with 400,000 members. It places women in one of the
four risk categories depending upon the individual woman’s constellation of risk factors
(Taplin et al., 1990). The risk factors for the model were obtained from literature review
and included age, family history of breast cancer, benign breast disease, age at menarche,
age at menopause, age at first live birth, and nulliparity. This model has been proposed
to be used for screening decisions. The model included women of all ages.
Gail model and National Surgical Adjuvant Breast and Bowel Project’s (NSABP)
adaptation of the Gail model
Details of Gail model are described in Chapter 3. Validation of the original Gail model
revealed that the model over-estimated absolute risk by about 40 % in women below age
55 in the general population where regular screening is not performed (Gail M et al.,
1992). Consequently, the NSABP's Breast Cancer Prevention Trial used an adapted
version of Gail model (1989) in which the 1983-1987 average annual breast cancer rates
were substituted by the baseline incidence from the Breast Cancer Demonstration Project
(BCDP), and 1988 U.S. mortality rates for all causes other than breast cancer was
substituted the 1979 mortality rates originally used in Gail model.
As mentioned in Chapter 1, this study will make use of NSABP adapted version
of Gail model in order to minimize the breast cancer risk over-estimating nature of
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original Gail model. Moreover, Gail model is considered to be a "gold standard" in
breast cancer risk assessment (Spiegelman et al., 1994). Finally, the proposed application
of the Gail model is in concordance with the main objective of phase I of this study,
which is to determine the proportion of high risk population.
Prevention Management of Breast Cancer

Evidence for Clinical Efficacy of Primary Prevention Strategy
Tamoxifen is one of the first therapies to be investigated in the primary
prevention of breast cancer. Newer agents such as raloxifene are being developed and
tested for their potential in chemoprevention of breast cancer. However, these agents are
still under investigation and currently no concrete data exists to validate their potential in
primary prevention of breast cancer. Tamoxifen has been widely used for more than 20
years as an adjuvant therapy in treatment of breast cancer. Studies using animal models
have indicated that tamoxifen affects both the initiation and promotion of tumors
(Terenius

L, 1971; Jordan V, et al., 1980).

Furthermore, evidence on effectiveness of tamoxifen in reducing mortality and
recurrence in women with early stage breast cancer has been well established through
numerous trials, a review of which has been presented in the article by the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG, 1998). Other studies evaluating
tamoxifen as an adjuvant therapy for breast cancer found that the incidence of
contralateral breast cancer was reduced among patients who received tamoxifen (Noe et
al., 1999). These trial results along with studies in animal models led to development and
initiation of the NSABP’s Breast Cancer Prevention Trial (BCPT) protocol P-1 (Fisher et
al., 1998).
For this double-blind placebo-controlled multi-center randomized clinical trial,
women with high risk of breast cancer (n = 13,175) were enrolled at 131 sites in United
States and Canada. The eligibility criteria included women: (1) those older than 60 years;
(2) those with history of lobular carcinoma in situ; and (3) those with a > 1.6 % risk of
the development of breast cancer in 5 years based on a breast cancer risk algorithm
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developing by Gail and colleagues (Gail et al., 1989), predicting a woman’s risk of
development of breast cancer. The subjects received tamoxifen 20 mg per day or placebo
for an average of 47 months. Multiple outcomes were measured in this trial which
allowed quantification of both benefits as well as risks associated with tamoxifen.
Tamoxifen was found to reduce the relative risk of invasive breast cancer by
about 49 % in woman of all age groups (35 to 49, 50 to 59, and 60 and above). It also
reduced the relative risk of noninvasive breast cancer by about 50 %. However, women
above 50 years of age who were treated with tamoxifen had a greater relative risk for
developing endometrial cancer (RR = 4.01) and pulmonary emboli (Relative Risk (RR) =
3.19). Tamoxifen treated women also developed more cataracts (RR = 1.14) and
underwent more cataract surgeries (RR = 1.57) than their counterparts who received
placebo. In tamoxifen treated women older than 50 years of age, there were fewer
fractures of the hip, wrist and spine (RR = 0.79) and more stroke events (RR = 1.75) and
deep vein thrombosis (RR = 1.71). However, frequency of these events was not
significantly different than in women who were in the placebo group.
Tamoxifen’s role in primary prevention of breast cancer was also studied in two
European trials (Powles et al., 1998, Veronesi et al., 1998). The British trial by Powles
and colleagues (1998) involved 2,494 healthy women aged between 30 to 70 years with
family history of breast cancer. The experimental group received 20-mg tamoxifen per
day with the primary outcome being occurrence of breast cancer. The median follow-up
for this trial was 70 months. The overall frequency of breast cancer was found to be
similar in both groups. The trial failed to show any effect of tamoxifen on breast cancer
incidence in healthy women. The Italian trial by Veronesi and colleagues included 5,408
hysterectomised women between ages of 35 to 70 years. The experimental group
received the standard 20-mg per day dose of tamoxifen. The median follow-up for this
trial was 46 months. Once again, no significant difference between tamoxifen and
placebo groups was observed in terms of breast cancer occurrence.
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Differences in power to detect reduction in breast cancer incidence may have a
partial role in explaining conflicting results between the NSABP’s BCPT trial and the
two European trials (Pritchard K, 1998). The European trials were much smaller and
accumulated only a little more than two-thirds of the women-years of follow up in BCPT.
Further, baseline breast cancer incidence among the placebo group in the Italian trial was
significantly lower than in BCPT. It is suggested that higher population base coupled
with greater baseline breast cancer incidence in the BCPT is more conducive in terms of
demonstrating an effect.
Furthermore, differences in drug compliance, population age, and genetic
differences in the population selected in the trials may have contributed to the outcomes.
For instance, in the Italian trial as high as one-fourth of the study population dropped out
within one year of trial. For other women who continued to remain in the trial for more
than a year, a preventive effect was close to achieving a significance level (p = 0.16).
Women included in the British trial tended to be younger than the ones enrolled into
BCPT. For instance, about 60 % of women were aged under 50 years, as compared to 40
% in BCPT trial. Since all the preventive effect of tamoxifen in the BCPT was limited to
estrogen-receptor positive tumors, which tend to occur more in older women, age
differences between trials can be a factor influencing significance. Strong family history
of breast cancer, a main eligibility criterion in the British trial, was different than
eligibility rules set in BCPT trial, which were mostly non-genetic in nature. It is
suspected that prevention effect of tamoxifen may be different among these two
populations.
The BCPT trial had higher power and high internal consistency, and had an
acceptable drug compliance rate. Moreover, the percent breast cancer risk reduction
observed in the BCPT trial was very similar to preventive effect observed in the Early
Breast Cancer Trialists Collaborative Group (EBCTCG) trials (EBCTCG, 1998). Finally,
the USFDA approval for tamoxifen in breast cancer risk reduction was based on results
of NSABP’s BCPT trial, which involved the North American population, a population
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similar to the one that is being considered in the present study. Hence, results from the
NSABP’s BCPT trial will be employed in the current study.
Evidence for Clinical Efficacy of Secondary Prevention Strategy
The following discussion involving trials on efficacy of mammography screening
is restricted to randomized controlled trials (RCTs) which involved random division of
women population into two groups, one that was offered screening while other that did
not and served as unscreened control. A total of nine RCTs have been conducted since
the early 1960s in United States, Canada, and Europe.
Among the first screening trials was the Health Insurance Plan of the New York
trial, which investigated whether screening asymptomatic women for breast cancer using
mammography in conjunction with CBE could lower the death rates (Kopans, 1998).
The trial involved 62,000 women between ages of 40 and 64 years. The trial
demonstrated a mortality reduction of 23 % in screened women, which appeared about 3
to 5 years after the first screen (Shapiro, 1988).
The European trials evaluated efficacy of mammography in absence of CBE. The
first two Swedish trials also known as the Two County Trial (Koppaberg and
Ostergotland trials), were separate trials, although their results were presented together
(Nystrom et al., 1993). The combined study population of two trials was 134,867 and the
women involved were between ages of 40 and 74 years. The trial results demonstrated a
30 % mortality reduction for screened population (Tabar et al., 1985).
Another RCT in Malmö, Sweden involved 42,000 women aged 45 to 69 years old
(Anderson et al., 1988). Results from early follow-up indicated a 20 % mortality
reductions in women 55 years and older, although these reductions did not reach
statistical significance. A ten-year follow up indicated a high mortality reduction of 49 %
among women between ages of 45 to 49 years. A separate Stockholm trial, which
included 38,525 women aged 40 to 65 years old reported a mortality reduction of 21 %,
which did not achieve statistical significance owing to relatively small number of women
31

Literature Review

enrolled in the trial (Frisell et al., 1986). The Gothenburg trial included 52,000 women
aged 40 to 59 years old. The results from the trial indicate a 14 %, non-significant
mammography-screening attributed mortality reduction (Kopans, 1998).
A RCT in Edinburgh involved 45,130 women between ages of 45 to 64 years
(Roberts et al., 1990). The results of this trial indicate almost 20 % relative reduction in
mortality after 7 to 9 years of follow-up. Once again, due to small size of the trial the
results did not achieve statistical significance.
The National Breast Screening Study of Canada trial composed of two sub-trials.
The first determined efficacy of screening in women aged 40 to 49 years (Miller et al.,
1992(a)) while the second trial determined efficacy in women aged between 50 and 59
years (Miller et al., 1992(b)). Results from the former trial failed to demonstrate
significant mortality reduction between study and control groups. The second trial
evaluated individual contribution of mammography screening in mortality reduction by
comparing study group, which received both annual mammography and CBE, and
control group that only received annual CBE. As the second trial did not have an
unscreened control group, it could not be determined if there was any benefit for the
women participating in the trial from either approach to screening (Kopans, 1998).
In summary, these trials do indicate efficacy of mammography screening and its
potential in reducing death rate through routine screening (Fletcher, 1993). A metaanalytic study, which combined results from all of the trials, indicated survival benefits
from screening (Elwood et al., 1993). Based on updates of the seven RCTs (the two
NBSS trials were excluded), Wald and colleagues calculated a overall 22 % mortality
reduction though screening women 40 to 74 years old (Wald et al., 1994).
Controversy, however, exists regarding screening effectiveness in women
younger than 50 years of age. However, evidence from a meta-analytic study involving
combined results from seven randomized trials that included women aged 40 to 49 years
suggests a statistically significant mortality reduction of 24 % among women in this age
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group who were offered screening for breast cancer (Smart et al., 1995). Adding to this
evidence are two separate Swedish trials, which have shown statistically significant
reductions in breast cancer mortality for women in their forties (Hendrick et al., 1997).
In addition, these studies show that more frequent screening is significantly more
effective than biennial screening for women aged 40 to49 years (Report of the organizing
committee and collaborators, 1996; Bjurstam N et al., 1997).
Economics of Prevention Strategies

Effectiveness alone is not sufficient in most cases to warrant implementation of
clinical services. Other factors such as short term trade-offs and long term consequences
resulting from the clinical services should also be factored-in during the decision making
process (Siegel J et al., U.S. Preventive Services Task Force). Among widely used
approaches to quantify these trade-offs in terms of costs and consequences are through
use of decision-analytic modeling like decision trees and Markov models. Following is a
brief discussion providing rationale of choosing Markov model over decision tree
approach in the current study.
Although convenient, application of decision tree is mostly limited to situations
involving events that occur once over a relatively short period of time. For health
problems that are either chronic in nature or involve events that occur repeatedly over
time, decision tree approach becomes unmanageable. It is difficult to represent events
that are repetitive or that occur with uncertain timings using a simple decision tree model.
Markov modeling overcomes this hurdle by allowing provisions to incorporate time
dependent events.
The model assumes that an individual is always in one of the finite number of
states of health referred to as the Markov states. All events are then based as transitions
of individuals from one state to another. Individuals make these transitions during each
cycle, which are equal increments of time horizon of the analysis. The cycles are model
specific. For instance, a unit cycle may constitute one year for one model and one month
for other depending upon the clinical problem under consideration.
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The transitions between Markov states are governed by pre-specified probabilities
that are input in the model. These probabilities are known as transitional probabilities.
Each state is assigned a unique utility value. The utility contribution of this state to the
overall utility then depends on time that an individual spent in that particular state. For
instance, if all that needs to be calculated is a patient’s life expectancy, then utility of all
non-dead states can be assigned ‘one’. There is a state in Markov model, which is called
the absorbing state. Once an individual transits into this state, he or she cannot leave this
state. For instance, DEAD state is an absorbing state in many Markov models. Once an
individual is in the DEAD state, he or she remains in this state forever. The absorbing
state depends upon the effectiveness endpoint of the study and need not be ‘Death’ for all
models.
In general, two types of Markov models can be employed in medical decision
making. In the first type, the transition probabilities are constant or non-time dependent
while in the second type the transition probabilities vary over time. The former types of
models are ‘Markov chains’ while the latter types are ‘Markov processes.’ Markov
chains have somewhat limited applicability in that they can be applied only to those
clinical problems in which likelihood of moving between the health states can be
assumed to be constant. Constant transition probabilities are only possible for clinical
problems with short time horizons. In more chronic diseases, probabilities of moving
between states vary over time and thus are time-dependent (Beck J et al., 1983). For
instance, there is an exponential increase in annual mortality of healthy population with
increasing age (Gompertz B, 1825; Pauker S et al., 1981). This translates into an
increasing time-dependent probability of transiting into the ‘Death’ state.
Rising health care expenditures coupled with limited resources have spurred
interest in evaluating new and existing health services both in terms of their benefits and
costs. The next two sections include discussion about studies that have investigated
economic efficiency of breast cancer prevention techniques.
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Economic Evaluation of Primary Prevention Strategy
To date, only three studies have investigated the economic potential of tamoxifen
in chemoprevention of breast cancer. The first study, by Smith et al., (2000) assumed the
perspective of a health service payer and compared tamoxifen to no therapy. Results of
the NSABP’s BCPT (Fisher et al., 1998) were used to determine the cost-effectiveness of
tamoxifen. Cost data was obtained from the Agency for the Health Care Policy and
Research. The economic analysis evaluated the direct costs for the period of 5 years of
trial. The study reported that the cost to reduce the risk of invasive breast cancer for one
woman would be about $292,523. Assuming breast cancer deaths could be entirely
prevented by 5 years of tamoxifen, then women in their early forties would gain about
34.5 years of life at a 3 % discount rate. This translates into a cost-effectiveness ratio of
$8,479 per additional year of life gained.
The above study, however, made assumptions, which markedly differed, from real
world experiences. For instance, the study assumed that benefits of tamoxifen with
regards to reduction in breast cancer risk lasted a lifetime. This is in contrast to data
derived from a recent evaluation of use of adjuvant tamoxifen for treatment of breast
cancer in more than 37,000 women in 55 trials, which suggests that the protective effect
of tamoxifen may last at most for only about 5 more years in addition to the 5 year time
when the drug is being taken (EBCTCG, 1998).
A second study by Noe L et al., (1999) used a decision analytic model to estimate
the age-based incremental cost-effectiveness of using tamoxifen compared to no
intervention in primary prevention of breast cancer. A multi-stage Markov model was
developed to evaluate the incremental cost-effectiveness. The model was populated
based on data derived from the BCPT trial. Different health states involved in the
Markov model construction included invasive and non-invasive breast cancer,
endometrial cancer, pulmonary embolism, and cataract surgery. The economic
evaluation was performed from the payer’s perspective and hence out-of-pocket costs,
costs due to lost productivity and time lost from work and non-medical costs were not
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calculated in the study. Cost parameters were obtained from published literature and
were adjusted to reflect 1997 dollars. The primary effectiveness measure of the analysis
was additional life years saved and the cost-effectiveness ratio depicts additional lifetime
costs required to gain one extra year of life with tamoxifen in comparison to no therapy.
The cost and benefits were discounted at the rate of 3 % in the base case analysis.
Assuming a 5-year breast cancer protective effect of tamoxifen, it was reported that for
women in general regardless of age, the incremental cost per life year gained was
$63,896. However, this cost-effectiveness ratio varied across different age groups. For
women between ages of 35 and 49 years, the incremental cost per life year gained was
$41,372. The cost-effectiveness ratio increased for higher age groups and was $68,349
per life year gained for women between ages of 50 and 59 years and $74,981 per life year
gained for women between 60 and 69 years. When the assumption of tamoxifen’s
protective effect was increased to a total of 10 years, lower cost-effectiveness ratios of
$20,806, $36,431, and $41,621 per life year gained were reported for women belonging
to 35-49, 50-59, and 60-69 year age-groups, respectively.
The third study by Grann and colleagues was similar to the one just discussed. A
computer-based decision analysis, involving Markov model with Monte Carlo
simulations, was employed to construct the study model (Grann et al., 2000). The costeffectiveness results were adjusted for quality of life by including utility measures which
were obtained by administering a time-trade off questionnaire to a group of community
based women. Although, the Markov model constructed had similarities to Noe et al.,
(1999), it differed in terms of health states. Different health states included in the model
were good health, good health after stopping tamoxifen, invasive and non-invasive breast
cancer, hip fracture, thrombophlebitis, endometrial cancer, cataracts, and death. The
study assumed a total of 5-year breast cancer protective effect of tamoxifen. The base
case discount rate of 3 % was used in the analysis. The study reported that for women
who start using tamoxifen at age 35, the cost-effectiveness ratio is $46,619 per life year
saved. For women who start taking tamoxifen at age of 50 and 60 have costeffectiveness ratio of $82,784 and $122,401 per life year saved, respectively. The quality
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adjusted cost-effectiveness ratios were $76,318, $130,660, and $142,227 per quality
adjusted life years for women starting at age 35, 50 and 60 years, respectively.
The above two studies evaluated economic potential of chemopreventive
tamoxifen in isolation in the sense that they failed to include either benefits or costs of
mammography screening technique. As will be evident from the following discussion on
economic evaluation of secondary preventive strategy, mammography screening on its
own entails substantial cost but delivers benefits independent of chemopreventive
tamoxifen. Hence, any attempt to quantify economic efficiency of breast cancer
preventive strategies should not only include the primary strategies like chemopreventive
tamoxifen but also secondary strategies such as mammography screening. Moreover,
these trials also failed to factor in drug compliance, which is an important issue for
chronic therapies like chemopreventive tamoxifen that lasts for 5 years.
Economic Evaluation of Secondary Prevention Strategy
There have been numerous studies involving economic evaluation of
mammography screening. Economic evaluation of mammography screening have
compared different aspects of screening such as differences in screening interval, age
range of women undergoing screening, compliance with screening, and proportion of
women who show abnormalities and consequently have to undergo follow-up tests. The
following discussion will review some of these studies so as to provide an overview on
the economics of screening effectiveness for different screening intervals and across
different age-groups of women undergoing mammography screening.
A literature review of cost-effectiveness studies reveals significant variations in
the cost-effectiveness ratio for mammography screening. Part of these differences have
been due to difference in mortality reduction attributed to mammography screening, and
failure on part of some economic studies to include time lag between actual initiation of
mammography screening and time when benefits in terms of mortality reduction start
accruing (Feig S, 1995). Despite these differences in results, the cost-effectiveness of
mammography screening ranges from $3,400 to $28,700 in general.
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A study by Salzmann et al., (1997) compared cost-effectiveness of screening
women in different age groups. Different mammography screening interventions
compared were: (a) biennial screening from 50 to 69 years of age compared to no
screening, and (b) screening women between ages of 40 to 49 years every 18 months
followed by biennial screening from ages 50 to 69 years was compared to biennial
screening from ages 50 to 69 years. A Markov model was used to compare life
expectancy of women undergoing different breast cancer screening strategies. The
Markov health states included healthy, developed breast cancer and remained alive, dying
of breast cancer, and dying of another cause. The strategy, which involved screening
women between 55 to 69 years of age, resulted in increased life expectancy by 12 days.
This improved life expectancy came at the cost of $704 per woman translating into a
cost-effectiveness ratio of $21,400 per year of life year saved. The study also reported a
high incremental cost-effectiveness of $105,000 for extending mammography screening
to women between ages of 40 to 49 years.
A similar study by Rosenquist and Lindfors (1998) assessed cost-effectiveness for
four different strategies: (a) screening women annually from ages 40 to 79 years, (b)
screening women annually from 40 to 64 years and biennially from ages 50 to 79 years,
(c) screening women annually from ages 40 to 49 years and biennially form ages 50 to 79
years, and (d) screening women annually from ages 40 to 49 years followed by annually
from ages 50 to 79 years in normal risk women. Markov model was employed in order to
estimate the marginal cost-effectiveness of individual strategies. The outcome of interest
was marginal cost per year-life saved (MCYLS) and ranged from $18,800 to $16,100.
The authors concluded that MCLYS for all evaluated strategies were well within
accepted ranges.
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Perceptions of Breast Cancer Risk, Knowledge, and Preventive Service Utilization

To be able to make informed decisions regarding utilization of preventive
strategies, women need accurate information about their individualized risk of developing
breast cancer and effectiveness of different breast cancer preventive strategies (Black W
et al., 1995). Similarly, from a clinical practice standpoint, understanding a woman’s risk
perception is essential for risk management and decision making.
Many studies have investigated relationships between breast cancer risk
perception, knowledge, and screening behavior. Literature suggests that women’s
perception of breast cancer risk remains imprecise (Hopwood P, 2000). For instance, it
has been reported that prior to undergoing genetic risk counseling, only a small
proportion of women had an accurate view of their risk of developing breast cancer.
Moreover, a majority of women either over- or under-estimated their risk of developing
the disease (Evans D et al., 1993; Cull A et al., 1999). The extent of over-estimation of
risk was found to be greater in studies that were conducted in US (Lerman C et al., 1994;
Lerman C et al., 1995). Furthermore, it was reported that women who were actually at a
high risk of developing breast cancer, underestimated their risk as compared to woman of
average risk (Hopwood P, 2000).
A study involving 500 economically disadvantaged women reported that a large
majority of respondents did not perceive themselves to be susceptible to breast cancer.
The same study also reported that those who were most knowledgeable about breast
cancer were more likely to perceive themselves as being more susceptible to breast
cancer than their less knowledgeable counterparts (Price J, 1994).
A meta-analytic review investigated the relationship between a woman’s risk and
likelihood of obtaining mammography screening (McCaul K et al.,,1996). The study
reported positive correlation between perceived risk and undergoing mammography
screening. Another study involving middle class women aged 37 to 77 years reported
positive relationship between mammography screening and perceived susceptibility.
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Although a lot of studies have investigated the relationship between risk,
knowledge and screening behavior, very few studies have investigated this relationship in
populations similar to the one being currently studied, WV Medicaid. Moreover, as
chemoprevention in breast cancer using drugs like tamoxifen is a fairly recent
phenomenon, only a few studies have investigated the relationship between risk,
knowledge and inclination towards using such drugs. A study by Cyrus-David et al.,
(2001) involved a focus group of 26 women with an elevated risk for breast cancer. It
assessed the knowledge and attitudes of these women towards the use of SERMs, such as
tamoxifen and raloxifene. Knowledge of breast cancer risk factors and the perception of
personal risk for breast cancer were reported to influence the acceptance of breast cancer
chemoprevention treatment with selective estrogen receptor modulator (SERM). A
thorough review of literature at the time of this study revealed no study assessing these
relationships in socio-economically under-privileged populations like the Medicaid
population.
Mammography screening has been employed in breast cancer screening for over
twenty years and its effectiveness in detecting breast tumors early has been well
documented. A large number of studies have evaluated mammography screening from
an economic perspective and most of these studies have found the screening to be costeffective. Tamoxifen’s effectiveness in reducing risk of developing breast cancer has
also been shown. However, few studies have evaluated the economic effectiveness of
chemopreventive tamoxifen. Lastly, no study has evaluated the combined economic
potential of chemopreventive tamoxifen and mammography screening in breast cancer
prevention. The next chapter provides objectives for both phase I and II of this study
along with detailed methodology that will be employed in order to achieve the study
objectives
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CHAPTER 3

METHODOLOGY
The study will be conducted in two phases. Phase I involves development of a
life expectancy model with an economic component while phase II involves a selfadministered mail survey to assess West Virginia Medicaid Program (WVMP) women
enrollees’ actual and perceived breast cancer risk, breast cancer knowledge, current
utilization of breast cancer preventive services, and willingness towards
chemoprevention.
The objectives of the study were: (1) To develop a Markov process in order to
assess the long term clinical benefits of chemopreventive tamoxifen in conjunction with
mammography screening in women at high risk of breast cancer, (2) To develop a costeffectiveness model in order to determine the incremental costs and benefits of
introducing chemopreventive tamoxifen in conjunction with mammography screening,
(3) To assess WVMP women’s actual and perceived risk of developing breast cancer, (4)
To assess WV Medicaid women’s knowledge of breast cancer prevention strategies and
their compliance with these strategies, and (5) To assess sample women’s willingness to
use tamoxifen for primary prevention of breast cancer.
Phase I

Design of the Model
A Markov process with time- and state-dependent transition probabilities was
developed. DATA 3.5 TreeAgeTM software (TreeAge Software, Inc., 1999) was used to
develop the model. Incremental costs and consequences of using chemopreventive
tamoxifen and mammography in women at high risk for developing breast cancer was
determined using this model. The model incorporated all relevant costs and benefits that
were significantly affected by chemopreventive tamoxifen and mammography screening.
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The intervention was modeled based on its impact on disease risks and disease
mortality. More specifically, the breast cancer prevention effectiveness of tamoxifen was
modeled as decreased risk of developing invasive breast cancer (IBC) and non-invasive
breast cancer (NIBC). Similarly, the secondary preventive effectiveness of
mammography screening was modeled as reduction in breast cancer mortality over a
period of time. Detailed discussion on modeling these interventions is presented later in
this chapter.
Costs included in the model were tamoxifen therapy cost, cost of mammogram
including follow up costs resulting from abnormal mammogram findings, and cost of
treating tamoxifen-related adverse events such as endometrial cancer (EC), pulmonary
embolism (PE), and cataract surgeries (Cat-S).
A relatively short-term effectiveness outcome such as “number of breast cancers
averted” could have been incorporated in the current model. However, as the model
incorporates consequences for multiple diseases, short-term outcomes may not provide
meaningful information (Zethraeus N et al., 2000). A more composite outcome measure
of effectiveness is needed. This measure must account for both positive and negative
aspects of an intervention. Life-expectancy gain estimation is one such composite
outcome measure and was therefore incorporated in the current model as the
effectiveness outcome.
Operationalizing the Model
Tamoxifen therapy in primary prevention of breast cancer lasts for 5 years (Fisher
B et al., 1998). Consequently, the time frame (treatment duration) of the current study
was five years so as to coincide with the duration of chemoprevention tamoxifen therapy.
According to the American Cancer Society (ACS), all women after the age of 40 should
undergo mammography screening every year (American Cancer Society). These criteria
regarding chemopreventive tamoxifen therapy and mammography screening were
incorporated in the two tamoxifen intervention arms of the model. In the first
intervention arm, total compliance with mammography screening was assumed while in
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the second intervention arm mammography compliance rates were adjusted to reflect
those that were observed in real world setting. Women in the non-intervention arm of the
model did not get chemoprevention tamoxifen and underwent mammography screening
at ‘observed’ rates.
The chemopreventive tamoxifen and mammography screening intervention was
modeled based on its impact on disease risks and associated mortality. Tamoxifen and
mammography screening impact the natural history of disease differently. Tamoxifen
reduces incidence of breast cancers, thereby reducing the number of new breast cancers
and thus indirectly reducing breast cancer mortality in the high-risk population.
Mammography screening, on the other hand, detects some proportion of breast cancers at
an earlier stage, thereby improving both prognosis and survival of breast cancer patients
(Kopans, 1998). Hence, these two interventions of disease risk and mortality were
modeled in distinct ways.
Operationalizing the Model for Tamoxifen Intervention
Tamoxifen’s role in primary prevention of breast cancer was studied in the Breast
Cancer Prevention Trial (BCPT) (Fisher B et al., 1998). The subjects received tamoxifen
or placebo 20 mg per day for an average of 47 months in this placebo-controlled
randomized trial. Multiple outcomes were measured in this trial which allowed
quantification of both benefits as well as risks associated with tamoxifen.
Trial results showed that tamoxifen reduces risk of IBC and NIBC and increases
risk of other diseases such as EC, PE, and cataract (Fisher B et al., 1998). Tamoxifen
reduced the risk of IBC by 49 % and NIBC by 50 %. This risk reduction was observed in
all age groups. Tamoxifen significantly increased risk of other events: EC by 2.53 times,
PE by 3.0 times, and cataracts by 1.14 times. Frequencies of other events such as
coronary events, or bone fractures were not significantly different in the tamoxifen and
placebo groups (Sweeney F et al., 1999).
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Tamoxifen’s impact on risk of different diseases was then operationalized in the
model using the trial results. Event rates obtained from BCPT could not be directly used
in the model as rates by definition represent “pressure to transit at a given point in time”
(Miller D et al., 1994). Hence, the ‘rates’ were converted to ‘risks’ (probabilities) which
represent actual transitions by individuals in a cohort over a period of time (Miller D et
al., 1994). There are multiple ways to derive risks from rates: the simple cumulative
method, the actuarial method, and the density method. The density method was used to
convert rates into risks. This method uses estimated group-specific incidence densities
(rates) to calculate risk for a specific group or time-interval (Miller D et al., 1994).
Thus, when instantaneous transition rate remains constant during the entire time
period, the ∆-year risk, P(t0, t) is determined by:
P(to,t) = 1 – (Nt/N0) = 1- exp [- ID(∆)]
Where,
ID = estimated average rate
∆ = elapsed time (t – t0)
This formula was employed in order to determine transition risks (probabilities).
Operationalizing the Model for Mammography Screening Intervention
As per the ACS breast cancer screening guidelines, this study assumes that all
women entering the cohort will be eligible candidates for routine mammography
screening (as women enter the cohort at age of forty). Mammography screening trials
failed to show mortality reductions for 7 to 9 years of screening in women between ages
of 40 to 49 years (Kerlikowske K et al., 1995; Elwood J et al., 1993; Glasziou P et al.,
1995; Nystrom L et al., 1993). However, a study reported a statistically significant 16 %
mortality reduction (Kerlikowske K, 1997) after 10 to 14 years of initiation of screening
(Kerlikowske K et al., 1995; Nystrom et al., 1993; Tabar L et al., 1992). This aspect of
delayed benefit of mortality reduction associated with beginning mammography
screening at age 40 was incorporated into the model.

44

Methodology

Another study, which estimated efficacy of mammography screening, indicated a
27 % mortality reduction in women who began screening at 50 years of age (Kerlikowske
K et al., 1995). In this case there was a delayed benefit of 5 years after initiation of
screening (Kerlikowske K et al., 1995; Nystrom et al., 1993; Tabar L et al., 1992).
Thus, in the current model, women who began screening at 40 years of age will
experience a 16 % mortality reduction benefit of screening at age 50 years (a 10-year
delayed benefit). At age 55, this increases to 27 % (5 years delayed benefit). This
modeling approach was based on a previous study evaluating cost-effectiveness of
extending mammography screening to include women 40 to 49 years of age (Salzmann P
et al., 1997).
Operationalizing the Model for Mortality
The BCPT trial was not designed to determine mortality difference between
treatment groups. Furthermore, the follow up period of the trial was not long enough to
determine impact of tamoxifen-associated risk alterations of different events such as IBC,
NIBC, EC, PE, DVT, and cataract on mortality. Hence, mortality data obtained from
various published sources (details on these sources are discussed later in the section titled
‘Data for the model’) were used in order to determine annual risk of mortality from the
above mentioned events. Mortality rates were adjusted for each diseased and nondiseased state. These mortality rates, then, were further adjusted to reflect age-sex-race
(ASR) dependent mortality.
Model Structure and Simulation
The model structure is illustrated in Figure 3.1.
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Figure 3.1: The Transition State Diagram

IBC

NIBC

H-Tam
EC

Death

PE

H-noTam

DVT

Cat-S

H-Tam: Healthy with Tamoxifen; H-noTam: Healthy with no Tamoxifen; IBC: Invasive breast
cancer; NIBC: Non-invasive breast cancer; EC: Endometrial cancer; PE: Pulmonary embolism;
DVT: Deep vein thrombosis; Cat-S: Cataract surgery
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The model illustrates the possible transition of individuals between the distinct
health states. The model comprises of 9 distinct health states: 1. Healthy with tamoxifen
(H-Tam), 2. Healthy without tamoxifen (H-noTam), 3. Invasive breast cancer (IBC), 4.
Non-invasive breast cancer (NIBC), 5. Endometrial cancer (EC), 6. Pulmonary embolism
(PE), 7. Deep Vein Thrombosis (DVT), 8. Cataract surgery (Cat-S), and 10. Death.
At any given point in time, an individual woman could reside in one of the 9
states. Change of state, or transitions, that occurred over a fixed time interval are
illustrated as arrows in the Figure 3.1. All women started in one of the ‘healthy’ state,
either with or without tamoxifen, depending upon the cohort they belonged to. Health
states from 3 to 8 are disease states and are specifically included in the model because
tamoxifen can potentially alter their risks significantly either in the positive or negative
direction. The BCPT results suggest that tamoxifen will negatively affect (lower) risks of
developing IBC and NIBC, and positively affect (increase) risk of developing EC, PE,
DVT, and Cat-S. The ‘Health’ state has been separated into two distinct states, ‘H-Tam’
and ‘H-noTam’. This is to discriminate those women who were healthy and consumed
chemopreventive tamoxifen from those who were healthy but did not consume
chemopreventive tamoxifen. These two states have different costs and event rates and
consequently are represented as two distinct states. This structure also allows for the fact
that a woman who develop tamoxifen-related adverse events such as PE, DVT or cataract
surgery can return to healthy state with no tamoxifen (refer to assumption # 4 of phase I
in Chapter 3: women who develop any of the tamoxifen related adverse event stop
consuming tamoxifen).
As is evident from the model, individuals from all states ultimately transitioned to
‘Death’ state. No arrow comes out of the ‘Death’ state (which means that once a woman
transitions to the ‘Death’ state she remains in the ‘Death’ state forever). Thus the ‘Death’
state is termed as an absorbing state. This also means that in the due course of time, the
proportion of women in the non-dead states will gradually diminish while it will increase
in the ‘Death’ state.
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All women in the two tamoxifen intervention arms start in the ‘healthy with
tamoxifen’ state reflecting perfect initial health for all members of the cohort. Once the
simulation begins, the initial cohort gets distributed into different health states including
‘healthy with tamoxifen’ and ‘Death’ depending upon the pre-specified transition
probabilities. Women who survived each cycle (1 year) moved to the next cycle and
were exposed to the risk of dying or going into one of the remaining health states. All
transitions are assumed to occur instantaneously halfway through each cycle. However,
some transitions were restricted in the model so as to make the model more manageable.
Once the women developed IBC, NIBC, EC they were not allowed to move into
any of the two (with or without tamoxifen) healthy states. Moreover, health states such as
IBC and NIBC were given priorities over other events excluding death. For instance,
once a woman developed IBC, she stayed in that state or died due to IBC or other
competing causes (all cause mortality). If the woman developed NIBC first, then she
would stay in NIBC state or transit into IBC or Death state. Similarly, if a woman
developed EC then she would either remain in the EC state or was allowed to transit into
IBC, NIBC or Death state. Women in the remaining disease states such as PE, DVT, or
cataract could remain in that states but were also allowed to transit to any remaining
states excluding ‘healthy with tamoxifen’. In other words, it was assumed that once a
woman develops any of the adverse events associated with tamoxifen, she would be
immediately taken off the tamoxifen therapy and thus transit into a healthy state with no
tamoxifen (healthy with no tamoxifen state). For more information on a complete list of
assumptions and their justification please refer to the next section ‘Model Assumption
and Rationale’.
Intuitively, the cohort simulation should terminate when all members of the
cohort are dead (100 % of cohort in dead state). However, Markov processes in cohort
simulations are evaluated probabilistically as if the cohort has infinite number of
members (DATA TreeAgeTM software manual). Thus, although more and more
proportion of cohort members transit into ‘Death’ state over time, there is never a time
when all the members are in the ‘Death’ state. In other words, the proportion of members
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in ‘non-dead’ states, although declines and approaching zero, is never equal to zero.
Thus, an approximation has to be introduced to artificially terminate the cohort such that
the approximation error is minimal. The simulation can be terminated when any error
introduced due to ‘pre-mature’ termination of simulation is small compared to the totalpatient-cycles accumulated during the analysis (Beck J et al., 1983). The cohort in the
present study was thus followed till 99.999 % of cohort was in ‘dead’ state and the
remainder was treated as an error of approximation. This is a typical feature of life
expectancy models.
Model Assumptions and Rationale
1. Results from the National Surgical Adjuvant Breast and Bowel Project (NSABP)
Breast Cancer Prevention Trial (BCPT) protocol P-1 (Fisher et al., 1998) are
generalizable.
Rationale: The BCPT was a double-blind placebo-controlled multi-center trial
involving 131 sites throughout United States and Canada. It enrolled 13,175 high-risk
women with a total of 46,858 woman years of follow-up (Pritchard K, 1998). Hence,
it was assumed that results from the BCPT were robust and generalizable.
2. Invasive breast cancer (IBC) took precedence over other health events.
Rationale: It was assumed in the model that once a woman develops invasive breast
cancer, she could either remain in that state or die from invasive breast. No transition
for invasive breast cancer to any other state, other than ‘Death’ was allowed. This
was to avoid creation of multiple health states (for instance, IBC + EC health state, in
which a women has both IBC and EC) which have very low probability of
occurrence. For instance, based on results from BCPT trial, incidence rates for IBC
in all women is 3.43 per 1,000 women in tamoxifen group and 6.76 per 1,000 women
in placebo group (Fisher B et al., 1998). Incidence rates for EC were 2.3 per 1,000 in
tamoxifen group and 0.91 per 1,000 women in placebo group. Probability of these
two events occurring in the same woman (i.e. IBC+EC health state) will be about 8 *
10-6 in tamoxifen group and 6 * 10-6, extremely small likelihood as compared to
likelihood of occurrence of other events considered in the model.
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3. The model assumes that once a woman develops IBC, NIBC, or EC she cannot transit
into ‘healthy’ state.
Rationale: This assumption is based on the observation that although patients with
IBC, NIBC or EC can be in remission there is no cure for these cancers. Because
IBC consumes more resources than EC and because no multiple states were allowed,
it was assumed that patients with EC could transit to IBC but opposite was not true.
Similarly as NIBC consumes more resources than EC, one way transition from EC to
NIBC was allowed. On similar basis, as IBC consumed more resources than NIBC
one-way transition from NIBC to IBC was allowed but the opposite was not true.
4. Tamoxifen therapy will be stopped as soon as a woman develops any of the
tamoxifen related adverse events.
Rationale: This assumption in accordance with the clinic practice followed in the
BCPT trial.
5. It was assumed that once tamoxifen therapy is stopped, subsequent tamoxifen-related
excess risk of developing adverse events would cease as soon as the therapy is
stopped. In other words, there will not be any ‘spill-over’ effect of tamoxifen.
Rationale: Here the assumption is that there is no ‘spill over’ effect of tamoxifen.
Although this may not be true in all cases, there is no way to determine the exact
extent of this “spill-over” effect. This assumption was employed for both the
‘beneficial’ and ‘harmful’ effects of tamoxifen. Thus, if a woman ceases to be on
tamoxifen therapy, the breast cancer risk reducing effects of tamoxifen would cease
as soon as the therapy is stopped.
Data for the Model
The following section involves detailed description of data that was used to
populate the model. Different types of data that were required to populate the model
were: (1) risk (probabilities) of diseases, (2) all-cause and disease-specific mortality rates,
and (3) disease treatment costs.
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Risk of diseases
Incidence rates for diseases were obtained from the NSABP’s BCPT study. Table
3.1 illustrates average rates for women of all ages. However, in the model age-specific
rates were employed.

Table 3.1: Incidence Rates based on the BCPT study*
Disease

Tamoxifen Group

Placebo (Non-tamoxifen) Group

Invasive breast cancer

0.343%

0.676%

Non-invasive breast cancer

0.135%

0.268%

Endometrial cancer

0.230%

0.091%

Pulmonary embolism

0.069%

0.023%

Deep vein thrombosis

0.134%

0.084%

Cataract surgery

0.472%

0.300%

* Average rates for women of all ages. However, age-specific rates from the BCPT were actually used in
the model

All-cause and Disease-specific Mortality Rates
All cause age- and sex-adjusted mortality were obtained from U.S. Bureau of
Census (1991). Disease specific-mortality was obtained from other published sources.
Mortality rates for IBC and DVT were obtained form Noe et al (1999). Mortality rates
for NIBC and EC were obtained from American Cancer Society (American Cancer
Society, 2000) and mortality rates for PE were obtained from a study by Carson et al
(1992). As before, these rates were converted into probabilities using the density method
and were then used in the model to determine the life expectancy (LE) of the cohort.
Disease Treatment Costs
The analysis was performed from WV Medicaid’s perspective (payer’s
perspective) and hence only direct costs were incorporated in the analysis. Indirect costs,
for instance, cost due to lost productivity, time lost from work, and non-medical costs
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were excluded. Direct medical costs included cost of chemopreventive tamoxifen, cost of
mammography screening including follow-up costs resulting from abnormal
mammogram report, and the cost of treating the major medical complications, which
resulted from tamoxifen chemopreventive intervention as reported by the NSABP study.
These complications include endometrial cancer, pulmonary thromboembolism, deep
vein thrombosis, and cataract. Although, greater proportion of women in the tamoxifen
group experienced hot flashes and vaginal discharge than in the placebo group, costs of
treating such events were not included in the model as it is difficult to quantify costs for
treating such events. Cost estimates of interventions and disease management were
derived from literature and are presented in Table 3.2.
All costs were adjusted for increases in the medical care component of the
Consumer Price Index and are given in 2001 dollars (U.S. Bureau of Labor Statistics).
All costs and benefits will be discounted at a rate of 3 % in the base case analysis. This is
the discount rate accepted by Panel on Cost-Effectiveness in Health and Medicine, US
Public Health Service (Gold M et al., 1996, Siegel J et al.,1996). Due to controversy
surrounding the exact discount rate to be used in such studies, the model was separately
run using 0 % and 5 % discount rates as a part of sensitivity analysis for the model.
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Table 3.2: Treatment and Drug Costs
Item

Base-Case Cost*

Source

$16,122

Taplin et al., 1995

Invasive Breast Cancer
Initial care cost
Continuing care cost
Terminal care cost

$1,603
$ 25,869

Non-Invasive Breast Cancer
Initial care cost
Continuing care cost
Terminal care cost

$ 12,219

Taplin et al., 1995

$ 1,274
$ 16,104

Endometrial Cancer

$ 5,649

Hershman D et al., 2001

Pulmonary Embolism

$ 9,634

Noe L et al., 1999

Deep Vein Thrombosis

$ 4,435

Noe L et al., 1999

Cataract Surgery

$ 3,488

Hershman D et al., 2001

Tamoxifen 10 mg twice daily (annual cost)

$ 1,221

WV Medicaid reimbursement rates &
Drug Topics Red Book, 1999

Mammography Screening (including follow-up)

$ 100

* All figures adjusted to 2001 dollars and rounded to the nearest whole number
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The usual course of most cancers involves intensive therapy, which usually
involves surgery and chemotherapy immediately following diagnosis. This initial phase
is then followed by period when little cancer-related medical care occurs other than
monitoring for recurrence or metastases. Finally, the intensity of medical care increases
significantly prior to death of the cancer patient. Since this pattern of medical care
utilization is relatively consistent with most cancers, including breast cancer, Taplin et
al., (1995) divided the treatment costs of the patients into three distinct phases (1) initial
phase, (2) intermediate phase, and (3) terminal phase. This approach has widely been
used for calculating cancer related treatment costs (Riley G et al). Hence, the weighted
costs of treating invasive and non-invasive breast cancer were calculated based on
estimates obtained from Taplin et al., (1995) study. Thus, in the current model, patients
experience higher costs in the first six months after they develop breast cancer and six
months before they die due to breast cancer. These breast cancer patients continue to
experience the ‘continuing care cost’ when they are in the breast cancer state of the
model.
The endometrial cancer costs and cataract surgery costs were obtained from
published literature (Hershman D et al., 2001). These costs were based on Medicare
payments for 1998 from the Centers for Medicare and Medicaid (CMS) (previously
known as the Health Care Financing Administration (HCFA)). The pulmonary embolism
cost and deep vein thrombosis costs were obtained from a study by Noe and colleagues
(1999). Tamoxifen costs were based on 1999 Red Book prices. The WV Medicaid
reimbursement formula (AWP * 88% +$ 3.90) per prescription was used to calculate the
annual drug costs. The mammography screening costs were obtained from a study by
Salzmann P et al., (1997). The screening costs included cost of mammography
examination and cost of evaluating subsequent abnormal mammograms. The
mammography examination cost was based on Medicare reimbursement fee for
screening. In the Salzmann et al., study, the incremental cost due to abnormal
mammograms were calculated as a weighted average of procedures that followed
abnormal mammograms based on report by the National Cancer Institute’s National
Survey of Mammography Facilities (Brown et al., 1995).
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Phase II

Data for phase II of the study will be collected using a mail survey. This survey
was developed in order to assess the respondents’ individual risk of developing breast
cancer, their perceived risk of breast cancer, their current usage and inclination for using
breast cancer preventive strategies, and knowledge about these strategies.
Defining the Study Population
Population is an aggregation of study elements (Babbie, 1989). In most cases, it
is practically impossible to survey the entire population. In such cases, a statistically
desirable proportion of this population has to be studied. This proportion is called the
‘study sample.’
Results obtained from studying the ‘sample’ can then be extrapolated to the entire
population. The population for Phase I of this study consists of all white women 40 years
of age and above who are enrollees of WV Medicaid enrollees.
Sampling Technique
A study sample was drawn from the sampling frame using Simple Random
Sampling (SRS) without replacement technique (Kalton G, 1987). In this technique, the
randomly selected elements in the sample are not replaced to be given further chance of
selection. As SRS without replacement gives more precise estimators than sampling with
replacement, this technique was used in creating the sample.
Objectives of Phase II require either mean (for instance, knowledge scores) or
proportion (for instance, proportion of high-risk women) estimations. SRS technique
allows estimation of both means as well as proportion along with the associated
confidence interval (Kalton G, 1987).
Study Sample & Sample Size Determination
All white women aged 40 years and above, who were West Virginia Medicaid
enrollees in 1999 (the last year of available data) were included for study sample
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determination for phase I. The year 1999 was selected in order to utilize the latest
available enrollment data in order to increase the likelihood that study subjects surveyed
in 2002 will still be WVMP enrollees. The survey questionnaire will be administered to
randomly selected Medicaid women enrollees satisfying the study inclusion criteria.
As SRS is employed for sampling, the following formula will be used in order to
determine appropriate sample size (Kalton G, 1987).
n = (z/e)2 * π (1- π)
where,
n is the size of the sample
z is the number of standard errors for given confidence interval
π is the estimated proportion of people at high risk of developing breast cancer
e is the required estimator
Based on table of normal distribution (95 % of normal distribution falls within
1.96 standard deviations around the distribution’s means), for confidence level of 95 %, z
= 1.96. An estimator that is within 5 % of the population percentage with 95 %
probability will be employed in the study (Kalton G, 1987).
In the NSABP’s BCPT trial, risk assessments were performed for 98,018 women
out of whom 57,641 were deemed to be at high risk of developing breast cancer (Fisher et
al., 1998). In other words, a total of about 59 % were in high-risk group. Thus, in the
above equation ‘π’ should assume a value of 0.59. However, in the present context, a
conservative approach was taken for sample size calculation by assuming a value of 0.50
for ‘π’ yielding a higher required sample size.
Inputting values just discussed into the above equation yielded N ≅ 384.
Net Sample Size = (Gross Sample Size) * (Mail Response Rate) * (Usable Response
Rate)
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Hence, Gross Sample Size = Net Sample Size / (Mail Response Rate) * (Usable
Response Rate)
Based on studies involving Medicaid population, we assumed a conservative response
rate of 20 % for mail survey. Moreover, we assumed that about 90 % of responses will
be usable. Hence,
Gross sample size = 384 / 0.20 * 0.9 ≅ 2000
Thus, a total of 2000 Medicaid women recipients were surveyed.
Instrument Development
The questionnaire used for phase I of the study was a structured-undisguised
survey (Seltiz C, et al.,), whereby the purpose of the study was disclosed to the
respondents by means of a cover letter enclosed with the questionnaire. A detailed
description of the survey questionnaire is provided in the section titled ‘Survey
Questionnaire’.
Survey Questionnaire
The survey questionnaire was designed to gather information on following
components of breast cancer prevention management: (1) current utilization of breast
cancer preventive strategies, (2) perceived risk of developing breast cancer, (3) actual risk
of developing breast cancer as calculated by Gail model, (4) breast cancer and breast
cancer prevention knowledge, and (5) willingness to use breast cancer preventive
strategies.
For assessing utilization, the surveyed women were asked about their
mammography screening status over a period of time. Utilization of chemopreventive
tamoxifen was assessed in a similar manner. The next set of questions gathered
information on woman's perceived risk of developing breast cancer. The women were
asked to estimate their probability of developing breast cancer in next 5 years, and over
their entire lifetime. This perceived probability was then compared to actual probabilities
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of developing breast cancer as calculated using Gail Model (Gail et al., 1989). These
perceptions were measured across various age- and risk-groups.
Woman’s actual risk of developing breast cancer was assessed next. This
included obtaining information on woman’s age, age at menarche, age at first live birth,
number of previous biopsies, number of first degree relatives with breast cancer, and
presence of atypical hyperplasia (AH). This information was used in breast cancer risk
assessment. Gail model for breast cancer risk assessment was employed to do the same.
Relative risks calculation are based on an unconditional logistic regression that included
main effects of age at menarche (AGEMEN), number of previous breast biopsies
(NBIOPS), age at first live birth (AGEFLB), and number of first degree relatives with
breast cancer (NUMREL) (Gail et al., 1989). Also included in the equation are
interaction effects between AGECAT and NBIOPS and between AGEFLB and
NUMREL. The final logistic regression equation on basis of which the relative risks are
calculated is:
ln (relative risk)= -0.74948 + 0.09401(AGEMEN) + 0.52926(NBIOPS) +
0.21863(AGEFLB) + 0.95830(NUMREL) + 0.01081(AGECAT) 0.28804(NBIOPS*AGECAT) + 0.19081(AGEFLB*NUMREL)
The above mentioned risk factors are coded either as 0,1 or 2 depending upon
status of risk factors. For example, for a woman with no history of biopsy, the variable
NBIOPS was coded as 0. On the other hand if the women has undergone biopsy once or
more than once then variable NBIOPS are coded as 1 or 2, respectively, as the case may
be.
Women’s breast cancer and breast cancer prevention knowledge was measured
next. They were asked to choose one of the options from the response set of “Agree”,
“Don’t Agree”, or “Don’t Know” on questionnaire items such as “breast cancer risk
increases with increasing age" and "family history of breast cancer increases the personal
risk of getting breast cancer.”
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Questionnaire Validity
Faculty members from School of Pharmacy and Department of Community
Medicine, and individuals from the West Virginia Medicaid Bureau provided comments
on questionnaire, which were incorporated in order to enhance the content validity of the
questionnaire. Some of the aspects for assessing content validity included relevance of
questions, language understanding, and instruction clarity. Other aspects of testing
questionnaire included assessment of ease of reading, and readability levels of the
respondents.
Instrument Administration
Information needed to accomplish phase I was obtained by means of a mail
survey. The survey process was initiated with an introductory letter to randomly selected
WV Medicaid enrollees informing them about the study and the possibility that they
might receive a survey regarding the study. This introductory mailing was followed by a
total of three survey mailings in order to obtain sufficient responses to the survey. A
non-response survey was sent to a random sample of those individuals who did not
respond to any of the three mailings.
Data was collected over a period of two months from August to September 2002.
Approvals for all survey related documents were sought from both the West Virginia
Medicaid Bureau (WVMB) and the West Virginia University’s Institutional Review
Board (WVU-IRB). Once the documents were approved by the WVMB, they were sent
to WVU-IRB for an expedited review and final approval.
An initial letter from the WV Medicaid Commissioner, informing the survey
recipients about the study, was mailed about four days prior to the first questionnaire.
The questionnaire was mailed along with a cover letter signed by the WV Medicaid
Commissioner. The cover letter informed the recipients of the intent of the survey and
the importance of recipients to respond to the survey. The cover letter also emphasized
that participation in the survey was purely voluntary, assured them confidentiality, and
indicated that their services will not be affected by their participation or non59
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participation. A second mailing of the survey was sent to non-respondents two weeks
after the first survey. Non-respondents to the second survey were mailed a third survey.
Last, a non-response survey was mailed to those not responding to any of the three
surveys. The non-response survey collected information on breast cancer risk factors and
also reasons for non-participation.
Survey Assumptions
1. Women who responded to the survey were similar to the WV Medicaid women
population in terms of their demographics and breast cancer risk characteristics
Rationale: The survey questionnaire did not gather information on demographics
characteristics such as the socio-economic status as it was specifically designed to
estimate breast cancer risk and other aspects of breast cancer prevention management.
Moreover, some of the breast cancer risk information such as age of menarche that was
gathered in the survey is not usually available in any Medicaid data. Hence, comparison
of the respondents to the WV Medicaid women population was not possible. However,
the survey ‘sample’ was created based on the simple random sampling technique, which
ensures that each member of the population has equal probability of being selected in the
sample, thereby increasing the likelihood that the ‘sample’ is similar to the population
from which it was created.
2. Self–reported data and associated recall bias
Rationale: As most of the information required to estimate a woman’s risk of developing
breast cancer is not readily available in secondary databases and records, significant
amount of information for phase II of this study was self-reported. The assumption in the
study was that the recall bias was minimal. A ‘Don’t know’ response option was
provided in the survey questionnaire for majority of the questions so that the respondents
could mark that in case they did not know or recollect the information asked.
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CHAPTER 4

RESULTS
Phase I

Phase I involved the development of a Markov process that simulated three
hypothetical cohorts of women who were otherwise healthy but were at a high risk of
developing breast cancer. Women in the first cohort started consuming chemopreventive
tamoxifen at age 40 and continued to do so till they were 45 years old and had routine
mammography screening in accordance with the American Cancer Society’s (ACS)
breast cancer screening guidelines. Women in the second cohort started consuming
chemopreventive tamoxifen at age 40 and continued to do so till they were 45 years old
and underwent mammography screening at rates that were observed in the real-world
setting. Women in the third cohort also entered the model at the age 40 but did not
consume chemopreventive tamoxifen but underwent mammography screening at rates
that were observed in the real-world setting.
The following list of tables present the transition probabilities between different
health states. These transition probabilities dictate the distribution of cohorts among
different states at the end of each Markov cycle. As many of the transition probabilities
are time-dependent, it is not possible to report them in the same table. Table 4.1 lists
transition probabilities that are time-independent (remain constant and do not vary with
time) and provides reference table numbers for other transition probabilities that are timedependent.

61

Results

Table 4.1: Transition Probability Matrix
Health State H-Tam H-noTam
IBC
H-Tam

NIBC

EC

PE

DVT

Cat-S

Death

*

0.0654

Tab 4.2

Tab 4.2

Tab 4.2

Tab 4.2

Tab 4.2

Tab 4.2

f (ASR)

H-noTam

0.0000

*

Tab 4.3

Tab 4.3

Tab 4.3

Tab 4.3

Tab 4.3

Tab 4.3

f (ASR)

IBC

0.0000

0.0000

*

0.0000

0.0000

0.0000

0.0000

0.0000

f (ASR+ IBC)

NIBC

0.0000

0.0000

0.0069

*

0.0000

0.0000

0.0000

0.0000

f (ASR+ NIBC)

EC

0.0000

0.0000

0.0067

0.0027

*

0.0000

0.0000

0.0000

f (ASR+ EC)

PE

0.0000

0.8000

0.0067

0.0027

0.0011

*

0.0000

0.0000

f (ASR+ PE)

DVT

0.0000

0.8000

0.0067

0.0027

0.0011

0.0000

*

0.0000

f (ASR+ DVT)

Cat-S

0.0000

*

0.0067

0.0027

0.0011

9.9*10-5

0.0008

0.0000

f (ASR+Cat-S)

Death

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.000

1.000

*represents 1 – (sum of the other transition probabilities from a particular state)
f (ASR+ IBC): Function of age-sex-race adjusted all cause mortality + IBC specific mortality
f (ASR+ NIBC): Function of age-sex-race adjusted all cause mortality + NIBC specific mortality
f (ASR+ EC): Function of age-sex-race adjusted all cause mortality + EC specific mortality
f (ASR+ PE): Function of age-sex-race adjusted all cause mortality + PE specific mortality
f (ASR+ DVT): Function of age-sex-race adjusted all cause mortality + DVT specific mortality
f (ASR+ Cat-S): Function of age-sex-race adjusted all cause mortality + Cat-S specific mortality
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Non-compliance with chemopreventive tamoxifen was incorporated in the model
by allowing direct transition between the ‘H-Tam’ to ‘H-nonTam’ health state. Based on
BCPT, non-compliance was estimated to be 23.7 % over a four year period (the mean
follow-up time for the BCPT was 47.7 months which is about 4 years) (Fisher B et al.,
1998). The ‘density method’ was employed to determine ‘risk’ or ‘probability’ over the
time interval (Miller D et al., 1994) in the following manner
Pnon-compliance = 1 – [1 – 0.237]1/4 = 0.0654
Age-dependent rates of transition from the ‘H-Tam’ state to other states were
obtained from the BCPT. The density method was used to convert these rates into
transition probabilities. The calculated transition probabilities are reported in Table 4.2.
The beneficial and adverse events of chemopreventive tamoxifen taken for 5 years were
assumed to last for the time period over which it was consumed i.e. 5 years. Thus,
transitions between ‘H-Tam’ state to other states become equivalent to those observed in
the non-tamoxifen group after 5-year time interval.
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Table 4.2: Age-dependent probabilities [H-Tam to other health states]
Health State/Age (years)
Transition Probabilities
From H-Tam to IBC
40 –44

0.00376

45-49

0.00668

50-59

0.00626

60- above

0.00730

From H-Tam to NIBC
40 –44

0.00135

45-above

0.00268

From H-Tam to EC
40 –44

0.00132

45-49

0.00109

50-above

0.00076

From H-Tam to PE
40 –44

0.00019

45-49

0.00009

50-above

0.00031

From H-Tam to DVT
40 –44

0.0011

45-49

0.00078

50-above

0.00088

From H-Tam to Cat-S
40 –44

0.00471

45-above

0.00299

From H-Tam to Death
40 – above

Age-Sex-Race adjusted mortality (US Census)

H-Tam: Healthy with Tamoxifen, H-noTam: Healthy with no Tamoxifen
IBC: Invasive breast cancer, NIBC: Non-invasive breast cancer, EC: Endometrial cancer
PE: Pulmonary embolism, DVT: Deep vein thrombosis, Cat-S: Cataract surgery
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Table 4.3 presents transition probabilities from the ‘H-noTam’ group to other
health states in the model. A comparison of probability estimates in Table 4.3 and Table
4.2 will reveal that transition probabilities after the first 5 years of cohort simulation
assume same values. It accounts for the fact that the effect (both beneficial and adverse)
of chemopreventive therapy with tamoxifen ceases after 5 years.

Once a woman develops invasive breast cancer, it was assumed that she remains
in the ‘IBC’ state or dies, either from IBC or non-IBC related cause. Hence, no
transitions were allowed from IBC to any other health state except the ‘Death’ state. In
real life, it is possible for a woman with breast cancer to move to any of the above health
states. However, in modeling terms it means creating more states, for instance, IBC + EC
wherein a woman has both IBC and EC or even IBC + EC + PE wherein a woman
develops all three conditions. This makes the model very complex and unmanageable.
Justification for this assumption is provided in phase I assumption section in Chapter 3
(assumption # 2).
Similar assumptions were applied to transitions from ‘NIBC’ to other states. An
exception here was that an additional transition was allowed from ‘NIBC’ to ‘IBC’. In
fact, the transition probability from ‘NIBC’ to ‘IBC’ was adjusted higher than general
transition probability (to ‘IBC’ from other states) based on the published literature
indicating higher rates of NIBC progressing to become IBC. Women who develop EC
could either transition to ‘IBC’ or ‘NIBC’, remain in ‘EC’, or die due to EC or non-EC
related cause. These assumptions regarding transitions were relaxed for ‘PE’, ‘DVT’ and
‘Cat-S’ in the sense that women who develop any of these conditions could transit back
to healthy state, ‘H-noTam.’ For ‘Cat-S’, all transitions were possible except that a
woman could remain in the ‘Cat-S’ state for no more than one year (one cycle) as cataract
surgery is an acute event and does not extend beyond one year or in this case one cycle.
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Table 4.3: Age-dependent probabilities [H-noTam to other health states]
Health State/Age (years)
Transition Probabilities
From H-noTam to IBC
40 –44

0.00668

45-49

0.00668

50-59

0.00626

60- above

0.00730

From H-noTam to NIBC
40 –above

0.00268

From H-noTam to EC
40 –49

0.00109

50-above

0.00076

From H-noTam to PE
40 –49

0.00009

50-above

0.00031

From H-noTam to DVT
40 –49

0.00078

50-above

0.00088

From H-noTam to Cat-S
40 –above

0.00299

From H-noTam to Death
40 – above

Age-Sex-Race adjusted mortality (US Census)

H-Tam: Healthy with Tamoxifen, H-noTam: Healthy with no Tamoxifen
IBC: Invasive breast cancer, NIBC: Non-invasive breast cancer, EC: Endometrial cancer
PE: Pulmonary embolism, DVT: Deep vein thrombosis, Cat-S: Cataract surgery
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Transition from individual health states to ‘Death’ can be considered as a
function of two independent forces: f (TPdsm + TPm), where TPdsm is disease specific
mortality and TPm is all-cause mortality excluding the disease under consideration. This
function reflects the fact that an individual in a particular disease state may either die due
to that disease (TPdsm) or may die due to non-disease specific cause (TPm). TPm is also
referred to as all-cause mortality. Age-Sex-Race (ASR) adjusted all-cause mortality rates
were obtained from Statistical Abstract of the United States (U.S. Census Bureau (Vital
Statistics), 1998) to simulate age-dependent mortality rates among white women. These
rates were then converted into probabilities using the density method. Mortality
transition probabilities for each of the health states, except cataract (Cat-S), are reported
in the following tables (Table 4.4 to Table 4.8). Mortality from cataract surgery was
assumed to be ‘zero’. However, women with cataract surgery could still die from allcause mortality in the model.
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Table 4.4: Invasive Breast Cancer (IBC)-adjusted mortality rates
Age

Mortality

Age

Mortality

Age

Mortality

Age

Mortality

40

0.03323

50

0.03497

60

0.03990

70

0.05094

80

0.07938

41

0.03332

51

0.03530

61

0.04070

71

0.05094

81

0.07938

42

0.03342

52

0.03565

62

0.04154

72

0.05094

82

0.07938

43

0.03354

53

0.03601

63

0.04239

73

0.05094

83

0.07938

44

0.03367

54

0.03640

64

0.04328

74

0.05094

84

0.07938

45

0.03381

55

0.03683

65

0.04423

75

0.06166

85

0.65203

46

0.03398

56

0.03730

66

0.04423

76

0.06166

86

0.65203

47

0.03417

57

0.03784

67

0.04423

77

0.06166

87

0.65203

48

0.03440

58

0.03845

68

0.04423

78

0.06166

88

0.65203

49

0.03467

59

0.03914

69

0.04423

79

0.06166

>89

0.65203
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Table 4.5: Non-Invasive Breast Cancer (NIBC)-adjusted mortality rates
Age

Mortality

Age

Mortality

Age

Mortality

Age

Mortality

40

0.00328

50

0.00505

60

0.01008

70

0.02133

80

0.05032

41

0.00337

51

0.00538

61

0.01089

71

0.02133

81

0.05032

42

0.00347

52

0.00574

62

0.01174

72

0.02133

82

0.05032

43

0.00359

53

0.00611

63

0.01261

73

0.02133

83

0.05032

44

0.00372

54

0.00651

64

0.01352

74

0.02133

84

0.05032

45

0.00387

55

0.00695

65

0.01449

75

0.03226

85

0.63412

46

0.00404

56

0.00743

66

0.01449

76

0.03226

86

0.63412

47

0.00424

57

0.00797

67

0.01449

77

0.03226

87

0.63412

48

0.00447

58

0.00860

68

0.01449

78

0.03226

88

0.63412

49

0.00475

59

0.00930

69

0.01449

79

0.03226

>89

0.63412
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Table 4.6: Endometrial Cancer (EC)-adjusted mortality rates
Age

Mortality

Age

Mortality

Age

Mortality

Age

Mortality

40

0.03555

50

0.03732

60

0.04235

70

0.05360

80

0.08259

41

0.03564

51

0.03765

61

0.04316

71

0.05360

81

0.08259

42

0.03574

52

0.03801

62

0.04401

72

0.05360

82

0.08259

43

0.03586

53

0.03838

63

0.04488

73

0.05360

83

0.08259

44

0.03599

54

0.03878

64

0.04579

74

0.05360

84

0.08259

45

0.03614

55

0.03922

65

0.04676

75

0.06453

85

0.66639

46

0.03631

56

0.03970

66

0.04676

76

0.06453

86

0.66639

47

0.03651

57

0.04024

67

0.04676

77

0.06453

87

0.66639

48

0.03674

58

0.04087

68

0.04676

78

0.06453

88

0.66639

49

0.03702

59

0.04157

69

0.04676

79

0.06453

>89

0.66639

70
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Table 4.7: Pulmonary Embolism (PE)-adjusted mortality rates
Age

Mortality

Age

Mortality

Age

Mortality

Age

Mortality

40

0.02628

50

0.00305

60

0.00808

70

0.01933

80

0.04832

41

0.00137

51

0.00338

61

0.00889

71

0.01933

81

0.04832

42

0.00147

52

0.00374

62

0.00974

72

0.01933

82

0.04832

43

0.00159

53

0.00411

63

0.01061

73

0.01933

83

0.04832

44

0.00172

54

0.00451

64

0.01152

74

0.01933

84

0.04832

45

0.00187

55

0.00495

65

0.01249

75

0.03026

85

0.63212

46

0.00204

56

0.00543

66

0.01249

76

0.03026

86

0.63212

47

0.00224

57

0.00597

67

0.01249

77

0.03026

87

0.63212

48

0.00247

58

0.00660

68

0.01249

78

0.03026

88

0.63212

49

0.00275

59

0.00730

69

0.01249

79

0.03026

>89

0.63212

71
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Table 4.8: Deep Vein Thrombosis (DVT)-adjusted mortality rates
Age

Mortality

Age

Mortality

Age

Mortality

Age

Mortality

40

0.00628

50

0.00305

60

0.00808

70

0.01933

80

0.04832

41

0.00137

51

0.00338

61

0.00889

71

0.01933

81

0.04832

42

0.00147

52

0.00374

62

0.00974

72

0.01933

82

0.04832

43

0.00159

53

0.00411

63

0.01061

73

0.01933

83

0.04832

44

0.00172

54

0.00451

64

0.01152

74

0.01933

84

0.04832

45

0.00187

55

0.00495

65

0.01249

75

0.03026

85

0.63212

46

0.00204

56

0.00543

66

0.01249

76

0.03026

86

0.63212

47

0.00224

57

0.00597

67

0.01249

77

0.03026

87

0.63212

48

0.00247

58

0.00660

68

0.01249

78

0.03026

88

0.63212

49

0.00275

59

0.00730

69

0.01249

79

0.03026

>89

0.63212

72

Age

Mortality

Results

Base-case Analysis Results
A 3 % discount rate was applied to both, benefits as well as costs, in the base case
analysis. The 3 % discount rate was employed based on recommendation of the “Panel
on Cost-effectiveness in Health and Medicine” which was convened by the United States
Public Health Service (Gold M et al., 1996). This discount rate reflects the current
available data on real economic growth and corresponding estimates of the real
consumption rate of interest according to the panel.
Full mammography compliance was assumed in the ‘Tam + Optimal Mam
Screen’ cohort since one of the goals of the model was to estimate the incremental costs
and benefits of chemopreventive tamoxifen in presence of mammography screening
under optimal utilization criteria. In the ‘Tam + Non-optimal Mam Screen’ cohort, the
mammography screening compliance was assumed to be 46.7 % (Centers for Medicare
and Medicaid (CMS), 1999). This estimate was based on mammography screening rates
reported for the West Virginia Medicare beneficiaries who were enrolled in Medicaid.
Although this population is different than the women population under consideration in
terms of age and socioeconomic status, the mammography screening rates were the best
available large-scale estimates and hence were used in the model. Moreover, a one way
sensitivity analysis was performed on mammography rates to account for differences in
screening rates among the two populations. The same screening compliance of 46.7 %
was applied to the ‘NoTam + Non-optimal Mam Screen’ cohort.
Table 4.9 reports the distribution of patient life-years among different health
states and total life expectancy for the three cohorts based on model simulation. As
indicated in Table 4.9, the average life expectancy of cohort in the ‘Tam + Optimal Mam
Screen’ group was 21.585 years as compared to 21.539 years in the ‘Tam + Non-optimal
Mam Screen’ cohort and 21.463 years in the ‘NoTam + Non-optimal Mam Screen’
cohort. This amounts to an incremental life expectancy gain of 0.122 years (or 44.53
days) in the ‘Tam + Optimal Mam Screen’ cohort and 0.076 years (or 27.74 days) in the
‘Tam + Non-optimal Mam Screen’ as compared to the ‘NoTam + Non-optimal Mam
Screen’ cohort.
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Table 4.9: Simulated Cohort Life-Years* Distribution – Base-case
Health State

Tam + Optimal Mam

Tam + Non-optimal Mam

NoTam + Non-optimal

Screen (years)

Screen (years)

Mam Screen (years)

H-Tam

13.137

13.137

N/A

H-noTam

5.879

5.879

18.724

IBC

1.557

1.511

1.663

NIBC

0.714

0.714

0.804

EC

0.205

0.205

0.191

PE

0.006

0.006

0.005

DVT

0.021

0.021

0.019

Cat-S

0.066

0.066

0.057

Death

0.000

0.000

0.000

Total

21.585 years

21.539 years

21.463 years

* 3% discount rate
H-Tam: Healthy with Tamoxifen, H-noTam: Healthy with no Tamoxifen, IBC: Invasive breast cancer,
NIBC: Non-invasive breast cancer, EC: Endometrial cancer, PE: Pulmonary embolism, DVT: Deep vein
thrombosis, Cat-S: Cataract surgery

Patients in the non-tamoxifen cohort spent more time in the ‘IBC’ and ‘NIBC’
disease states (2.47 years in the ‘non-tamoxifen’ cohort versus 2.27 years in the ‘Tam +
Optimal Mam Screen’ cohort and 2.23 years in the ‘Tam + Non-optimal Mam Screen’ cohort)

while patients in the tamoxifen cohorts spent more time in the non-breast cancer disease
states (0.29 years in the ‘Tam + Optimal Mam Screen’ and ‘Tam + Non-optimal Mam Screen’
cohorts versus 0.27 years in the ‘NoTam + Non-optimal Mam Screen’ cohort).
These results are consistent with the fact that tamoxifen results in lowering risk of
IBC and NIBC while increasing risk of other disease conditions that are in the model.
Obviously, years spent is the ‘Death’ state cannot be counted as life years and so ‘zero’
years are indicated in the table for ‘Death’ state, irrespective of the amount of time that a
cohort spent in that state.
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These comparisons are shown in Figure 4.1 which is a graphical illustration of
simulated life years distribution among three broad combined health states: Healthy (HTam and H-noTam), Breast Cancer (IBC+NIBC) state, and Non-breast cancer state
(EC+PE+DVT+Cat-S).

Figure 4.1: Simulated Cohort Life-Years Distribution for Combined States– Base-case
Simulated Cohort Life-Years Distribution: Base Case
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0.298

0.298

0.272

2.271

2.225

2.467

19.016

19.016

18.724

Life years

21

20

19
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17
Tam + Optimal Mam Screen

Tam + Non-optimal Mam
Screen

NoTam + Non-optimal Mam
Screen

Non-Breast Cancer States

0.298

0.298

0.272

Breast Cancer States

2.271

2.225

2.467

Healthy States

19.016

19.016

18.724

Healthy States

Breast Cancer States

Non-Breast Cancer States

Magnitude of the costs within each disease state not only depends upon the cost of
treating that disease condition but also on the amount of time spent by an individual in
that disease state. Table 4.10 reports distribution of costs among different health states
and the total costs for the three cohorts. For instance, due to breast cancer risk reduction
attribute of chemopreventive tamoxifen, less average time is spent in the breast cancer
states (both IBC and NIBC) by individuals in the ‘tamoxifen’ cohorts as compared to
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individuals in the ‘non-tamoxifen’ cohort (refer to Table 4.9). Hence, breast cancer costs
(IBC + NIBC + Death; cost of the ‘Death’ state is included because costs in ‘Death’ state
incur as a result of ‘terminal’ breast cancer treatment) are lower in the ‘Tam + Optimal
Mam Screen’ cohort ($9,502.22) and ‘Tam + Non-optimal Mam Screen’ cohort
($9,467.79) as compared to ‘NoTam + Non-optimal Mam Screen’ cohort ($10,281.85)
(Table 4.10). As chemopreventive tamoxifen increases risk of other disease conditions
(EC, PE, DVT, and Cat-S), costs attributable to these conditions are higher in the ‘Tam +
Optimal Mam Screen’ cohort ($1,567.48) and ‘Tam + Non-optimal Mam Screen’ cohort
($1,551.76) as compared to ‘no-tamoxifen’ group ($1,427.06).
Table 4.10: Simulated Cohort Cost* Distribution – Base-case
Health

Tam + Optimal Mam

Tam + Non-optimal

NoTam + Non-optimal

State

Screen (years)

Mam Screen (years)

Mam Screen (years)

$6,892.34

$6,199.62

N/A

$581.61

$271.61

$865.05

IBC

$5,014.86

$4,940.39

$5,383.50

NIBC

$1,634.40

$1,634.40

$1,816.14

EC

$1,180.19

$1,169.37

$1,088.49

PE

$54.36

$54.07

$48.60

DVT

$96.59

$95.46

$87.23

Cat-S

$236.34

$232.87

$202.73

Death

$2,852.96

$2,893.00

$3,082.21

Total

$18,543.65

$17,490.79

$12,573.96

H-Tam
H-noTam

* 3% discount rate
H-Tam: Healthy with Tamoxifen, H-noTam: Healthy with no Tamoxifen, IBC: Invasive breast cancer,
NIBC: Non-invasive breast cancer, EC: Endometrial cancer, PE: Pulmonary embolism, DVT: Deep vein
thrombosis, Cat-S: Cataract surgery
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Figure 4.2 is a graphical illustration of simulated costs distribution among three
broad combined health states: Healthy (H-Tam and H-noTam), Breast Cancer
(IBC+NIBC+Death) state, and Non-breast cancer states (EC+PE+DVT+Cat-S).
Figure 4.2: Simulated Cohort Cost Distribution – Base-case
Simulated Cohort Cost Distribution: Base Case
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As is evident from the prior discussion, individuals in ‘tamoxifen’ cohorts
experienced a higher average survival than their counterparts in the ‘non-tamoxifen’
cohort (refer to Table 4.9). However, this improvement in expected survival came at a
cost (refer to Table 4.10). Incremental cost-effectiveness analysis was performed in order
to determine whether the additional costs that need to be expended for chemopreventive
tamoxifen to achieve additional benefits are justifiable. This involved determining
incremental cost-effectiveness ratios (ICER).
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An incremental benefit of 0.122 years in the ‘Tam + Optimal Mam Screen’ cohort
compared to ‘No-Tam + Non-optimal Mam Screen’ cohort at an incremental cost of
$5,969.70 resulted in an ICER of $48,931.80 per life year gained. This estimate is much
below the incremental cost-effectiveness ratio benchmark range of $50,000 to $100,000
per life year gained indicating that chemopreventive tamoxifen along with routine
mammography screening is cost effective in breast cancer risk reduction in high risk
women (Mark et al., 1995). An incremental benefit of 0.076 years in the ‘Tam + Nonoptimal Mam Screen’ cohort compared to ‘No-Tam + Non-optimal Mam Screen’ cohort
at an incremental cost of $4,916.84 resulted in an ICER of $64,695.20 per life year
gained. This ICER lies between the initially referred cost effective benchmark range of
$50,000 to $100,000 per life year gained indicating that chemopreventive tamoxifen in
presence of sub-optimal mammography screening may be cost effective in breast cancer
risk reduction in high risk women (Mark et al., 1995). These results are summarized in
Table 4.11.
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Table 4.11: Incremental Cost-effectiveness Ratios for the Cohorts1
Cohort
Life-expectancy
Incremental
(years)
Effectiveness2
(years)
21.463
No-Tam + Non-optimal Mam Screen

Cost
($)

Incremental
Cost2

ICER2

$12,573.95

Tam + Optimal Mam Screen

21.585

0.122

$18,543.65

$5,969.70

$48,931.80

Tam + Non-optimal Mam Screen

21.539

0.076

$17,490.79

$4,916.84

$64,695.20

1: at 3% discount rate
2: all interventions compared to the reference case: No-Tam + Non-optimal Mam Screen
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Univariate Sensitivity Analysis Results
The input estimates, both costs and effectiveness, that were used to populate the
Markov model were derived and integrated from various sources. Hence, similar to any
other economic model, the present model contains some level of uncertainty. A standard
method for dealing with uncertainty of input parameters is sensitivity analysis (Briggs A
et al., 1994). For the sensitivity analysis, the input parameters are varied over a certain
range and the cost-effectiveness ratios are recalculated. A comparison between the
original cost-effectiveness ratio and the sensitivity analysis cost-effectiveness ratios for
an input parameter provides indication of how sensitive the overall model results is to
changes in that particular parameter. If the results are found to be stable over a
reasonable variation in input parameter, the model’s conclusions are considered to be
robust (Gold M et al., 1996).
Traditional approaches to sensitivity analysis involve univariate analysis in which
one input parameter is varied at a time. Sensitivity analysis was first performed on
clinical parameters and then on cost parameters. Clinical parameters included in the
analysis were: compliance with screening mammography, compliance with
chemopreventive tamoxifen, effectiveness of tamoxifen in reducing risk of IBC and
NIBC, tamoxifen related adverse event risk, IBC and EC mortality rates.
Results of the ‘clinical’ parameter sensitivity analysis are reported in Table 4.12.
The first row in Table 4.12 are the base-case values and serve as a benchmark against
which all the subsequent derived values in the table can be compared. The first column
represents the ‘clinical’ parameters and the pre-specified range across which their values
were varied for sensitivity analysis.
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Table 4.12: One-way Sensitivity Analysis at 3 % Discount Rate: Efficacy Parameters
Parameter/range

§

§

§

§

§

§

Cohort 1
(Life-years)

Cohort 2
(Life-years)

Cohort 3
(Life-years)

Cohort 1
(Cost)

21.586

21.539

21.464

$18,543.64

$17,491.26

$12,573.96

21.586
21.586

21.531
21.547

21.455
21.473

$18,543.64
$18,543.64

$17,299.94
$17,674.74

$12,385.23
$12,754.97

21.584
21.587

21.537
21.541

21.464
21.464

$18,560.01
$18,526.88

$17,507.96
$17,474.10

$12,573.96
$12,573.96

21.565
21.606

21.518
21.56

21.464
21.464

$18,728.60
$18,357.94

$17,679.00
$17,302.10

$12,573.96
$12,573.96

21.578
21.593

21.531
21.547

21.464
21.464

$18,633.32
$18,453.46

$17,567.43
$17,414.93

$12,573.96
$12,573.96

20% up

21.475

21.426

21.338

$18,462.74

$17,408.45

$12,482.08

20% down

21.715

21.673

21.612

$18,638.74

$17,589.21

$12,682.62

21.568
21.606

21.522
21.559

21.448
21.483

$18,445.22
$18,660.08

$17,393.67
$17,606.68

$12,483.27
$12,681.25

Base Case

Cohort 2
(Cost)

Cohort 3
(Cost)

Mammography Compliance
Mammography Compliance (20% down)
Mammography Compliance (20% up)

Tamoxifen Compliance
Tamoxifen non-Compliance (20% up)
Tamoxifen non-Compliance (20% down)

IBC & NIBC Risk (Tam effectiveness)
20% up (worst case)
20% down (best case)

Adverse Events (EC, PE, DVT,Cat)
20% up (worst case)
20% down (best case)

Mortalities
IBC

EC
20% up
20% down

§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
H-Tam: Healthy with Tamoxifen, H-noTam: Healthy with no Tamoxifen, IBC: Invasive breast cancer, NIBC: Non-invasive breast cancer, EC: Endometrial
cancer, PE: Pulmonary embolism, DVT: Deep vein thrombosis, Cat-S: Cataract surgery
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The higher the deviation from the base-case value due to change in the ‘clinical
parameter’, the higher is the influence of that parameter on end-points, in this case ‘cohort lifeyears’ and ‘cohort costs’. This ability of ‘clinical’ parameters to influence ‘cohort life years’ and
‘cohort costs’ gets reflected in the final incremental cost-effectiveness ratios which are
summarized in Table 4.13. As is evident from Table 4.12, changes in ‘clinical’ input parameters
not only affect the clinical end-point such as ‘cohort life-years’ but also the ‘cohort costs.’ This
is because the final cost of the cohort not only depends upon cost of treating an individual
clinical state but also on amount of time that the cohort spent in that state.
Figures 4.3, 4.4, and 4.5 provide graphical summary of results presented in Table 4.13.
These figures illustrate the relationship between change in individual input parameter and their
influence on ICER. In all the figures, the X-axis represents the base case estimate and the bars
above and below the X-axis represent variation in the base case estimate resulting from variation
in the input parameters. As is evident from Figure 4.3, the two input parameters that have the
largest impact on ICER between the ‘Tam + Optimal Mam Screen’ and ‘NoTam + Non-optimal
Mam Screen’ are chemopreventive tamoxifen’s effectiveness in reducing risk of IBC and NIBC,
and assumption regarding mortality from IBC. Thus, an assumption of an increase in
chemopreventive tamoxifen’s effectiveness substantially decreases the ICER while an
assumption of decreased effectiveness increases the ICER. Figure 4.4 indicates that the two input
parameters which have the largest impact on ICER between the 'Tam + Non-optimal Mam
Screen' and ‘NoTam + Non-optimal Mam Screen’ are once again chemopreventive tamoxifen’s
effectiveness in reducing risk of IBC and NIBC and assumption regarding mortality from IBC.
Figure 4.5 indicates that the assumption regarding IBC mortality has the highest impact on the
ICER between 'Tam + Optimal Mam Screen' and 'Tam + Non-optimal Mam Screen'
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Table 4.13: One-way Sensitivity Analysis at 3 % Discount Rate: Efficacy Parameters and Incremental Analysis*
Parameter/range

ICER
Cohort 1 vs. 3

ICER
Cohort 2 vs. 3

ICER
Cohort 1 vs. 2

Base Case

$48,931.80

$65,564.03

$22,391.02

$47,010.76
$51,227.17

$64,667.20
$66,483.39

$22,612.78
$22,279.46

$49,883.75
$48,397.72

$67,589.08
$63,638.18

$22,383.98
$22,886.52

$60,937.07
$40,732.30

$94,537.81
$49,251.51

$22,331.96
$22,953.07

$53,152.28
$45,577.52

$74,529.40
$58,324.95

$22,678.51
$22,576.72

20% up

$43,654.46

$55,981.47

$21,516.16

20% down

$57,826.43

$80,435.90

$24,988.86

$49,682.90
$48,608.38

$66,356.77
$64,808.30

$22,859.72
$22,412.77

Mammography Compliance
Mammography Compliance (20% up)
Mammography Compliance (20% down)

Tamoxifen Compliance
Tamoxifen non-Compliance (20% up)
Tamoxifen non-Compliance (20% down)

IBC & NIBC Risk (Tam effectiveness)
20% up (worst case)
20% down (best case)

Adverse Events (EC, PE, DVT, CAT)
20% up (worst case)
20% down (best case)

Mortalities
IBC

EC
20% up
20% down

* all interventions compared to the reference case: No-Tam + Non-optimal Mam Screen

§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam
Screen
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Figure 4.3: Sensitivity Analysis: Tam + Optimal Mam Screen vs. NoTam+Non-optimal
Mam Screen
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Figure 4.4: Sensitivity Analysis: Tam + Non-optimal Mam Screen vs. NoTam + Nonoptimal Mam Screen
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Figure 4.5: Sensitivity Analysis: Tam + Optimal Mam Screen vs. Tam + Non-optimal
Mam Screen
Tam+Optimal Mam Screen vs. Tam+Non-optimal Mam Screen
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Results of the ‘cost’ parameter sensitivity analysis are reported in Tables 4.14, 4.15, 4.16,
4.17, 4.18, and 4.19. The first rows in each of these tables are the base-case values and serve as
a benchmark against which all the subsequent derived values in the table can be compared to.
The first column represents the ‘cost’ parameters and the pre-specified range across which their
values were varied for sensitivity analysis.
The higher the deviation from the base-case value due to change in the ‘cost parameter’,
the higher is the influence of that parameter on end-points, in this case ‘cohort costs’. Unlike,
clinical parameters, which influence both ‘cohort life years’ and cohort costs,’ ‘cost parameters’
only influence ‘cohort costs’ as is evident from following tables.
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Table 4.14: One-way Sensitivity Analysis at 3 % Discount Rate: Cost Parameters for IBC and NIBC
Parameter/range

Base case

§

§

§

§

§

§

Cohort 1
(Life-years)

Cohort 2
(Life-years)

Cohort 3
(Life-years)

Cohort 1
(Cost)

21.586

21.539

21.464

$18,543.65

$17,491.26

$12,573.96

21.586
21.586

21.539
21.539

21.464
21.464

$18,963.67
$18,123.63

$17,911.27
$17,071.24

$13,027.15
$12,120.78

21.586
21.586

21.539
21.539

21.464
21.464

$19,179.55
$17,906.70

$18,113.16
$16,868.32

$13,254.93
$11,891.87

21.586
21.586

21.539
21.539

21.464
21.464

$18,975.87
$18,111.43

$17,930.68
$17,051.83

$13,042.97
$12,104.96

21.586
21.586

21.539
21.539

21.464
21.464

$18,663.55
$18,423.75

$17,611.15
$17,371.35

$12,704.93
$12,442.99

21.586
21.586

21.539
21.539

21.464
21.464

$18,762.22
$18,325.08

$17,709.82
$17,272.69

$12,818.42
$12,329.51

21.586
21.586

21.539
21.539

21.464
21.464

$18,616.86
$18,470.44

$17,564.47
$17,418.04

$12,651.07
$12,496.86

Cohort 2
(Cost)

Cohort 3
(Cost)

IBC
Initial Care Cost
20% higher
20% Lower

Maintenance Cost
20% higher
20% Lower

Terminal Care Cost
20% higher
20% Lower

NIBC
Initial Care Cost
20% higher
20% Lower

Maintenance Cost
20% higher
20% Lower

Terminal Care Cost
20% higher
20% Lower

§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
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Table 4.15: One-way Sensitivity Analysis at 3 % Discount Rate: Cost Parameters and Incremental Analysis for IBC and
NIBC*
Parameter/range
ICER
ICER
ICER
Cohort 1 vs. 3
Cohort 2 vs. 3
Cohort 1 vs. 2
$48,931.86
$65,563.88
$22,391.40
Base case
IBC
Initial Care Cost
20% higher
20% Lower

$48,659.97
$49,203.75

$65,121.60
$66,006.15

$22,391.40
$22,391.40

$48,562.40
$49,301.92

$64,776.41
$66,352.63

$22,688.98
$22,093.34

$48,630.34
$49,233.38

$65,169.52
$65,958.23

$22,238.02
$22,544.79

$48,841.10
$49,022.62

$65,416.24
$65,711.43

$22,391.40
$22,391.53

$48,719.63
$49,144.08

$65,218.64
$65,909.10

$22,391.43
$22,391.40

$48,899.98
$48,963.75

$65,512.01
$65,615.75

$22,391.40
$22,391.40

Maintenance Cost
20% higher
20% Lower

Terminal Care Cost
20% higher
20% Lower

NIBC
Initial Care Cost
20% higher
20% Lower

Maintenance Cost
20% higher
20% Lower

Terminal Care Cost
20% higher
20% Lower

*all interventions compared to the reference case: No-Tam + Non-optimal Mam Screen
Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
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Table 4.16: One-way Sensitivity Analysis at 3 % Discount Rate: Cost Parameters for Non-breast Cancer States
Parameter/range
Cohort 1§
Cohort 2§
Cohort 3§
Cohort 1§
Cohort 2§
Cohort 3§
(Life-years)
(Life-years)
(Life-years)
(Cost)
(Cost)
(Cost)
21.586
21.539
21.464
$18,543.65
$17,491.26
$12,573.96
Base case
EC Cost
20% higher
20% Lower

21.586
21.586

21.539
21.539

21.464
21.464

$18,775.63
$18,311.68

$17,723.23
$17,259.28

$12,789.90
$12,358.03

PE Cost
20% higher
20% Lower

21.586
21.586

21.539
21.539

21.464
21.464

$18,554.41
$18,532.89

$17,502.02
$17,480.49

$12,583.64
$12,564.29

DVT Cost
20% higher
20% Lower

21.586
21.586

21.539
21.539

21.464
21.464

$18,562.55
$18,524.76

$17,510.15
$17,472.36

$12,591.23
$12,556.70

Cat-S Cost
20% higher
20% Lower

21.586
21.586

21.539
21.539

21.464
21.464

$18,589.62
$18,497.69

$17,537.22
$17,445.29

$12,613.98
$12,533.95

§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
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Table 4.17: One-way Sensitivity Analysis at 3 % Discount Rate: Cost Parameters and Incremental Analysis for Non-Breast
Cancer States*
Parameter/range
ICER
ICER
ICER
Cohort 1 vs. 3
Cohort 2 vs. 3
Cohort 1 vs. 2
$48,931.86
$65,563.88
$22,391.40
Base case
EC Cost
20% higher

$49,063.36

$65,777.78

$22,391.40

20% Lower

$48,800.35

$65,349.96

$22,391.40

PE Cost
20% higher
20% Lower

$48,940.75
$48,922.94

$65,578.37
$65,549.33

$22,391.36
$22,391.47

DVT Cost
20% higher
20% Lower

$48,945.21
$48,918.50

$65,585.59
$65,542.15

$22,391.41
$22,391.40

Cat-S Cost
20% higher
20% Lower

$48,980.62
$48,883.09

$65,643.18
$65,484.55

$22,391.41
$22,391.40

* all interventions compared to the reference case: No-Tam + Non-optimal Mam Screen
Cohort 1: No-Tam + Non-optimal Mam Screen, Cohort 2: Tam + Optimal Mam Screen, Cohort 3: Tam + Non-optimal Mam Screen
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Table 4.18: One-way Sensitivity Analysis at 3 % Discount Rate: Cost Parameters for Intervention Strategies
Cohort 1§
(Life-years)
21.586

Cohort 2§
(Life-years)
21.539

Cohort 3§
(Life-years)
21.464

Cohort 1§
(Cost)
$18,543.65

Cohort 2§
(Cost)
$17,491.26

Cohort 3§
(Cost)
$12,573.96

20% higher

21.586

21.539

21.464

$19,662.18

$18,609.78

$12,573.96

20% Lower

21.586

21.539

21.464

$17,425.12

$16,372.72

$12,573.96

21.586
21.586

21.539
21.539

21.464
21.464

$18,925.88
$18,161.61

$17,669.76
$17,312.84

$12,749.53
$12,398.49

Parameter/range
Base case
Tamoxifen Cost

Mammography Screening Cost
20% higher
20% Lower

§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
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Table 4.19: One-way Sensitivity Analysis at 3 % Discount Rate: Cost Parameters and Incremental Analysis for Intervention
Strategies*
Parameter/range
ICER
ICER
ICER
Cohort 1 vs. 3
Cohort 2 vs. 3
Cohort 1 vs. 2
$48,931.86
$65,563.88
$22,391.40
Base case
Tamoxifen Cost
20% higher

$58,100.14

$80,477.61

$22,391.41

20% Lower

$39,763.58

$50,650.14

$22,391.41

$50,625.83
$47,238.74

$65,603.00
$65,524.75

$26,726.09
$18,058.94

Mammography Screening Cost
20% higher
20% Lower

* all interventions compared to the reference case: No-Tam + Non-optimal Mam Screen
Cohort 1: No-Tam + Non-optimal Mam Screen, Cohort 2: Tam + Optimal Mam Screen, Cohort 3: Tam + Non-optimal Mam Screen
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Figures 4.6, 4.7, and 4.8 provide graphical summary of results presented in Tables
4.15, 4.17, and 4.19. In all the figures, the X-axis represents the base case estimate and
the bars above and below the X-axis represent variation in the base case estimate
resulting from variation in the input parameters.
As is evident from Figure 4.6, the two input parameters that have the largest
impact on ICER between the ‘Tam + Optimal Mam Screen’ and ‘NoTam + Non-optimal
Mam Screen’ are cost of chemopreventive tamoxifen and cost of mammography
screening.
Figure 4.7 indicates that the single most influential input parameter that
substantially affects the ICER between 'Tam + Non-optimal Mam Screen' and 'NoTam +
Non-optimal Mam Screen' is chemopreventive tamoxifen cost.
Figure 4.8 indicates that the single most influential input parameter that
substantially affects the ICER between 'Tam + Non-optimal Mam Screen' and 'NoTam +
Non-optimal Mam Screen' is cost of mammography screening.
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Figure 4.6: Sensitivity Analysis: Tam + Optimal Mam Screen vs. NoTam + Non-optimal
Mam Screen
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Figure 4.7: Sensitivity Analysis: Tam + Non-optimal Mam Screen vs. NoTam + Nonoptimal Mam Screen
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Figure 4.8: Sensitivity Analysis: Tam + Optimal Mam Screen vs. Tam + Non-optimal
Mam Screen
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Discounting
Discounting principle is based on the assumption that costs that are incurred and
benefits that are realized in the present time are not equivalent to the ones that are
incurred or realized in some point in the future (Kielhorn A, Graf van der Schulenburg,
2000). A discount rate of 3 % was used to perform the base case analysis based on
recommendations of the “Panel on Cost-effectiveness in Health and Medicine”(Gold M
et al., 1996). However, the same panel also recommended using the traditional discount
rate of 5 % in the sensitivity analysis as a large number of studies have used this discount
rate in their analysis. Hence, results using 5 % discount rate have been presented in
Table 4.20 and 4.21. The same table also reports results of bivariate sensitivity analysis,
which was performed changing both the discounting rate and the individual clinical
parameter at the same time. Thus, the first row in Table 4.20 reports univariate
sensitivity analysis results of changing the discount rate alone while all rows thereafter
report the bivariate results.
In addition to using, 5 % discount rate, the analysis was also performed at 0 %
discount rate (undiscounted costs and benefits), the results of which are reported in
Tables 4.22 and 4.23. The base case results using 0 % discounting rate are reported in the
first row followed by bivariate sensitivity analysis results in the rows thereafter.
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Table 4.20: One-way Sensitivity Analysis at 5 % Discount Rate: Efficacy Parameters
Parameter/range

§

§

§

§

§

§

Cohort 1
(Life-years)

Cohort 2
(Life-years)

Cohort 3
(Life-years)

Cohort 1
(Cost)

16.145

16.118

16.070

$14,308.99

$13,530.30

$8,509.82

16.145
16.145

16.114
16.123

16.075
16.065

$14,308.99
$14,308.99

$13,388.61
$13,666.15

$8,643.56
$8,370.33

16.143
16.146

16.117
16.119

16.070
16.070

$14,322.54
$14,295.08

$13,544.14
$13,516.09

$8,509.82
$8,509.82

16.132
16.158

16.105
16.132

16.070
16.070

$14,466.35
$14,151.00

$13,690.63
$13,369.34

$8,509.82
$8,509.82

16.14
16.15

16.113
16.123

16.070
16.070

$14,383.91
$14,233.66

$13,592.41
$13,468.06

$8,509.82
$8,509.82

20% up

16.082

16.054

15.998

$14,299.69

$13,520.74

$8,499.04

20% down

16.216

16.192

16.154

$14,319.70

$13,541.37

$8,522.31

16.134
16.156

16.108
16.130

16.061
16.081

$14,250.12
$14,377.23

$13,471.94
$13,597.96

$8,455.92
$8,572.32

Base Case

Cohort 2
(Cost)

Cohort 3
(Cost)

Mammography Compliance
Mammography Compliance (20% down)
Mammography Compliance (20% up)

Tamoxifen Compliance
Tamoxifen non-Compliance (20% up)
Tamoxifen non-Compliance (20% down)

IBC & NIBC Risk (Tam effectiveness)
20% up (worst case)
20% down (best case)

Adverse Events (EC, PE, DVT,Cat)
20% up (worst case)
20% down (best case)

Mortalities
IBC

EC
20% up
20% down

§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
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Table 4.21: One-way Sensitivity Analysis at 5 % Discount Rate: Efficacy Parameters and Incremental Analysis*
Parameter/range

ICER
Cohort 2 vs. 1

ICER
Cohort 3 vs. 1

ICER
Cohort 2 vs. 3

Base Case

$77,322.24

$104,593.33

$28,840.30

$80,934.71
$74,326.05

$121,668.00
$91,464.89

$29,689.61
$29,219.73

$79,626.32
$76,121.82

$107,113.30
$102,168.78

$29,938.31
$28,851.41

$96,073.06
$64,104.35

$148,023.34
$78,379.42

$28,730.11
$30,063.81

$83,915.54
$71,547.98

$118,199.91
$93,551.75

$29,314.52
$28,355.37

20% up

$69,055.36

$89,673.30

$27,819.46

20% down

$93,506.31

$132,080.71

$32,430.17

$79,372.66
$77,398.81

$106,723.79
$102,564.04

$29,930.23
$29,972.04

Mammography Compliance
Mammography Compliance (20% down)
Mammography Compliance (20% up)

Tamoxifen Compliance
Tamoxifen non-Compliance (20% up)
Tamoxifen non-Compliance (20% down)

IBC & NIBC Risk (Tam effectiveness)
20% up (worst case)
20% down (best case)

Adverse Events (EC, PE, DVT,Cat)
20% up (worst case)
20% down (best case)

Mortalities
IBC

EC
20% up
20% down

* all interventions compared to the reference case: No-Tam + Non-optimal Mam Screen
§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
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Table 4.22: One-way Sensitivity Analysis at 0 % Discount Rate: Efficacy Parameters
Parameter/range

§

§

§

§

§

§

Cohort 1
(Life-years)

Cohort 2
(Life-years)

Cohort 3
(Life-years)

Cohort 1
(Cost)

37.252

37.135

36.974

$32,603.11

$30,712.25

$26,074.74

37.252
37.252

37.115
37.155

36.995
36.952

$32,603.11
$32,603.11

$30,369.34
$31,041.36

$26,401.11
$25,734.72

37.248
37.256

37.131
37.139

36.974
36.974

$32,627.16
$32,578.40

$30,736.66
$30,687.17

$26,074.74
$26,074.74

37.209
37.295

37.09
37.181

36.974
36.974

$32,861.70
$32,343.46

$30,974.47
$30,448.96

$26,074.74
$26,074.74

37.235
37.269

37.119
37.152

36.974
36.974

$32,711.96
$32,494.16

$30,821.88
$30,602.40

$26,074.74
$26,074.74

20% up

36.962

36.841

36.654

$32,138.87

$30,240.35

$25,561.97

20% down

37.602

37.493

37.363

$33,167.19

$31,289.31

$26,702.01

37.211
37.302

37.094
37.185

36.935
37.020

$32,367.08
$32,891.84

$30,478.22
$30,998.40

$25,855.41
$26,342.92

Base Case

Cohort 2
(Cost)

Cohort 3
(Cost)

Mammography Compliance
Mammography Compliance (20% down)
Mammography Compliance (20% up)

Tamoxifen Compliance
Tamoxifen non-Compliance (20% up)
Tamoxifen non-Compliance (20% down)

IBC & NIBC Risk (Tam effectiveness)
20% up (worst case)
20% down (best case)

Adverse Events (EC, PE, DVT,Cat)
20% up (worst case)
20% down (best case)

Mortalities
IBC

EC
20% up
20% down

§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
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Table 4.23: One-way Sensitivity Analysis at 0 % Discount Rate: Efficacy Parameters and Incremental Analysis*
Parameter/range

ICER
Cohort 2 vs. 1

ICER
Cohort 3 vs. 1

ICER
Cohort 2 vs. 3

Base Case

$23,483.35

$28,804.44

$16,161.17

$24,132.30
$22,894.63

$33,068.64
$26,141.10

$16,304.84
$16,100.46

$23,913.97
$23,062.63

$29,693.81
$27,954.16

$16,158.12
$16,164.32

$28,880.69
$19,528.75

$42,239.09
$21,131.53

$15,859.04
$16,618.44

$25,429.98
$21,760.77

$32,738.90
$25,436.31

$16,293.83
$16,168.92

20% up

$21,353.56

$25,018.07

$15,690.23

20% down

$27,050.95

$35,286.95

$17,228.19

$23,593.00
$23,223.10

$29,074.29
$28,214.99

$16,144.06
$16,183.26

Mammography Compliance
Mammography Compliance (20% down)
Mammography Compliance (20% up)

Tamoxifen Compliance
Tamoxifen non-Compliance (20% up)
Tamoxifen non-Compliance (20% down)

IBC & NIBC Risk (Tam effectiveness)
20% up (worst case)
20% down (best case)

Adverse Events (EC, PE, DVT,Cat)
20% up (worst case)
20% down (best case)

Mortalities
IBC

EC
20% up
20% down

* all interventions compared to the reference case: No-Tam + Non-optimal Mam Screen
§ Cohort 1: Tam + Optimal Mam Screen, Cohort 2: Tam + Non-optimal Mam Screen, Cohort 3: No-Tam + Non-optimal Mam Screen
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Sensitivity analysis suggested that the overall results of the model were not
substantially affected over the range of variables confirming that the study results were
robust.
Tamoxifen in Hysterectomized Women (sub-group analysis)
One of the major side effects of tamoxifen is an increased risk of endometrial
cancer (Fischer et al., 1998). Hence, an additional analysis was performed to determine
incremental survival benefits and incremental cost per life years gained in
hysterectomized women who were healthy but at a higher risk of developing breast
cancer. As there is no risk of developing endometrial cancer in this cohort of women, a
‘zero’ probability of transiting to disease state ‘EC’ was assigned to both
‘chemopreventive tamoxifen plus mammography screening’ cohort and ‘mammography
screening’ cohort. Chemopreventive tamoxifen plus screening mammography with
optimal compliance was found to yield an average survival benefit of 0.129 years (about
47 days) at an incremental cost of $5,897 resulting in ICER of $45,712 per life year
gained. Similarly, chemopreventive tamoxifen plus screening mammography at rates
observed in real-world setting was found to yield an average survival benefit of 0.083
years (about 30 days) at an incremental cost of $4,840 resulting in ICER of $58,308 per
life year gained. As is evident, the ICERs in hysterectomized women was slightly better
than in general women population who were at a high risk of developing breast cancer.
These lower ICERs can be explained on basis that the increased risk of endometrial
cancer in chemopreventive tamoxifen group, which had a diminishing effect on average
survival and positive effect on cost, was eliminated in the hysterectomized women.
Phase II

Phase II of this study involved a cross sectional mail survey of randomly selected
white women 40 years of age and older who were enrollees of West Virginia Medicaid
Program (WVMP). A total of 2,000 surveys were mailed initially followed by a second
and a third mailing to all non respondents from previous mailings. Out of the 2,000
surveys, a total of 498 surveys were returned due to wrong address resulting in a
reachable sample size of 1502. A total of 606 responses were obtained from three
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mailings yielding a response rate of 40.34 %. However, 25 women among the 606
respondents noted they were diagnosed with invasive breast cancer at some point in time
and were excluded from further analysis yielding an eligibility rate of 95.87 % (eligibility
rate = 581/606).
A total of 41 women returned the non-respondent survey. The most common
reasons for non-response was ‘I do not respond to surveys’ followed by ‘lost the survey,’
‘I am not interested in this issue.’ A student’s t-test analysis that was performed to
compare any age differences among the respondents and non-respondents revealed that
there was no significant differences between the two groups (respondent’s mean age:
55.2 years (SD: 7.62 years) vs. non-respondent’s age: 56.9 (SD: 6.05 years), p = 0.165).
Furthermore, there were no differences in terms of ‘proportion of women at high risk of
developing breast cancer’ in the two groups.
Data Analysis
Data analysis was done using Statistical Package for Social Sciences – Version 10
software (Copyright © 2002, SPSS Inc.). Average age of responding women was about
55.2 years (SD: 7.62 years, range: 27 years - 68 years) out of which 26.5 % were 49 years
of age or less, 40.0 % were between 50 to 59 years of age, and 33.5 % were 60 years or
older. Table 4.24 reports the baseline characteristics of all responding women who met
the eligibility criteria of not having invasive breast cancer.
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Table 4.24: Characteristics of All Respondents
Item/Variable

N (Valid %)

Breast Cancer Prevention Behavior
Ever had mammography
Yes
No
Not sure
Total

521 (90.5%)
54 (9.3%)
01 (0.2%)
576 (100.0%)

How long since the last mammography
Less than a year
> 1 year but < 2 years
> 2 years
Total

259 (50.7%)
132 (25.8%)
120 (23.5%)
511 (100.0%)

Ever taken tamoxifen
Yes
No
Not sure
Total

02 (0.3%)
556 (96.7%)
17 (3.0%)
575 (100.0%)

Actual Risk of Breast Cancer1
Women not at high risk(5-year risk <1.7%)
Women at high risk(5-year risk >1.7%)
Total

258 (46.7%)
295 (53.3%)
553 (100.0%)

Perceived Risk of Breast Cancer
Five-year perceived risk of breast cancer
Lower than an average woman
Similar to an average woman
Higher than an average woman
Not sure
Total

84 (15.0%)
137 (24.4%)
65 (11.6%)
275 (49.0%)
561 (100.0%)

Lifetime perceived risk of breast cancer
Lower than an average woman
Similar to an average woman
Higher than an average woman
Not sure
Total

79 (13.9%)
154 (26.5%)
81 (14.3%)
253 (44.6%)
567 (100.0%)

1: Actual risk as calculated by Gail Model (1989)
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As is evident from Table 4.24, a majority of women (90.5 %) had undergone
mammography screening at some point of time. However, only 50.7 % of respondents
reported to have had mammography screening in the past year and were thus deemed to
be compliant consistent with the ACS breast cancer screening guidelines(American
Cancer Society, 2002). With respect to primary prevention behavior through use of
chemopreventive tamoxifen, the majority of women reported to have never taken the
drug for breast cancer risk reduction.
The information provided by the respondents on their age, age of menarche, age
at first live birth, family history of breast cancer, number of previous biopsies and their
results was inputted into the ‘Breast Risk Assessment’ software (based on Gail model,
1989) developed by Cardinal Health System Inc. (Copyright 2000 ©, Cardinal Health
Systems Inc.) in order to obtain women’s five-year relative risk of developing breast
cancer. Based on the criteria used in the BCPT trial (Fischer et al., 1998) any woman
below age of 60 years was deemed to be at high risk of breast cancer if her 5-year relative
risk was equal to or above 1.7 %. Also, consistent with the BCPT trial eligibility criteria,
any women who was 60 years of age or older was deemed to be at high risk of breast
cancer irrespective of her actual breast cancer risk determined through the Gail model
(1989). Based on these criteria, about 53 % of respondents were estimated to be at high
risk for breast cancer and thus eligible for chemoprevention.
Frequency runs on five-year and lifetime perceived risk revealed that most
women were not sure about their 5-year and lifetime risk of developing breast cancer
(49.0 % and 44.6 %, respectively). This was followed by about 25 % women who
perceived themselves to be at a similar 5-year risk of developing breast cancer to that of
an average woman and about 27 % women who perceived themselves to be at a similar
lifetime risk of developing breast cancer as compared to an average women. A relatively
lower proportion of women perceived themselves to be at a higher risk of breast cancer
(11.6 % for 5-year risk and 14.3 % for lifetime risk).
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A total of fourteen questions assessed respondent’s knowledge of breast cancer,
its risk factors, and mammography screening. A summary of their responses is reported
in Table 4.25.
Table 4.25: Proportion of women correctly responding to knowledge items
Knowledge Item

Proportion
(Valid %)

Mammograms can detect breast lumps early

85.0 %

One mammogram is enough to ensure that you will not get breast cancer

82.1 %

Regular mammography screening reduces the risk of dying from breast cancer

77.1 %

Women with close relatives with breast cancer have higher risk of breast cancer

75.6 %

Mammography can cure breast cancer

70.4 %

Mammography can spread breast cancer

62.8 %

The risk of breast cancer increases with age

53.7 %

A woman currently using birth control pills has a slightly greater risk of breast cancer as
compared to a woman not using them

46.8 %

Long term use of estrogen replacement therapy (also known as hormone replacement
therapy) after menopause, slightly increases breast cancer risk

45.3 %

Breast cancer is usually painful when it is just getting started

35.5 %

Breast cancers can be prevented

29.6 %

Giving birth to a first child after 30 years of age increases the risk of breast cancer

17.5 %

Obesity (being overweight) is a risk factor for breast cancer

17.4 %

Alcohol consumption increases the risk of developing breast cancer

16.5 %
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For all the fourteen knowledge items, the responses were collected on a ‘agree’,
‘don’t agree’, and ‘don’t know’ scale. A ‘don’t know’ response was deemed to be an
incorrect response and was added to the incorrect response tally. In general, respondents
were very knowledgeable on questions pertaining to mammography screening as is
evident from Table 4.25. Eighty-five percent of the respondents believed that
mammograms can detect breast lumps early and about 82 % respondents agree with the
fact that one mammogram was not enough to ensure secondary prevention through
mammography screening. Also, a high number (about 77 %) of respondents agreed with
the statements about mammography screening’s ability to reduce the risk of dying from
breast cancer. Respondents were least knowledgeable with respect to dietary issues such
as ‘alcohol consumption’ and ‘obesity’ and its relationship to breast cancer risk with only
16.5 % and 17.4 % responding correctly to questions on alcohol consumption and
obesity, respectively. Interestingly, a large proportion (about 70 %) of respondents
reported that breast cancers can be prevented. A knowledge index was created by
summing up all fourteen knowledge items and dividing the total knowledge score by
fourteen (prior to adding the responses, all correct responses were coded as ‘1’ while all
other responses were coded as ‘0’). This resulted in a knowledge index between 0 and 1
for every respondent. The standardized item alpha for the knowledge index was found to
be 0.79 indicating high internal consistency. This knowledge index was then used for all
further analysis.
As indicated in Table 4.24 about 53 % of the respondents were at high risk of
developing breast cancer. Baseline characteristics of this sub-group is presented and
discussed next.
Average age of high-risk women who responded to the survey was 59.9 years
(SD: 6.20 years, range: 42 years - 68 years) out of which 8.8 % were 49 years of age or
less, 28.1 % were between 50 to 59 years of age and 63.1 % were 60 years or older.
Table 4.26 reports additional baseline characteristics of these high-risk women.
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Table 4.26: Characteristics of Respondents at High Risk for Breast Cancer
Item/Variable

N (Valid %)

Breast Cancer Prevention Behavior
Ever had mammography
Yes
No
Total

273 (92.5%)
22 (7.5%)
295 (100.0%)

How long since the last mammography
Less than a year
> 1 year but < 2 years
> 2 years
Total

143 (54.0%)
68 (25.7%)
54 (20.4%)
265 (100.0%)

Ever taken tamoxifen
Yes
No
Not sure
Total

2 (0.7%)
287 (97.6%)
5 (1.7%)
294 (100%)

Perceived Risk of Breast Cancer
Five-year perceived risk of breast cancer
Lower than an average woman
Similar to an average woman
Higher than an average woman
Not sure
Total

40 (13.9%)
58 (20.1%)
41 (14.2%)
149 (51.7%)
288 (100.0%)

Lifetime perceived risk of breast cancer
Lower than an average woman
Similar to an average woman
Higher than an average woman
Not sure
Total

30 (13.4%)
72 (24.8%)
45 (15.5%)
134 (46.2%)
290 (100.0%)
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As is evident from Table 4.26, a majority of women (92.5 %) had undergone
mammography screening at some point of time. Fifty-four percent of these women
reported to have had mammography screening in the past year and were thus deemed to
be compliant consistent with breast cancer screening guidelines of the American Cancer
Society (American Cancer Society, 2002). With respect to primary prevention through
use of chemopreventive tamoxifen, the majority of women (about 98 %) reported to have
never taken the drug for breast cancer risk reduction.
Frequency runs on five-year and lifetime perceived risk revealed that most
women were not sure about their 5-year and lifetime risks of developing breast cancer
(51.7 % and 46.2 %, respectively). This was followed by about 20 % women who
perceived themselves to be at a similar 5-year risk of developing breast cancer to that of
an average woman and about 25 % women who perceived themselves to be at a similar
lifetime risk of developing breast cancer as compared to an average woman. A relatively
lower proportion of women perceived themselves to be at a higher risk of breast cancer
(14.2 % for 5-year risk and 15.5 % for lifetime risk).
Table 4.27 reports responses of these high-risk women on the 14 knowledge items
of breast cancer, its risk factors, and mammography screening.
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Table 4.27: Proportion of high-risk women who gave correct responses on knowledge
items
Knowledge Item

Proportion
(Valid %)

Mammograms can detect breast lumps early

85.4%

One mammogram is enough to ensure that you will not get breast cancer

83.1%

Regular mammography screening reduces the risk of dying from breast cancer

78.6%

Women with close relatives with breast cancer have higher risk of breast cancer

72.9%

Mammography can cure breast cancer

67.1%

Mammography can spread breast cancer

60.3%

The risk of breast cancer increases with age

49.2%

A woman currently using birth control pills has a slightly greater risk of breast
cancer as compared to a woman not using them

46.4%

Long term use of estrogen replacement therapy (also known as hormone
replacement therapy) after menopause, slightly increases breast cancer risk

46.4%

Breast cancer is usually painful when it is just getting started

35.6%

Breast cancers can be prevented

27.5%

Giving birth to a first child after 30 years of age increases the risk of breast cancer

20.0%

Alcohol consumption increases the risk of developing breast cancer

16.6%

Obesity (being overweight) is a risk factor for breast cancer

16.3%
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Relationships between Actual Risk of Breast cancer, Perceived Risk of Breast Cancer,
Breast Cancer Knowledge, and Screening Behavior
The relationship between a respondent’s actual 5-year risk (as determined by the
Gail, model. 1989) and perceived 5-year risk of developing breast cancer was assessed by
determining correlation coefficients between the two variables. The original 5-year
perceived risk variable was re-coded to include patients who perceived themselves to be
either at high or low risk of developing breast cancer. Those respondents who perceived
themselves as having similar risk to an average woman or who were not sure about their
5-year breast cancer risk were excluded from this analysis. As both the variables i.e. the
perceived of breast cancer as well as actual risk of breast cancer were dichotomous in
nature, ‘Phi’ correlation coefficient, instead of Pearson Product-Moment Correlation, was
determined. A statistically significant (r = 0.167, p = 0.045) positive correlation was
observed between the perceived 5-year risk and actual 5-year risk. However, the
magnitude of correlation was found to be low (Miller L, 1994) and a ‘coefficient of
determination’ calculation indicated that only 2.8 % of variance in 5-year perceived risk
is accounted for by actual risk.
Differences in knowledge index scores between high-risk respondents and their
low-risk counterparts were investigated using t-tests. Interestingly, low-risk respondents
were found to have significantly higher mean knowledge scores as compared to
respondents who were at a high risk of developing breast cancer (low risk group = 0.54
(+ 0.21) vs. high risk group = 0.50 (+ 0.22), p = 0.036). Further details are presented in
Table 4.28.
A chi-square test was performed to assess if there was a relationship between
respondent’s actual risk of breast cancer and their mammography screening behavior. No
significant relationship was observed between a woman’s actual risk of breast cancer and
her compliance with mammography screening.
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Table 4.28: Knowledge Score and Respondent’s Actual Risk of Breast CanceR
Mean† (+SD)

t-statistic

Df

Sig.

Low risk women

0.54 (+0.21)

-2.10

549.67

0.036*

High risk women

0.50 (+0.22)

Item
Actual risk of breast cancer

*significant at 0.05 level
† Range: 0 and 1, where ‘0’ indicates no correct answers and ‘1’ indicates all correct answers

Relationships between Perceived Risk of Breast Cancer, Breast Cancer Knowledge, and
Screening Behavior
Relationship between respondent’s 5-year perceived risk of breast cancer and her
knowledge index score was assessed by means of a two-tailed student t-test. The
relationship between the respondent’s lifetime perceived risk of breast cancer and
knowledge index was also evaluated. These results are reported in Table 4.29. Those
respondents who perceived themselves to be at a high risk of developing breast cancer in
the next 5 years had, on average, a significantly higher knowledge index score as
compared to their counterparts who perceived themselves to be at a lower risk of breast
cancer. Similarly, respondents who perceived themselves to be at a high risk of
developing breast cancer in their lifetime had, on average, a significantly higher
knowledge index score compared to those respondents who perceived themselves to be at
a lower risk. Details are provided in Table 4.29.
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Table 4.29: Knowledge Score and Respondent’s Perceived Risk of Breast Cancer
Mean† (+SD)

t-statistic

df.

Sig.

Low risk women

0.50 (+0.24)

-4.23

147

0.000*

High risk women

0.65 (+0.16)

-3.89

158

0.000*

Item
5-year perceived risk of breast
cancer

Lifetime perceived risk of breast
cancer
Low risk women

0.52(+0.23)

High risk women

0.64(+0.16)

*significant at 0.05 level
† Range: 0 and 1, where ‘0’ indicates no correct answers and ‘1’ indicates all correct answers

Next, the relationship between respondents perceived risk and mammography
screening behavior was assessed. Chi-square analysis was performed in order to assess
the relationship between 5-year and lifetime perceived risk and respondent’s screening
behavior. No significant relationship was observed between a woman’s 5-year and
lifetime perceived risk of breast cancer and her compliance with mammography
screening.
Using Chemopreventive Tamoxifen and its Relation to Actual Risk, and Perceived Risk
Willingness to consume chemopreventive therapy among responding women
revealed that a large proportion of these women (n=236, 42.3 %) were not sure with
respect to consuming tamoxifen for their breast cancer risk reduction. This is closely
followed by those women (n=228, 40.9 %) who indicated that they would not consume
chemopreventive tamoxifen even if the drug was covered by their insurance and their
doctors told them that they were at a high risk of developing breast cancer. The
remaining 16.8 % (n=94) indicated their willingness to consume tamoxifen if their
doctors told them that they were at a high risk for breast cancer and their insurance paid
for the drug.
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Relationships between respondent’s willingness to consume tamoxifen and their
actual risk and perceived risk were assessed using chi-square tests. The results are
reported in Table 4.30. No significant relationship was found between the respondent’s
actual risk of developing breast cancer and her willingness to consume chemopreventive
tamoxifen. Similarly, there seems to be no relationship between how a woman perceives
her 5-year and lifetime risk and her willingness to consume chemopreventive tamoxifen.

Table 4.30: Willingness to consume chemopreventive tamoxifen and breast cancer risk
Willingness to consume
Item

χ2

tamoxifen
Yes

No

Low-risk

44(32.84%)

90(67.16%)

1.792

High-risk

45(25.86%)

129(74.14%)

(p=0.181)

low-risk

18(34.62%)

34(65.38%)

0.458

high-risk

17(41.46%)

24(58.54%)

(p=0.499)

Low-risk

15(31.25%)

33(68.75%)

1.503

High-risk

20(43.48%)

26(56.52%)

(p=0.220)

Actual risk of breast cancer

5-year perceived risk of breast cancer

Lifetime perceived risk of breast cancer
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CHAPTER 5

DISCUSSION & RECOMMENDATIONS
Results of the BCPT trial indicated chemopreventive tamoxifen’s ability to
significantly reduce the risk of breast cancer in healthy women who were at a high risk of
developing breast cancer (Fisher et al., 1998). Ability of mammography screening to
detect breast tumors at an earlier stage thereby reducing breast cancer mortality has also
been well documented (Costanza, 1992; Shapiro, 1988; Shapiro, 1989; Seidman et al.,
1987; Tabar et al., 1992). However, very little is known about the effect of breast cancer
risk reduction through use of chemopreventive tamoxifen on overall survival of women,
especially, since the BCPT trial was not designed to detect mortality differences. Also,
the BCPT trial follow-up was not sufficient to determine mortality benefits of
chemopreventive tamoxifen. In addition, there is no data that estimates ‘survival benefit’
and ‘costs’ of using chemopreventive tamoxifen in presence of the more traditional breast
cancer preventive strategy i.e. mammography screening. Finally, relationships between
real risk of breast cancer, perceived risk of breast cancer, breast cancer knowledge, and
willingness to consume tamoxifen have also not been very well documented, especially
in populations like the Medicaid.
Consequently, a model, which quantifies the net costs and benefits of employing
these two preventive strategies in tandem, was developed in the current study. Data were
also collected prospectively by means of a mail survey to investigate the abovementioned relationships between breast cancer risk (actual and perceived), and
willingness or reluctance to consume chemoprevention tamoxifen. Methodology
employed in the development of the model and collection of survey data has been
discussed in Chapter 3. The results of the model and the survey are reported in Chapter
4. This chapter includes a review of study findings and their implications. Major
limitations of this study will be discussed, the significance of study results will be
presented, and finally recommendations for future research will be made in this chapter.
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Background

Breast cancer is one of the most common types of malignancy in women, second
only to lung cancer in terms of cancer-related deaths (Alberg et al., 2000). This clinical
significance directly translates into substantial economic burden of approximately $6.6
billion (1990 dollars) in treatment costs alone (about $9.7 billion when inflated to reflect
1997 dollars) (Brown D, 1999). Until now, mammography screening has been the most
effective method for preventing pre-mature mortality due to breast cancer. However, the
recent approval of tamoxifen by the Food and Drug Administration (FDA) as a breast
cancer risk reducing chemopreventive agent in healthy women who have high risk of
developing breast cancer has provided an additional option in breast cancer prevention
management.
Introduction of such preventive strategy will result in utilization of additional
health care resources, which in turn will increase healthcare costs. For instance, the
annual economic cost of screening in a mobile mammography program in 1998 amounted
to more than $381,000 for a low volume program and more than $789,000 for a high
volume program (Brown D et al., 1999). These costs put additional burden on third party
payer systems, which are already facing resource constraints and consequently are
looking for ways to reduce their expenditures. Among these third party payer systems,
the Medicaid program, which is a joint federal-state program, may be one of the most
susceptible systems to rising costs, especially drug costs, as it provides insurance to
population that are generally in worst health than the general population and rely on
Medicaid for their prescription drug coverage (Bruen B, 2002). Introducing newer
prescription drugs or adding newer indications to existing drugs like tamoxifen will strain
budgets of Medicaid programs which are already experiencing difficult fiscal conditions
due to federal and state budget deficits (Bruen B, 2002). Consequently, there is growing
pressure on state and federal governments to evaluate medical interventions that are not
only effective but also economically feasible.
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The State Medicaid programs are under no obligation to cover prescription drugs
in their benefit package. But once the states opt to cover prescription drugs, barring few
classes of drugs, the federal law requires these states to cover all FDA-approved drugs
made by manufacturers with federal rebate agreements (Bruen B, 2002). Under such
federal requirements, the total prescription expenditures are bound to increase.
Moreover, some drugs like chemopreventive tamoxifen can affect total drug expenditures
to a greater extent than others. Being a primary preventive drug, there is a possibility for
it to be prescribed to a large proportion of women population who although are at a high
risk of developing breast cancer may never go on to develop the disease. For instance,
among the 6,599 high-risk women who were enrolled in the placebo arm of the BCPT
trial, less than 3 % women (n = 175) developed breast cancer (Fisher et al., 1998). The
other significant cost driver in this case is the chronic nature of the chemopreventive
therapy, lasting 5 years. With an annual cost of more than $1,200 per woman, a five-year
chemopreventive therapy may result in costs in excess of $6,000 per chemopreventive
therapy per woman in drug costs alone. Under such circumstances, addition of newer
interventions like chemopreventive tamoxifen in addition to existing interventions like
mammography screening in programs such as the Medicaid will require strict economic
assessment. This in turn necessitates quantitative determination of incremental costs and
consequences of newer interventions over existing ones. In absence of real world long
term costs and efficacy data on chemopreventive tamoxifen, one way of quantifying these
outcomes (costs and consequences) is to develop a life expectancy model, similar to the
one developed in the present study. Such life expectancy models integrate data from
diverse sources including randomized trials, real world observational studies etc in order
to project survival benefits of an intervention.
The current study utilized results from the BCPT trial, which, at the time of this
study, was the only large-scale trial in United States evaluating chemoprevention using
tamoxifen. In addition to the BCPT trial there were two more trials (Powles T et al.,
1998; Veronesi et al., 1995) in Europe that evaluated chemopreventive properties of
tamoxifen in reducing breast cancer risk. Results from these trials, however, were not
consistent with those found in the BCPT trial. Many theories were put forth to explain
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the discrepancies between the BCPT trial and the two European trials. One of them was
in relation to ‘power’ of these European trials to detect differences seen in much larger
BCPT trial. For instance, the two smaller European trials provide only slightly more than
66 % of the woman–years of follow up captured in the BCPT trial. Moreover, it has been
suggested that higher baseline incidence and the larger size of the BCPT trial may have
been responsible for demonstrating tamoxifen’s chemopreventive effect (Pritchard K,
1998). Also, there were differences in baseline characteristics of women participating the
BCPT trial and the European trials in terms of their age and drug compliance profiles.
Nevertheless the BCPT trial findings were argued to be robust (Pritchard K, 1998) and
the decision to base the current model on BCPT trial results was driven by two main
factors: (1) applicability of model results to the US population and setting, and (2) the US
FDA’s approval of chemopreventive tamoxifen on basis of BCPT trial results, which
involved the North American population, a population similar to the one that is being
considered in the current study. Results derived from this model are discussed in the
following section.
Review of Study Results

A life expectancy Markov model was developed in the current study to determine
the incremental costs and benefits of introducing chemopreventive tamoxifen in tandem
with existing mammography screening in those women who are healthy but at a high risk
of developing breast cancer. The base case model simulation, at a 3 % discount rate,
yielded an average incremental life expectancy gain of 0.122 years (about 45 days) in the
tamoxifen plus optimal mammography screening cohort and a gain of 0.076 (about 28
days) in the tamoxifen plus non-optimal mammography screening cohort as compared to
only-mammography screening cohort. This incremental gain of 0.122 life years and
0.076 life years came at a cost of $5,969.68 and $4,916.84 (2001 dollars) resulting in an
ICER of $48,932 and $64,695.20 per life year gained, respectively.
As this study was the first study to evaluate the combination effect of
chemopreventive tamoxifen and mammography screening, results from this study were
not directly comparable to other studies. However, a literature review identified studies
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that had investigated costs and benefits of chemopreventive tamoxifen alone compared to
no therapy in high-risk women and although not directly comparable to the present study
they did provide a benchmark against which to compare the current results. A study by
Noe et al., (1999), demonstrated that high-risk women who begin consuming
chemopreventive tamoxifen between ages of 35 to 49 years, experience on average, a life
expectancy gain of 0.1028 years (about 38 days) at 3 % discount rate. This life
expectancy gain is comparable to the gain of 0.122 years (about 45 days) found in the
current study. The ICER for cost per life years gained in the Noe et al., (1999) study was
reported to be $41,372 which again was comparable to the ICER of $48,932 per life year
gained determined in the current study. The slightly higher gain in life expectancy and
higher costs in the current study can be, in part, attributed to the fact that the effects (both
costs and benefits) of mammography screening were modeled in the current study unlike
the Noe et al., (1999) study, which compared chemopreventive tamoxifen alone to no
therapy.
A second study (Grann et al., 2000), which compared incremental costs and
benefits of chemopreventive tamoxifen alone to no therapy, estimated the survival
benefits of 69 days (about 0.189 years). Slight differences can be once again attributed to
different interventions being investigated in the Grann et al., (2000) study
(chemopreventive tamoxifen vs. no therapy) and the current study (chemopreventive
tamoxifen plus mammography screening vs. mammography screening alone) and also on
basis of starting age of cohort which was 35 years in Grann et al., study as opposed to 40
years in the current study. For instance, Grann et al., (2000) found a diminished survival
benefit of 40 days in women who started on chemopreventive tamoxifen at 50 years of
age and a survival benefit of 27 days in women who started the therapy at 60 years of
age. The incremental cost per life years gained of $46,619 found in the Grann et al.,
(2000) study was also found to be comparable to $48,932 per life year gained determined
in the current study.
Although, it is difficult to establish a benchmark for cost-effectiveness, in general,
any strategy resulting in less than $50,000 per life year saved is considered to be cost119
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effective while anything above $100,000 is considered excessive (Mark et al., 1995).
However, a significant number of interventions that cost as much as $100,000 per-life
year saved or even more have been accepted in clinical practice (Hillman et al., 1995).
Based on the current model, chemopreventive tamoxifen in presence of optimal
mammography screening resulted in a incremental cost-effectiveness ratio of $48,932 per
life year saved which is slightly below the cost-effectiveness “threshold” of $50,000 per
life year saved. This incremental cost effectiveness ratio increased to $64,695.20 per life
year gained when mammography screening rates were adjusted to reflect ‘real-world’
rates. As was evident from the sensitivity analysis tables and graphs in Chapter 4, these
base case values of $48,932 and $64,695.20 per life year gained fluctuated with variation
in input parameters and in some instances approached the threshold value of $100,000.
For instance, a 20 % decrease in tamoxifen efficacy in reducing breast cancer risk
resulted in incremental cost-effectiveness ratio of $94,537 per life year gained in the
tamoxifen plus non-optimal mammography screening cohort. However, despite these
variations in input parameters over a relatively wide range of values (20 % from base
case), the incremental cost-effectiveness ratio for both the tamoxifen cohorts remained
below $100,000 per life year saved suggesting economic viability of tamoxifen as a
chemopreventive agent.
The basic principles of cost-effectiveness analysis in health care are that resources
in health sector should be allocated across the interventions and population groups so as
to generate highest possible health benefit through fixed resources (Murray C. et al.,
2000). Thus, by moving resources from cost-ineffective interventions to more costeffective ones, similar or more amount of health benefits can be achieved with greater
efficiency (i.e. similar or more benefits at lesser cost). Economic evaluations, although
have a clear role in healthcare resource allocation decisions, they do not by themselves
dictate resource allocation decisions. For instance, reimbursement and formulary
approval agencies have started questioning the coverage of certain medicines on many
instances despite their favorable cost-effectiveness profiles (Trueman et al., 2001). This
reluctance to accept newer interventions purely on their cost-effectiveness profiles is
based on the reasoning that despite the goal of economic analysis is to maximize
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efficiency these agencies have to function within a constrained budgets (Trueman et al.,
2001).
For instance, in the United Kingdom, the Standing Medical Advisory Council
(SMAC) published guidelines on ‘statin’ use among certain groups of patients who would
benefit most thereby prioritizing use of the drug to those individuals who had a high risk
of developing coronary heart disease or those individuals who had experienced
myocardial infarction in the past (Standing Medical Advisory Council, 1997; Trueman et
al., 2001). Based on these criteria, it was estimated that about 8.2 % of the population
would be eligible to receive the statins. Despite the risk based ‘selective’ approach of the
guidelines, it was estimated that adherence to these guidelines would result in a 20 %
increase in annual drug budget of the involved parties (Trueman et al., 2001). Later, a
study (Primatesta P et al., 2000) found that prescribing of statins, despite their significant
clinical effectiveness as demonstrated by numerous clinical trials (Scandinavian
Simvastatin Survival Group, 1994), was significantly below the recommended levels.
This discrepancy between prescribing levels and recommended level was thought to be
related to substantial costs of providing treatment consistent with the guidelines
(Trueman et al., 2001) highlighting the distinction between being effective and being
affordable. In other words, being cost effective and thus being efficient does not
automatically translate into being affordable. As is clearly evident from the above
example, affordability of an intervention in a given health care setting is not only dictated
by its cost-effectiveness but also by the extent to which that intervention is accepted and
utilized in that setting. Thus, in the present case, ability of WVMP to afford
chemopreventive tamoxifen in addition to ongoing mammography screening, will not
only depend on tamoxifen’s cost-effectiveness profile, which was already demonstrated
in phase I of this study, but also on total number of women in the program who are likely
to consume the drug. This lack of information on proportion of women in the WVMP
who can be potential consumers of chemopreventive tamoxifen and thus partly affect its
affordability led to development of phase II of this study.
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One of the primary objectives of phase II was to estimate the proportion of
women in the WVMP who were at a high risk of developing breast cancer and were thus
eligible for chemoprevention through use of tamoxifen. A woman’s individualized risk
of developing breast cancer was assessed by means of a mail survey to randomly selected
women who were enrollees of the WVMP. Information obtained from the survey was
then inputted into the Gail model in order to obtain the 5-year breast cancer risk. Based
on the BCPT trial guidelines (Fisher et al., 1998), all women who were 60 years of age
and above or were between ages of 40 to 59 years (40 and 59 included) and had a 5-year
breast cancer risk > 1.7 % were deemed high risk women. Data analysis based on survey
responses revealed that about 53 % of respondents were at a high risk of developing
breast cancer.
The WVMP in the year 1999 (the year from which the study sample was derived)
had a total of 35,657 female enrollees who were greater than 40 years of age. Out of
these 2,451 enrollees were part of Medicaid-managed care and were excluded from
further analysis as costs incurred to these women may not be reimbursed by the program
directly. Extrapolating the results from the current survey to West Virginia Medicaid
enrollee population revealed that an estimated 17,600 women may be at high risk of
developing breast cancer and thereby eligible to receive chemopreventive tamoxifen.
However, eligibility for an intervention does not automatically ensure its acceptance.
Stated otherwise, the use of chemopreventive tamoxifen in an otherwise healthy
population may not be purely based on baseline risk of the individual or population but
rather on a thorough risk-and-benefit analysis of the drug in terms of its protective
antiestrogenic effects and harmful estrogenic effects (Bastian L et al., 2001). This was
apparent when the respondents in the current survey were asked about their willingness to
consume tamoxifen if they had no financial risk with respect to cost of the drug and that
their doctor had told them that they were at a high risk of developing breast cancer. Only
about 17 % respondents said that they would be willing to take the drug under such
circumstances. This finding was slightly lower than the one reported in a previous study
by Bastian et al., (2001) where about 23 % of surveyed women showed inclination
towards using chemopreventive drugs. This can be explained in part on the basis that
122

Discussion & Recommendations

Bastian et al., (2001) assessed women’s interest in chemoprevention without providing
information on potential risks of chemopreventive drug. In the current study, however,
the surveyed women were sensitized to the issue of serious adverse events that may occur
as a result tamoxifen, which may have resulted in relatively lower willingness to consume
the drug.
Since many women may not be aware of their actual risk of developing breast
cancer (Evans D et al., 1993; Cull A et al., 1999), it is very likely that acceptance or
reluctance towards chemopreventive drugs will be driven by their perceived susceptibility
towards breast cancer rather than their actual risk of breast cancer (Bastion et al., 2001).
Results from the current study were consistent with those observed in the Bastion et al.,
(2001) study. Thus, when ‘willingness to consume chemopreventive tamoxifen’ was
assessed based on actual breast cancer risk-stratification (into higher and lower breast
cancer risk) no significant relationship was observed. Interestingly, no relationship was
observed between willingness to consume the drug and woman’s perceived 5-year and
lifetime risk, which was contrary to what was observed in the Bastion et al., (2001) study.
It has been frequently reported in the literature (Woloshin et al., 1999; Hopwood,
2000) that women’s breast cancer risk perceptions are in variance with medical
perspectives. This is consistent with a positive but low correlation (r = 0.167, p = 0.045)
found between woman’s actual risk and perceived risk in the current study. Moreover,
studies indicate that some women significantly over-predict their breast cancer risk while
others under-predict their risk. More specifically, younger women have been found to
overestimate their breast cancer risk (Lee J, 1993; Eddy D et al., 1988; Baines C, 1992).
This was observed in the current study in which women who perceived themselves at
high risk (for both 5-year and lifetime risk) were significantly younger than their
counterparts who perceived themselves at a lower risk.
The current study also investigated the relationship between breast cancer risk and
compliance with mammography screening. No significant relationship was observed
between woman’s actual or perceived risk of breast cancer and her mammography
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screening behavior. Results from published studies that have evaluated relationships
between women’s screening behavior and their breast cancer risk have found
contradictory results with some studies reporting positive relationship while others
reporting no relationship (Carney P et al., 2002; Beaulieu M et al., 1996; Cole S et al.,
1997; Aiken L et al., 1995).
So far, the results from phase I and phase II of this study have been presented in
isolation from each other as they represent different aspects of prevention management.
Phase I dealt with quantifying costs and consequences of introducing chemopreventive
tamoxifen in addition to more traditional mammography screening in women who were
healthy but at high risk of developing breast cancer. These costs and consequences,
however, were determined on per woman basis. Phase II of the study was an extension of
phase I in that it determined proportion of population that was eligible to receive
chemopreventive tamoxifen thereby allowing estimation of total costs and benefits to the
entire health system, in this case the WVMP. This impact of introducing
chemopreventive tamoxifen in WVMP is discussed next.
Implication of Study Findings

Results from the life expectancy model in phase I of the current study indicate
that high risk women who start on chemopreventive tamoxifen at age 40 will experience
an average (per patient) a life expectancy gain of 0.122 years (about 45 days) if they
undergo routine mammography screening or experience a gain of 0.076 years (about 28
days) if they continue mammography screening at currently observed rates.
Incorporating costs in this model indicated that the women in the two tamoxifen cohorts
would also incur an average incremental cost (over and above what is incurred to women
in non-tamoxifen group) of $5,969.68 and $ 4,916.84, respectively. Phase II of the study
indicated that about 53 % of the surveyed WVMP women were at high risk of developing
breast cancer and thereby eligible for chemopreventive tamoxifen. Based on an analysis
presented earlier in this chapter, a total of about 17,600 WVMP women enrollees can be
expected to be at high risk of developing breast cancer.
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If every woman in the WVMP, who was eligible to receive chemopreventive
tamoxifen, started consuming the drug at age 40 years, there will be a total life
expectancy gain of 2,147 life years (per woman life expectancy gain of 0.122 years *
eligible population of 17,600 women) in the entire eligible population if everyone
underwent routine mammography screening. This increase in total life expectancy gain of
2,147 life years will come at a total cost of about $105 million (incremental cost of
$5,969.68 per woman * eligible population of 17,600 women). A relatively lower gains
in life expectancy of 1,338 years (per woman life expectancy gain of 0.076 years *
eligible population of 17,600 women) will be achieved if all women in the WVMP
consume chemopreventive tamoxifen but undergo mammography screening at currently
observed sub-optimal rates. This increase in total life expectancy gain of 1,338 life years
will come at a total cost of about $87 million (incremental cost of $ 4,916.84 per woman
* eligible population of 17,600 women).
An issue in direct extrapolation of costs and benefits is acceptability of
intervention irrespective of its efficacy. As discussed earlier, eligibility for a given
intervention does not directly translate into its acceptance in the desired population. As
was evident in the current as well as an earlier study (Bastion et al., 2001) very few
women expressed interest in chemopreventive tamoxifen despite its clinical efficacy in
breast cancer risk reduction. Results from the mail survey in the current study estimated
that only about 17 % of women would consume tamoxifen given its risks and benefits.
Hence, a more appropriate extrapolation in the present case may be to include only 17 %
of the eligible population as opposed to the entire population. Based on this reasoning,
the total number of the WVMP enrollees that may get chemopreventive tamoxifen is
estimated to be about 2,992 women. Hence, life expectancy gains as well as costs were
recalculated for this sub-set of women who showed positive inclination of using
tamoxifen in breast cancer chemoprevention. This scaled down estimate of baseline
population indicated that introduction of chemopreventive tamoxifen in the WVMP will
result in a gain of about 365 life years at an additional total cost of approximately $18
million in a population which undergoes routine mammography screening. At currently
observed mammography screening rates, introduction of chemopreventive tamoxifen in
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the WVMP will result in a gain of about 227 life years at an additional total cost of
approximately $15 million.
As is evident from the above calculations, acceptance rate of chemopreventive
tamoxifen within a population has a significant impact on its total costs and benefits in
that population. These acceptance rates may vary across different populations due to
differences in baseline characteristics, cultural differences, susceptibility towards breast
cancer, perceived risk, and knowledge among other factors. Very limited knowledge
exists with regards to this issue due to the fact that chemopreventive tamoxifen is a
relatively recent phenomenon. The current study provides preliminary data on primary
preventive behavior of women, which needs to be explored further in more details to be
able to make better estimation of tamoxifen’s impact on a particular system. This is one
of the limitations of the current study and is discussed in more details along with other
study limitations in the next section.
Study Limitations

Following is a list of limitations that the current study possesses. Some of these
limitations may affect the results and their interpretability to a greater extent than others.
Nevertheless, these limitations need to be considered when deriving inferences from the
reported results.
1. The implicit assumption made in the current study is that results from the BCPT trial
are generalizable and thus are applicable from one population setting to another.
Differences in study results between the US based BCPT trial and the two European trials
suggest that there may be population differences in terms of response to chemopreventive
tamoxifen. However, many theories have been proposed, mostly statistical, which
downplay the effect of different populations on inconsistent results. The current study
was performed assuming a US perspective and BCPT trial was a population based large
randomized trial involving multiple centers across North America ascertaining its broad
applicability, at least within the US.
2. A major issue with chronic therapy is that of drug compliance. This sub-optimal
compliance expected with chemopreventive tamoxifen was modeled in the current study.
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However, the assumption that was made for modeling compliance is that women who
were considered compliant consumed 100 % of their drug while the remaining noncompliant women consumed no drug at all. In reality, consumption of tamoxifen by
women can be expected to be along a continuous scale from low compliers to high
compliers rather than a dichotomous relationship that was used in the current model. The
main reason for adopting the latter approach is complete lack of information on
relationship between amount and duration of drug consumed and relative magnitude of its
effect. In absence of this information, it was better to model compliance using the
dichotomous approach rather than assuming a highly unlikely scenario wherein all
women would be compliant with tamoxifen over the 5-year therapy period.
3. As was evident from the analysis conducted in an earlier section of this chapter, the
degree of acceptance of an intervention in a given population will have a significant
effect on both the costs and consequences of that intervention in that population. In the
current study, the interest in taking chemopreventive tamoxifen was assessed by selfreporting as opposed to using a observational database or validated behavioral models.
Chemopreventive tamoxifen, being a fairly recent phenomenon, it is highly unlikely for
compliance information to be available through observational databases nor are there any
validated models in the literature that predict compliance with this drug or other
chemopreventive drugs. Hence, there is a strong need for further research to get more
robust data on patient acceptance of certain interventions. Till then, simplistic estimates
derived from self-reported data can serve as a benchmark to assess acceptance/reluctance
towards newer interventions an its subsequent impact on the health system.
4. One of the tamoxifen intervention arms in the current model assumes 100 %
compliance with screening mammography. This assumption was necessary so as to be
able to fully quantify the costs and consequences of introducing chemopreventive
tamoxifen under ideal mammography screening conditions versus existing sub-optimal
use of mammography screening that was generally observed in a given population.
However, the model in its current form does not incorporate the costs of enhancing
mammography rates from sub-optimal levels to 100 % compliance level. The reasoning
behind not including these costs was significant amount of indirect and intangible costs
and behavioral confounders, which may not be directly pertinent to the Medicaid
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program. However, despite the limitations, a simplistic analysis was performed based on
estimates from a study which examined cost-effectiveness of five combinations of
interventions such as physician recommendation, and telephone and in-person
individualized counseling strategies for increasing compliance with mammography
(Saywell R et al., 1999). This study estimated cost per every percent increase in
mammography screening rate and reported that telephone plus letter was most costeffective approach with $0.78 per one % increase in mammography rate. For the current
analysis, these estimates were inputted in the model. In the non-tamoxifen cohort, a rate
of 46.7 % was used for defining mammography screening compliance rate. Thus, based
on Saywell et al., (1999) mammography compliance cost-effectiveness study, it will cost
about $42 per woman (cost per 1 % increase in mammography screening rate of $0.78 *
percentage increase needed to achieve 100 % compliance) to increase mammography
rates to 100 %. Inputting this value in the tamoxifen cohort of the model resulted in a
incremental cost-effectiveness ratio of about $55,580 per life year saved.
5. The phase II of this study was a mail survey and therefore all limitations inherent to
mail surveys will be associated with this study as well. One of the major limitations that
may affect this study is recall bias, which will affect the accuracy of inferences and
extrapolations, based on survey responses.
6. Another important issue associated with mail survey is that of a low response rate. It
is quite possible that women who did not respond were different than those who did in
terms of their attitudes, behaviors, and baseline characteristics. A non-response survey,
which followed the three survey mailings, indicated that the non-respondents were
similar to respondents in terms of their age and risk profile, thereby addressing the issue
of non-response bias to some degree.
Recommendations for Future Research

A model is only as good as the data that is used to develop that model.
Chemoprevention through use of tamoxifen is a recent phenomenon and most of the
clinical data that currently exists is based purely on randomized trials, which are
conducted in a very controlled setting. Such data provides more information on the
‘efficacy’ of the drug more than its ‘effectiveness.’ Future research should be targeted at
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developing models, similar to the one developed in the current study, based on more real
world data. Although, many precautions were taken in the current model to make the
results more generalizable, for instance, by means of factoring drug non-compliance,
including population based transition rates for mortality determinations etc., there is no
substitute for real world data which may be only available at a later point of time.
The present analysis compared chemopreventive tamoxifen in addition to more
traditional mammography screening to mammography screening alone. Similar agents
with much improved side effect profiles such as raloxifene are being currently
investigated for their role in breast cancer chemoprevention. One of the main issues in
incorporating raloxifene intervention in the current study was that raloxifene has never
been evaluated in premenopausal high-risk women (Jordan V et al., 2002). Thus future
research should investigate incremental costs and consequence of agents like raloxifene
to determine which agents deliver most benefits at least cost.
As is evident from the discussion, the total impact of an intervention does not
only depend on its clinical and cost-effectiveness profile but also on its general
acceptance in the population in which the intervention is being targeted. In the current
study, willingness of women to consume chemopreventive tamoxifen for reducing their
risk of breast cancer was assessed. Although, these women were made aware of potential
benefits and risks of the drug, it still was a simplistic approach lacking any established
behavioral theories or model. Complicating this matter is the fact that there is extreme
lack of ‘willingness or reluctance to consume” data in the literature, which can
substantiate the current study findings. Also, it is too early to predict the inclination of
population towards consuming such drug as these agents have been a fairly recent
phenomenon. It is quite possible that inclination towards using such agents may sway
either way once these agents become routinely available in clinical practice. Future
research should be directed at addressing some of the limitations that were inherent in the
current study. Secondary and observational databases in the future should be evaluated to
assess ‘real world’ consumer acceptance of such chemopreventive interventions. Also,
behavioral models need to be developed, which can better predict an individual’s
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acceptance/reluctance towards such agents. Once more data (through behavioral
approach and ‘real world’ database analysis) are available to accurately predict who will
accept chemoprevention and who will not, cost-effectiveness models like the one
developed in the current study, can be reapplied in those situations to obtain more precise
estimates of impact of interventions to third party payers and insurance systems like the
Medicaid program.
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Conclusions

Tamoxifen coupled with mammography screening prolonged the average survival
of cohort members who started consuming the drug at age forty as compared to the
mammography screening only group. Among the two tamoxifen cohorts, average
survival was found to be higher in the group which underwent routine mammography
screening as compared to the group that underwent mammography screening at rates
observed in real-world setting. In terms of cost, the tamoxifen cohort which underwent
routine mammography screening incurred the highest cost followed by tamoxifen cohort
which underwent screening at observed rates. The mammography-screening cohort
incurred the least cost. Results from the univariate and bivariate sensitivity analysis
(which involved varying intervention-related effectiveness parameters, rates of
intervention-related adverse events, compliance with intervention, and mortality rates
associated with different health states in the model) indicated that for all variations in
input parameters, tamoxifen plus mammography screening (both optimal rates and
observed rates) had an incremental cost-effectiveness ratio that was within the accepted
threshold of $50,000 to $100,000 per life years saved as compared to mammography
screening only. About half of the surveyed population was at a high risk of developing
breast cancer and thus eligible to receive chemopreventive tamoxifen. However, only
about 17 % of the respondents indicated their inclination towards consuming the drug for
reducing their risk of breast cancer. A statistically significant but low correlation was
observed between the respondent’s perceived risk and real risk indicating the need for
increasing breast cancer awareness. No significant relationship was observed between a
woman’s risk of breast cancer, either actual or perceived, and her compliance with
mammography screening. Respondent’s actual risk of developing breast cancer did not
appear to have any relationship with willingness to consume chemopreventive tamoxifen.
This supports the need for enhancing breast cancer awareness. Interestingly, no
relationship was observed between how a woman perceives her breast cancer risk and her
willingness to consume chemopreventive tamoxifen. In summary, tamoxifen plus
mammography screening in high-risk women is a cost-effective strategy. However, at
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present, very few of these high-risk women may actually utilize the intervention.
Moreover, additional research is needed to understand women’s behaviors and attitudes
in relation to chemoprevention.
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Introductory Cover Letter
August 5, 2002

Dear Madam:
Breast cancer is an important health problem. It is one of the major causes of
deaths in West Virginia. We at the Medicaid Program are working with the West
Virginia University School of Pharmacy to deal with this important concern.
You may receive a survey on breast cancer screening and its risk assessment in
the next few weeks. Your participation in this survey is entirely up to you and will not
affect your services in any way. However, the information that you may provide by
answering the survey will help us to understand the health care needs of West Virginia
women as they relate to breast cancer. Hence, your participation in this study will be
very much valued. Thank you.

Sincerely,
Nancy V Atkins, MSN, RNC, NP
Commissioner
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First Cover Letter

August 8, 2002
Dear Madam:
Breast cancer is an important health problem. It is one of the major causes of
deaths in West Virginia. We at the Medicaid Program are working with the West
Virginia University School of Pharmacy to deal with this important concern. This study
is part of a doctoral (Ph.D.) research project.
Please find attached a survey on breast cancer screening and its risk assessment.
We would really appreciate it if you will kindly take a few minutes to complete the
survey and return it in the postage-paid business reply envelope.
Your participation in this survey is entirely up to you and will not affect your
Medicaid services in any way. Your responses will be coded, and your name will not
appear in any reports. Your names will be stored in the master codebook by the
investigator. This codebook will be destroyed upon completion of this study. Therefore,
we assure you of as much confidentiality as legally possible.
Although we hope that you will answer all of the questions, you do not have to
answer any question that makes you uncomfortable. However, your response will
provide useful information and is very important to the results of this study. Hence, your
participation in this study will be very much valued. Thank you.
If you have any questions or concerns, please contact Dr. Suresh Madhavan (304
293-1652) at the West Virginia University School of Pharmacy. Thank you.

Sincerely,
Nancy V Atkins, MSN, RNC, NP
Commissioner
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Second Cover Letter

August 22, 2002
Dear Madam:
About two weeks ago, we sent you a survey on breast cancer screening and its
risk assessment. If you have already completed the survey and returned it we thank you
for your time and participation. If you have not completed the survey we request you to
kindly do so.
We understand that you are busy or may not have received the survey. However,
your views are extremely important to us. Therefore, we are again sending you this
survey and would appreciate it if you will kindly complete the survey and return it in the
postage-paid business reply envelope.
Your participation in this survey is entirely up to you and will not affect your
Medicaid services in any way. Your responses will be coded, and your name will not
appear in any reports. Your names will be stored in the master codebook by the
investigator. This codebook will be destroyed upon completion of this study. Therefore,
we assure you of as much confidentiality as legally possible.
Although we hope that you will answer all of the questions, you do not have to
answer any question that makes you uncomfortable. However, your response will
provide useful information and is very important to the results of this study. Hence, your
participation in this study will be very much valued. Thank you.
If you have any questions or concerns, please do not hesitate to contact Dr. Suresh
Madhavan (304 293-1652) at the West Virginia University School of Pharmacy. Thank
you.
Sincerely,
Nancy V Atkins, MSN, RNC, NP
Commissioner
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Third Cover Letter

September 5, 2002
Dear Madam:
About four weeks ago, we sent you a survey on breast cancer screening and its
risk assessment. If you have already completed the survey and returned it we thank you
for your time and participation. If you have not completed the survey we request you to
kindly do so.
We understand that you are busy or may not have received the survey. However,
your views are extremely important to us. Therefore, we are again sending you this
survey and would appreciate it if you will kindly complete the survey and return it in the
postage-paid business reply envelope.
Your participation in this survey is entirely up to you and will not affect your
Medicaid services in any way. Your responses will be coded, and your name will not
appear in any reports. Your names will be stored in the master codebook by the
investigator. This codebook will be destroyed upon completion of this study. Therefore,
we assure you of as much confidentiality as legally possible.
Although we hope that you will answer all of the questions, you do not have to
answer any question that makes you uncomfortable. However, your response will
provide useful information and is very important to the results of this study. Hence, your
participation in this study will be very much valued. Thank you.
If you have any questions or concerns, please do not hesitate to contact Dr. Suresh
Madhavan (304 293-1652) at the West Virginia University School of Pharmacy. Thank
you.
Sincerely,
Nancy V Atkins, MSN, RNC, NP
Commissioner
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BREAST CANCER PREVENTION MANAGEMENT QUESTIONNAIRE
Please answer the following questions to the best of your ability by marking (X) in the box that represents
the best chosen answer.
Q1. Have you EVER had a mammogram? (A mammogram is an x-ray of the breast to look for breast cancer.)
Yes

No

Not sure

If your answer to Q1 is "Yes", then continue with Q2. If your answer to Q1 is 'no' or 'not sure', then go
to Q5.
Q2. How long has it been since you had your LAST mammogram?
Less than a year
More than 1 year but less than 2 years
More than 2 years
Q3. Why was your LAST mammogram done?
Routine checkup
Follow-up for a lump detected
Breast problem other than breast cancer
Follow up to breast cancer diagnosed in the past
Q4. What was the result of your last mammogram?
Normal

Abnormal

Do Not Know

Q5. Have you EVER taken the drug tamoxifen at the recommendation of your doctor?
[This drug is used in treatment of breast cancer and also to lower the risk of developing breast cancer in women who
are healthy but at relatively high risk of developing breast cancer as determined by a physician]
Yes

No

Not sure

Q6. In your opinion, how do you compare your likelihood of developing breast cancer in next 5 years to that of
any woman in the general population?
Lower

Similar

Higher

Not sure

Q7. In your opinion, how do you compare your lifetime risk of developing breast cancer to that of any woman
in the general population?
Lower

Similar

Higher

Not sure

Q8. Have you ever had a breast biopsy?
("Breast biopsy" refers to surgical removal of sample of breast tissue, usually under local or general
anesthesia, for the purpose of determining the presence or absence of cancer.)
Yes

No

Do Not Know
151

If your answer to Q8 is "Yes", then continue with Q9. If your answer to Q8 is ‘no’, then go to Q12.
Q9. How many breast biopsies have you had in your lifetime?
____________
Q10. Did your doctor ever tell you that one of your biopsies showed atypical hyperplasia (abnormal growth of
cells)?
Yes

No

Do Not Know

Q11. Have you ever had a breast biopsy that showed lobular carcinoma in situ (LCIS) or ductal carcinoma
in situ (DCIS)? (These are non-invasive breast cancers involving only the cells lining the milk ducts in the
breast with no evidence that the disease has spread outside of these ducts.)
Yes

No

Do Not Know

Q12. Have you ever had breast cancer?
Yes

No

Q13. What is your age?
_________(years)
Q14. How old were you when you had your first menstrual cycle?
Less than 12 years old

12 years or greater

Do Not Know

Q15. Have you ever given birth?
Yes

No

If your answer to Q15 is "Yes", then continue with Q16. If your answer to Q15 is ‘no’, then go to Q17.
Q16. How old were you when your first child was born?
Less than 30 years old
Don’t know

30 years old

More than 30 years old

Q17. Did your mother have breast cancer?
Yes

No

Do Not Know

Q18. Do you have or have you had any sister(s)?
Yes

No

If your answer to Q18 is "Yes", then continue with Q19. If your answer to Q18 is ‘no’, then go to Q20.
Q19. Do any of your sisters or did any of your sisters have breast cancer?
Yes (If yes, how many of your sisters had breast cancer? __________)
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No

Q20. Do you have or have you had any daughter(s)?
Yes

No

If your answer to Q20 is "Yes", then continue with Q21. If your answer to Q20 is ‘no’, then go to Q22.
Q21. Do any of your daughters or did any of your daughters have breast cancer?
Yes (If yes, how many of your daughters had breast cancer? __________)

No

Q22. Please indicate the extent of agreement or disagreement with each of the following statements:
The risk of breast cancer increases with age

Agree

Don't Agree

Don't know

Women with close relatives with breast
cancer have higher risk of breast cancer

Agree

Don't Agree

Don't know

Breast cancer is usually painful when it
is just getting started

Agree

Don't Agree

Don't know

Giving birth to a first child after 30 years
of age increases the risk of breast cancer

Agree

Don't Agree

Don't know

A woman currently using birth control pills
has a slightly greater risk of breast cancer as
compared to a woman not using them

Agree

Don't Agree

Don't know

Long term use of estrogen replacement therapy
(also known as hormone replacement therapy)
after menopause, slightly increases breast cancer risk

Agree

Don't Agree

Don't know

Alcohol consumption increases the risk of
developing breast cancer

Agree

Don't Agree

Don't know

Obesity (being overweight) is a risk factor
for breast cancer

Agree

Don't Agree

Don't know

Mammograms can detect breast lumps early

Agree

Don't Agree

Don't know

Regular mammography screening reduces
the risk of dying from breast cancer

Agree

Don't Agree

Don't know

Mammography can spread breast cancer

Agree

Don't Agree

Don't know

Mammography can cure breast cancer

Agree

Don't Agree

Don't know

One mammogram is enough to ensure
that you will not get breast cancer

Agree

Don't Agree

Don't know

Breast cancers can be prevented

Agree

Don't Agree

Don't know
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Q23. Are you currently a West Virginia Medicaid enrollee?
Yes

No

Don't know

Q24. Were you a West Virginia Medicaid enrollee at any time in the year 2001?
Yes

No

Don't know

Q25. A large clinical trial in women with a relatively high risk of developing breast cancer showed that taking the
drug tamoxifen for a period of 5 years cuts the risk of developing breast cancer by almost one half for that 5-year
time period during which the drug was being taken.
We would like to know how willing you are to take this drug if your health insurance program pays for it and your
doctor tells you that you are at a relatively high risk of developing breast cancer.
However, before you answer this question please consider the following benefits and harmful effects that may
result from consuming the drug tamoxifen:
BENEFITS of Tamoxifen – Taking the drug tamoxifen will reduce your risk of breast cancer by almost one-half.
HARMFUL EFFECTS of Tamoxifen – Taking the drug tamoxifen will increase the risk of other events such as
endometrial cancer (cancer of uterus lining) by 2.5 times, pulmonary embolism (blood clot formation in lungs) by
3 times and cataract (thickening of cornea) slightly.

However, it has to be noted that in general a woman is much more likely to develop breast cancer than
endometrial cancer.
Bearing in mind these benefits and risks of tamoxifen (and also if your insurance pays for it and you are told by
your doctor that you are at high risk for breast cancer), will you be willing to take the drug tamoxifen for reducing
your risk of developing breast cancer?
Yes

No

Not sure

Thank you for taking the time to complete this questionnaire.

Disclaimer: This study uses Gail Model Risk Assessment Tool (as modified by the National Surgical Adjuvant Breast and
Bowel Project (NSABP) for the Breast Cancer Prevention Trial) to estimate a woman’s risk of developing invasive breast
cancer. The survey is designed for research purposes only, and is not intended for diagnosing or treating a health problem
or a disease. If you have concerns about your own risk of developing breast cancer, you should consult your health care
provider.
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Breast Cancer Prevention Management Questionnaire: Non-Response Survey
Dear Madam:
We sent you a survey asking you about your general awareness regarding breast cancer and certain factors that may affect your
chances of developing breast cancer. Since your views are extremely important to us, we would like to know your reason for not
responding to this survey and some key information for the study. Please answer the few questions below and mail it to us in the
postage-paid business reply envelope. If you have any questions or concerns, please do not hesitate to contact Dr. Suresh Madhavan
(304 293-1652) at the West Virginia University School of Pharmacy. Thank you.
Sincerely,
Nancy Atkins, MSN, RNC, NP
Commissioner

I did not respond to the survey because:
❏ I did not receive it
❏ I was not at home
❏ I did not have time to complete it
❏ Lost the survey
❏ I haven’t finished it yet

❏
❏
❏
❏
❏
❑ Yes

I do not respond to mail surveys
The survey was too long
The survey was confusing
I am not interested in this issue
Other reasons (Please specify): ___

1.

Have you ever had breast cancer?

❑ No

2.

Have you ever had a breast biopsy that showed lobular carcinoma in situ (LCIS) or ductal carcinoma in situ?
❑ Yes
❑ No
❑ Don't know

3.

How old are you?

4.

How old were you when you had your first menstrual period?
❑ Less than 12 years old
❑ 12 years old ❑ More than 12 years old

_________(years)
❑ Don’t know

5.

How old were you when your first child was born?
❑ Less than 30 years old
❑ 30 years old ❑ More than 30 years old
❑ Don’t know
❑ No children

6.

Did your mother have breast cancer?

7.

Did your sisters (if any) have had breast cancer? If yes how many sisters? (if none, enter ‘0’ in the blank below)
❑ Yes
❑ No
Number of sisters who have had breast cancer
_______

8.

Did your daughters (if any) have had breast cancer? If yes how many daughters? (if none, enter ‘0’ in the blank below)
❑ Yes
❑ No
Number of daughters who have had breast cancer
_______

9.

How many breast biopsies have you had in your lifetime? [If none, indicate ‘0’ in the blank below]
__________ (number of biopsies)

❑ Yes

❑ No

10. Did your doctor ever tell you that one of your biopsies showed atypical hyperplasia?
❑ Yes
❑ No
❑ Not sure
11. What is your race?
❑ Caucasians
❑ African Americans
❑ Others(please specify)_________________

❑ Pacific/Asian Islanders
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